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Abstract 
It has been suggested that methamphetamine (MA) self-administration is 
dependent on dopaminergic mechanisms, and that exposure to high doses of 
methamphetamine is toxic to central dopamine (DA) and serotonin (5-HT) neurons. 
Most studies, however, have utilised a short duration, high dose, experimenter-
administered MA exposure regime, which is not representative of exposure that 
results from MA use in humans. The present studies sought to investigate the effects 
of self-administered MA on brain monoamine levels following a short and longer 
withdrawal period, and to determine the role of D1- and D2-like receptors in the 
maintenance of MA self-administration and in relapse to MA-seeking. 
The effects of self-administered MA (0.1 mg/kg/infusion) on tissue 
monoamine levels were determined in rats either 24 hours or seven days following 
20 daily six hour sessions. A yoked-control self-administration protocol was 
employed to determine the effects of response contingency. 
The effect of pre-treatment with the D1-like receptor antagonist, SCH 23390 
(0.0; 0.01; 0.02 mg/kg; subcutaneous [SC]), or the D2-like receptor antagonist, 
eticlopride (0.0; 0.0125; 0.025; 0.05 mg/kg; intraperitoneal [IP]) on MA self-
administration reinforced according to a fixed ratio (FR) 1, and progressive ratio (PR; 
0.2 mg/kg MA) schedule was determined. The effect of these pharmacological 
manipulations on relapse to MA-seeking was also determined. Additionally, the role 
of DA in drug-seeking was examined by measuring the effect of priming injections 
of the direct D1 receptor agonist, SKF 81297 (0.0; 1.0; 2.0; 4.0 mg/kg; IP), the direct 
D2 receptor agonist, quinpirole (0.0; 1.0 mg/kg; IP), or the DA transporter (DAT) 
inhibitor, GBR 12909 (0.0; 1.0; 10.0 mg/kg; IP), on MA-seeking behaviour. 
Self-administered MA produced a transient decrease in tissue levels of DA 
and an increase in DA turnover. This effect was produced at 24 hours, but not seven 
days following the final self-administration session. Similar effects were produced in 
yoked rats that received the same, non-contingent exposure to MA. Pre-treatment 
with SCH 23390, but not eticlopride, produced a significant alteration in the dose-
response curve of MA self-administration reinforced on an FR1 schedule, and 
reduced MA produced BPs on the PR schedule. MA-seeking was produced by MA, 
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cocaine and GBR 12909. SCH 23390 pre-treatment significantly reduced drug-
primed MA-seeking, whereas eticlopride had no significant effect. Finally, neither 
SKF 81297, nor quinpirole significantly increased MA-seeking.  
These findings suggest that self-administered MA does not produce the 
extensive neurotoxicity seen following high-dose experimenter-administered 
treatment regimes. The finding that pre-treatment with a D1-, but not a D2-like 
receptor antagonist altered the maintenance of MA self-administration suggests that 
neuroadaptations take place as a function of MA self-administration, rendering this 
behaviour more reliant on D1-like receptor mechanisms. This idea is further 
supported by the finding that a D1-, but not a D2-like antagonist reduced drug-
primed MA-seeking, and that priming injections with a D2 agonist failed to increase 
MA-seeking behaviour. These results are in contrast to the literature on self-
administration and reinstatement of drug-seeking following self-administration of 
other drugs of abuse, and suggest that dependence on different drugs may become 
mediated by different DA receptor mechanisms.  
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Introduction 
1 Methamphetamine 
Methamphetamine (MA) is a highly addictive drug that has devastating 
effects on those who become dependent. Dependence on MA, like all psychoactive 
drugs, is characterized by tolerance, withdrawal upon a short period of abstinence, 
preoccupation with MA and thoughts of acquiring it, an inability to reduce use, and 
continued use despite significant social, health and/or psychological impairment 
(APA, 2000). Tolerance to the subjective effects of MA can lead to a transition from 
non-injecting routes of administration to injecting MA, more frequent and longer use 
(Darke, Kaye, McKetin, & Duflou, 2008; Degenhardt, et al., 2008). Injecting MA 
can increase the risk of blood-borne virus transmission, but also through risky sexual 
behaviour, as MA increases sexual arousal, and reports have shown that half of MA 
users are more likely to engage in high-risk sexual activities while intoxicated on 
MA (Darke, et al., 2008; Gonzales, Mooney, & Rawson, 2010). Indicative of its high 
potential for addiction is the finding that MA abuse and dependence has been 
increasing across the globe - it is now considered to be one of the most consumed 
illicit drugs world-wide, second only to cannabis (UNODC, 2010). 
1.1 Brief history 
Originally synthesized in 1919 as a synthetic substitute for ephedrine 
(Buxton & Dove, 2008), MA was initially sold over the counter in Japan to „fight 
sleepiness and enhance vitality‟ (Anglin, Burke, Perrochet, Stamper, & Dawud-
Noursi, 2000). During World War II Japan, Germany, and the US issued the drug to 
combat personnel to increase endurance and performance (Gonzales, et al., 2010). It 
wasn‟t until the post-war period that widespread abuse began to occur, as surplus 
military stock flooded the market, leading to Japan‟s so-called “First Epidemic” 
(1945-1957; Anglin, et al., 2000). Use of MA slowly spread to blue-collar workers 
as well as students, house-wives and office workers creating what has been called 
Japan‟s “Second Epidemic” of MA abuse stretching from 1970 to the present day 
(Anglin, et al., 2000).  
In the United States, a liquid form of MA was being used to treat heroin 
addiction in the 1960s, which quickly led to intravenous (IV) abuse. By the 1980s, 
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MA was being illicitly manufactured by the reduction of the β-hydroxyl group on 
ephedrine using a mixture of iodine and red phosphorous (Cho & Melega, 2002). 
This produced the crystallized, smokable and more potent form of crystal MA 
("Ice", "P"; Buxton & Dove, 2008). MA has been used therapeutically to treat a 
variety of disorders such as narcolepsy, attention-deficit/hyperactivity disorder 
(ADHD), and obesity (Berman, O'Neill, Fears, Bartzokis, & London, 2008; Eddy, 
Hallbach, Isbell, & Seevers, 1965; G. R. Hanson & Fleckenstein, 2009), but the 
growing public health threat of MA abuse and production led to the Comprehensive 
Methamphetamine Control Act of 1996 (Anglin, et al., 2000). 
1.2 Epidemiology 
Unlike plant based crops, such as cocaine and heroin, that depend on climate 
and geography for growth, a clandestine MA-lab can be established almost 
anywhere. The ease of production and evasion of detection has seen a spread of MA 
abuse in the USA from the west of the US (Hawaii, California) to rural and urban 
sections of the South and Midwest (Nicosia, Pacula, Kilmer, Lundberg, & Chiesa, 
2009; NSDUH, 2007). This spread of MA abuse is mirrored across the globe and the 
United Nations Office on Drugs and Crime: World Drug Report (UNODC, 2010) 
estimated between 13.7 and 59.2 million people abused amphetamine-type-
stimulants, including MA, in the past year, equating to 0.3 – 1.2% of the global 
population. This indicates that worldwide MA abuse is more common than cocaine 
and heroin abuse combined (up to 40.9 million). Rates of MA use in New Zealand 
exceed the global average with prevalence rates of 2.1% among those 16-64 years of 
age (UNODC, 2010). MA abuse and addiction has thus become one the largest drug 
problems in the world.  
1.3 Pharmacology and pharmacokinetics of MA 
Compounds that contain a phenylisopropyl amine structure with different 
side groups can be collectively referred to as amphetamines, and MA is a structural 
analogue of this family. MA is synthesized in illicit laboratories by the Leukart 
reaction in which phenylacetone is condensed with methylamine in the presence of 
formic acid, producing the racemic d/l compound (Cho & Melega, 2002). A more 
pure and potent form of the d isomer, often called “ice” or “crystal meth” due to its 
resemblance to ice crystals, can be produced by the reduction of the β-hydroxyl 
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group on ephedrine using a mixture of red phosphorous and iodine (Cho & Melega, 
2002). Figure 1 depicts the chemical structure of amphetamine and MA.  
 
Figure 1. Chemical structure of amphetamine and MA 
MA is a psychostimulant that causes most of its effects on the central 
nervous system (CNS) through a non-exocytotic mechanism, acting as an indirect 
agonist for the monoamine neurotransmitters serotonin (5-HT), norepinephrine (NE) 
and dopamine (DA; Barr, et al., 2006; Cruickshank & Dyer, 2009; Fleckenstein, 
Volz, Riddle, Gibb, & Hanson, 2007; Julien, 2001; Kish, 2008; Sulzer, 2001; Sulzer, 
Sonders, Poulsen, & Galli, 2005). Due to structural similarity with the monoamines, 
MA binds to membrane-bound transporters for DA (DAT), 5-HT (SERT), NE 
(NET) and the vesicular monoamine transporter-2 (VMAT-2). The primary 
mechanism by which MA increases synaptic levels of monoamines is to reverse 
these transporters. By reversing the action of the VMAT-2, monoamines are 
redistributed from synaptic vesicles into the cytosol, where they are available to be 
pumped into the synaptic cleft via MA-induced reverse transport of the membrane-
bound monoamine transporters (Barr, et al., 2006; Cruickshank & Dyer, 2009; 
Dwoskin & Crooks, 2002; Elkashef, 2008; Fischer & Cho, 1979; Fleckenstein, et al., 
2007; Kish, 2008; Partilla, et al., 2006; Raiteri, Cerrito, & Cervoni, 1979; Schmitt & 
Reith, 2010; Zaczek, Culp, & De Souza, 1991). Synaptic monoamine levels are 
drastically increased and are then able to stimulate monoamine receptors.  
MA limits the metabolism of monoamines in the cytosol and in the synaptic 
cleft by inhibiting monoamine oxidase (MAO), thereby further increasing the 
duration and pool of monoamines available for reverse transport and the possibility 
of receptor activation (Barr, et al., 2006; Cruickshank & Dyer, 2009; Elkashef, 2008; 
Suzuki, Hattori, Asano, Oya, & Katsumata, 1980). The combined pharmacological 
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mechanism of MA is a substantial increase in synaptic monoamine levels. Further, 
MA has a long elimination half-life (11-12 hours) that is greater than most other 
psychostimulants, producing behavioural and psychological effects lasting much 
longer than, for example, cocaine (1-2 hours; Julien, 2001; Newton, De La Garza II, 
Kalechstein, & Nestor, 2005).  
2 Short- and long-term effects of MA 
Like other amphetamines, MA produces effects in the sympathetic nervous 
system similar to a “flight-or-fight” response, such as vasoconstriction, 
hypertension, and tachycardia (Julien, 2001). The short-term subjective effects can 
include pleasurable feelings of euphoria, increased alertness, motor activity and 
sexual drive, and decreased appetite (Caldwell, Dring, & Williams, 1972; Cho & 
Melega, 2002; Martin, Sloan, Sapira, & Jasinski, 1971). Hyperthermia is common 
and high doses can induce convulsions, and can result in death (Cruickshank & 
Dyer, 2009; Darke, et al., 2008).  
In addition to the many detrimental effects of MA abuse to the abuser 
themselves; there are severe indirect damaging effects on individuals close to the 
abuser, and society in general. Unlike many drugs of abuse, MA appeals to both men 
and women equally (Gonzales, et al., 2010), and children of MA abusers run a 
particularly high risk of neglect and physical and emotional abuse (Anglin, et al., 
2000). Costs associated with morbidity from MA overdose, criminal justice, social 
welfare services, environmental cleanup from MA-production, lost productivity and 
reduced quality of life cost the US an estimated $23.4 billion in 2005 alone (Nicosia, 
et al., 2009). In NZ in 2005/06, it was estimated that 42% of social costs of illicit 
drug use, roughly $551 million, were caused by illicit stimulants, such as MA 
(METHCON, 2008). 
Following chronic MA abuse, tolerance to certain actions of MA develops, 
particularly the euphoric effects, leading to an increase in dose and frequency of use. 
The tolerance to some of MA‟s effects is indicative of neuronal adaptations, and 
may include reduced receptor binding densities, altered monoamine 
neurotransmission, and even neurotoxicity (Bakit, Morgan, Peat, & Gibb, 1974; 
Degenhardt, et al., 2008; Martin, et al., 1971; Rogers, De Santis, & See, 2008; 
Shishido, et al., 1997; Stefanski, et al., 2004; Stefanski, Ladenheim, Lee, Cadet, & 
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Goldberg, 1999). Markers of neurotoxicity, such as neuronal cell death, silver 
staining or reactive microgliosis, and alterations of neurotransmission have been 
documented, especially in dopaminergic neurons (Anglin, et al., 2000; Cho & 
Melega, 2002; Derlet, Rice, Horowitz, & Lord, 1989; J. E. Hanson, et al., 2009). For 
instance, magnetic resonance imaging (MRI) has revealed structural brain 
abnormalities in MA addicts, showing reductions in the volume of the temporal 
lobes (Berman, et al., 2008), and positron emission tomography (PET) scans indicate 
that MA abusers have significantly lower levels of DA D2-like receptor availability, 
compared to control subjects (Volkow, et al., 2001). A reduction in DA D2-like 
receptors has been linked to compulsive behaviours, such as chronic drug abuse 
(Everitt, et al., 2008), and the mediation of impulsive temperament (B. Lee, et al., 
2009), potentially perpetuating addictive behaviours (Belin, Mar, Dalley, Robbins, 
& Everitt, 2008).  
MA-produced neuroadaptations can contribute to tolerance, craving and 
drug-seeking that are characteristic of compulsive drug dependence (APA, 2000; 
Cho & Melega, 2002; Copeland & Sorensen, 2001; Darke, et al., 2008; Hartz, 
Frederick-Osborne, & Galloway, 2001). Tolerance to the euphoric effects of MA can 
lead to greater time and effort being spent on drug-seeking and drug-taking, along 
with larger doses being consumed more often, over longer periods, and self-
administration via the potentially risky IV route in an attempt to recapture the “rush” 
of initial use (Anglin, et al., 2000; Degenhardt, et al., 2008). This high frequency, 
high dose consumption pattern, with little or no sleep during a binge, can produce an 
extremely paranoid and irritable state. Anxiety, confusion, mood disturbances (e.g. 
depression, suicidal ideation), and violent, criminal behaviour can ensue (Darke, et 
al., 2008; Degenhardt, et al., 2008; Eddy, et al., 1965; NIDA, 2006). Psychotic 
features may also present, such as delusions and hallucinations (e.g. tactile-
hallucination of the sensation of insects crawling under the skin), which may be 
present months or years after cessation of drug use (Barlow & Durand, 2002; Julien, 
2001).  
Studies have attempted to investigate the consequences of repeated exposure 
to MA in humans as the high frequency and high dose consumption have both short- 
and long-term effects on physiology and behaviour. Research on these effects in 
humans, however, are subject to ethical constraints, and are confounded by 
numerous issues. Patterns of illicit drug use (frequency, duration) and dosage in 
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general are often obtained through self-report, and are retrospective in nature. The 
reliability of these reports can be questionable and is likely to be compromised given 
a drug‟s illicit status, and fragmented recall of use patterns and doses consumed 
(Bradburn, Rips, & Shevill, 1987; Darke, et al., 2008). For instance, Ehrman, 
Robbins and Cornish (1997) demonstrated discrepancies between self-reported drug 
use and urine samples with two measures of self-report: simple yes/no report; and 
scores on the Addiction Severity Index (ASI; McLellan, et al., 1992). Positive urine 
samples confirmed that there was significant underreporting of cocaine use in both 
48 hour self-reports, and on 30 day retrospective reports provided by the ASI 
(Ehrman, et al., 1997). Drug use and assessments of subsequent/previous use are 
often separated by substantial delay, potentially decreasing recall accuracy, and low 
statistical power from between-subject experimental designs may increase the 
likelihood of type II errors (Hartz, et al., 2001). Several routes of administration (e.g. 
snorting; smoking; IV injection) are popular among MA users and may alter the 
neurobiological consequences of exposure (Degenhardt, et al., 2008; Elkashef, 
2008). Furthermore, because MA is illicitly manufactured, the dose and purity are 
variable (Anglin, et al., 2000; Gonzales, et al., 2010; Nicosia, et al., 2009). Polydrug 
use is often reported among MA users (Booth, Leukefeld, Falck, Wang, & Carlson, 
2006; Degenhardt, et al., 2008), making it difficult to ascertain whether 
physiological and/or psychological impairments are due to the consequences of MA 
exposure alone, or the combination of drugs consumed. Additionally, ethical 
constraints limit the ability to administer MA to naïve participants.  
Animal models, however, can provide the advantage of flexibility of method, 
precision in measurement, reproducibility and opportunity for experimental 
manipulation and control of extraneous variables that permits conclusions to be 
made that would not be possible using human studies. These models can then be 
appropriately adapted to investigate the consequences of repeated, chronic MA 
exposure, and the neurobiological mechanisms underlying its abuse. 
2.1 Measuring Effects of Repeated Exposure to MA 
Many studies have investigated the effects of repeated MA on the brain of 
laboratory animals. Of great concern is that a single, or repeated, high dose exposure 
to MA causes neurotoxic effects, and neuronal apoptosis, particularly in 
dopaminergic and serotonergic neurons (Cadet, et al., 2009; Cadet, Ladenheim, & 
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Hirata, 1998; Fleckenstein, Gibb, & Hanson, 2000; Fuller & Hemrick-Leuke, 1980; 
J. E. Hanson, et al., 2009; Hotchkiss & Gibb, 1980; Itzhak, 2004; Lorez, 1981; 
Melega, et al., 2008; Segal, Kuczenski, O'Neill, Melega, & Cho, 2005). These 
neuroadaptations may account for the various adverse neurological deficits (Cadet, 
Jayanthi, & Deng, 2003; Friedman, Castañeda, & Hodge, 1998) and cognitive and 
behavioural problems seen in MA abusers (Barr, et al., 2006). High doses of MA 
produced persistent DA (Melega, et al., 2008; Segal, et al., 2005; Wagner, et al., 
1980), and 5-HT reductions (Cadet, et al., 2009; Ricaurte, Schuster, & Seiden, 1980) 
in several brain regions (Friedman, et al., 1998; Hotchkiss, Morgan, & Gibb, 1979; 
Ricaurte, et al., 1980). These reductions were evident long after the final exposure 
(237 days), suggesting extensive neurotoxicity (Friedman, et al., 1998). The effects 
of MA on DA and 5-HT neurons appear to be region specific; MA-induced DA 
reductions are most pronounced in the dorsal striatum (Str; Chu, et al., 2008; 
Stephans & Yamamoto, 1996; Wagner, et al., 1980), whereas the prefrontal cortex 
(PFC) and hippocampus (Hpc) appear most susceptible to 5-HT reductions 
(Friedman, et al., 1998; Ricaurte, et al., 1980; Stephans & Yamamoto, 1996).  
In many studies, the consequences of MA exposure have been assessed 
following experimenter administration. A typical dosing procedure that has 
produced neurotoxicity comprises four injections of 10 mg/kg MA every two hours 
for a total of 40 mg/kg, administered to drug-naïve animals  (e.g. Cadet, et al., 1998; 
T. L. Wallace, Gudelsky, & Vorhees, 2001). This pattern of exposure has been 
justified as representative of “a naïve user overdose” (p. 189, Davidson, Lee, & 
Ellinwood, 2005). The results from studies employing experimenter-administrated, 
repeated high-dose injection MA exposure have been crucial in exploring the 
neurobiological substrates that are affected by MA abuse and dependence, but may 
not be representative of the effects produced by the chronic MA self-administration 
of dependent individuals. Specifically, MA use is typically initiated at lower doses 
with long intervals between administrations, before progressing to higher doses with 
shorter intervals between administrations, and eventually multiple daily high dose 
administrations (Cho & Melega, 2002; Degenhardt, et al., 2008; Fischman & 
Schuster, 1974; Robinson & Camp, 1987; Segal, Kuczenski, O'Neil, Melega, & Cho, 
2003). A number of studies have, however, attempted to administer MA in a manner 
that is more comparable to human abuse patterns. These include escalating dose 
(ED) protocols (e.g. Cadet, et al., 2009; C. J. Schmidt, Sonsalla, Hanson, Peat, & 
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Gibb, 1985; Stephans & Yamamoto, 1996), pharmacokinetic modelling (e.g. Cho, 
Melega, Kuczenski, & Segal, 2001; Herring, Schaefer, Gudelsky, Vorhees, & 
Williams, 2008), passive chronic exposure using osmotic minipumps (e.g. Davidson, 
et al., 2005), and IV self-administration (e.g. Deneau, Yanagita, & Seevers, 1969; 
Krasnova, et al., 2010; Schwendt, et al., 2009; Shepard, Chuang, Shaham, & 
Morales, 2006; Weeks, 1962).  
2.2 Effects of response contingency on effects of repeated MA exposure 
ED and pharmacokinetic modelling studies may provide greater 
approximations of human MA abuse patterns attempting to produce similar effects. 
Because MA users progressively increase their drug intake, ED procedures may 
more accurately simulate this gradual increase in drug dose by treating naïve animals 
with small doses that are progressively increased (O'Neil, et al., 2006; C. J. Schmidt, 
et al., 1985; Segal, et al., 2003). Pharmacokinetic modelling, on the other hand, 
attempts to more accurately model the accumulation of drug in blood plasma by 
adjusting dosing intervals in laboratory animals to mimic steady-state plasma 
concentrations in human MA users. This is due to the significant differences in the 
rate of drug metabolism between humans and laboratory animals – MA elimination 
half-life in the rat is ca 70 minutes, and for humans ca 12 hours (Cho, et al., 2001). 
Greater approximations of human doses and exposure patterns can be attained using 
ED regimens and pharmacokinetic modelling, but they still employ a non-contingent 
exposure methodology whereby MA is administered by the experimenter. This may 
have profound effects on the consequences of that exposure, as several studies have 
demonstrated different effects of self- and experimenter-administered drugs on 
neuroadaptations (Dworkin, Co, & Smith, 1995; Hemby, Co, Koves, Smith, & 
Dworkin, 1997; Jacobs, Smit, de Vries, & Schoffelmeer, 2003; Stefanski, et al., 
2004; Stefanski, et al., 1999). For instance, Sigma1 receptor (Sig-1R) proteins were 
up-regulated in the midbrain, and altered levels of Sig-1R mRNA in the frontal 
cortex (FC) and Hpc were found only in rats self-administering MA (Stefanski, et 
al., 2004). There were significantly higher extracellular DA levels in the nucleus 
accumbens (NAc) in rats self-administering cocaine, compared to littermates 
receiving identical passive infusions of cocaine (Hemby, et al., 1997), and evidence 
suggests that non-contingent exposure to cocaine produced aversive properties in 
rats and reduced the incentive motivation for further drug reinforcement (Twining, 
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Bolan, & Grigson, 2009). There were also significant reductions in DA receptor 
binding densities in the ventral tegmental area (VTA), substantia nigra (SN) and 
NAc only in rats exposed to self-administered MA (Stefanski, et al., 1999). These 
findings suggests that the neuroadaptive changes taking place in the brain as a 
consequence of drug exposure depend on the exposure protocol employed 
(active/contingent vs. passive/non-contingent), and that studies employing 
experimenter-administered MA protocols may fail to obtain relevant consequences 
of self-administered drug exposure. 
Drug self-administration procedures, in addition to a high degree of control 
of extraneous variables, permits investigation of the mechanisms associated with 
voluntary initiation of drug-taking behaviour; the maintenance of drug-taking; drug-
craving and relapse to drug-seeking behaviours; and the consequences of drug self-
administration. The fundamental principle of drug self-administration adheres to the 
behaviourist view that behaviour is controlled by the consequences it produces 
(Deneau, et al., 1969; Schuster & Thompson, 1969). Thus, drugs are self-
administered because they produce positive reinforcing effects. Animal models often 
focus on the ability of drugs of abuse to directly control behaviour, a critical 
diagnostic feature of drug dependence (APA, 2000), and have demonstrated that 
self-administered drug exposure is sufficient to motivate further drug-taking 
behaviour.  
The validity of drug self-administration in laboratory animals stems from the 
observation that laboratory animals self-administered drugs that are abused by 
humans, whereas drugs that do not maintain self-administration are typically not 
abused by humans (Deneau, et al., 1969; Weeks, 1962; Wilson, Hitomi, & Schuster, 
1971; Wilson & Schuster, 1972). This finding also suggests that drugs may act as 
universal reinforcers. That is, many of the complex chains of behaviour associated 
with drug abuse in humans are not necessary for the reinforcing effects to be 
experienced; rather, drug reinforcement appears to involve biological processes that 
are common to mammalian species (Lynch, Nicholson, Dance, Morgan, & Foley, 
2010). Obviously, the how and why of drug self-administration varies between a 
human within their social environment(s); and an animal experimental subject in a 
controlled laboratory setting. The neural chemistry involved in the behavioural 
patterns of drug-seeking, drug-taking, and its consequences, however, are similar in 
both situations (Sanchis-Segura & Spanagel, 2006). Accordingly, animal models of 
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drug self-administration may be able to elucidate the common neural mechanisms 
and therefore contribute to identifying useful strategies of intervention in human 
drug abuse and dependence.  
3 Drug self-administration 
“All models are wrong, but some are useful.” 
George Box, “Robustness in the strategy of scientific model building,” in 
Robustness in Statistics, R. L. Launer and G. N. Wilkinson, editors. 1979, Academic 
Press, New York. 
The study of drug addiction using drug self-administration stems from 
operant theory, stipulating that drugs can function as reinforcers in and of 
themselves and will therefore increase the likelihood of the behaviour that produces 
their delivery. Operant responding for drug reinforcers can become controlled in the 
same manner that food and water reinforcers can control the behaviour of a food or 
water deprived animal (Deneau, et al., 1969; Schuster & Thompson, 1969; Wilson, 
et al., 1971). Drug reinforcement, however, through the neuroadaptations of repeated 
drug exposure on the brain, can eventually become far more potent than natural 
rewards, gaining the astonishing power over behaviour that is part of the dependent 
state (Gardner, 2000; Spealman & Goldberg, 1978). Further, because drug exposure 
is behaviourally contingent, drug self-administration represents arguably the most 
appropriate animal model for studying the positive reinforcing and addictive 
properties of drugs of abuse (Stephens, Duka, Crombag, Cunningham, & Heilig, 
2010). These methods of studying drug dependence can be widely used in basic and 
preclinical drug abuse research as they possesses substantial construct and face 
validity as models of human drug consumption and provide the most direct point-to-
point correspondence with human drug abuse in the natural environment (Gardner, 
2008; Panlilio & Goldberg, 2007; Sanchis-Segura & Spanagel, 2006).  
A number of routes of administration are able to maintain successful drug 
self-administration in the laboratory. These include IV, intramuscular, 
intraperitoneal (IP), and intracranial (IC) injections, in addition to oral ingestion and 
inhalation. The most commonly used are IV and oral. For oral self-administration 
studies, drinking spigots are inserted into experimental chambers with automated 
apparatus to measure licking behaviour, whereas for IV self-administration, chronic 
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indwelling IV catheters are surgically implanted in experimental animals and 
attached to automated syringe pump systems (Collins, Weeks, Cooper, Good, & 
Russell, 1984; Gardner, 2000; Weeks, 1962). Due to the rapid onset of effects, the 
IV route of administration further strengthens the association between the operant 
behaviour and subjective drug effects (Carlson, 2004). A variety of species self-
administered drugs of abuse (e.g. rodents, non-human primates, dogs) and these 
methods have demonstrated reliable self-administration of virtually all drugs of 
abuse including cocaine, amphetamines (including MA and MDMA), caffeine, 
opiates, ethanol, sedative-hypnotics (e.g. valium, xanax), dissociative anaesthetics 
(e.g. ketamine), and cannabinoids (Deneau, et al., 1969; Di Chiara & Imperato, 
1988; Gardner, 2000; Roberts, 1993)
1
. 
A limitation of the drug self-administration paradigms is that they are 
relatively expensive in terms of resources and time. Using IV delivery, for example, 
demands correct and safe surgical implantation of IV catheters requiring substantial 
training and specialized equipment. Catheter patency must then be constantly 
maintained, and checked throughout a study to ensure efficient and reliable drug 
delivery. In the event of catheter patency failure another catheter may be inserted in 
the second jugular vein. This delays data collection, however, and may interfere in 
training schedules or experiment time frames. Further, drug self-administration 
studies using rodents are limited by the simple fact that the patency of IV catheters 
can be maintained, at best, for a few months. This precludes studies over longer 
periods, and the use of long, complex training schedules (Sanchis-Segura & 
Spanagel, 2006). 
Using animal drug self-administration as a model of human drug 
consumption, paradigms have been developed to ask questions about drug abuse and 
dependence that were not previously possible without clinical study confounds. For 
instance, the possible abuse liability of a compound can be evaluated by 
investigating whether a drug naïve animal voluntarily initiates and maintains self-
administration of that compound (Deneau, et al., 1969). Patterns of drug-taking (e.g. 
Downs & Woods, 1974; Wilson, et al., 1971), response contingency effects on drug-
                                               
1 For the purposes of exploring the neurobiological mechanisms involved in MA self-administration 
in this thesis, comparisons of self-administration behaviour will focus predominantly on other 
psychostimulants, particularly cocaine, as this is where the majority of research has been conducted.  
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taking (e.g. Goldberg, 1973; Roberts, 1993), the development of addiction-like 
behaviours (e.g. Roberts, Morgan, & Liu, 2007), relapse to drug-seeking and –taking 
(e.g. de Wit & Stewart, 1981; Stretch & Gerber, 1973), and the neural mechanisms 
involved in the reinforcing properties of drugs of abuse (e.g. Roberts, Andrews, & 
Vickers, 1996) are but a number of questions that can be asked using animal models 
of drug self-administration.  
As a method for investigating the neurobiological mechanisms of drug abuse 
and dependence, animal drug self-administration paradigms must be adapted and 
appropriately tuned in order to model the particular aspect of addiction-like 
behaviour that is under consideration – no single paradigm will be effective in 
evaluating all questions relevant to the study of MA abuse and dependence. Only by 
investigating MA self-administration under a number of paradigms designed to 
model different aspects of addiction-like behaviours can we gain a proper 
understanding of the neurobiological mechanisms underlying MA dependence. 
There are many paradigms of drug self-administration that can model several aspects 
of human drug dependence, but introduction and discussion will be limited to those 
relevant to the interpretation of the results contained herein.  
3.1 Fixed ratio schedules of reinforcement  
The great majority of drug self-administration studies have used a fixed ratio 
(FR) schedule of reinforcement. Under this schedule, the reinforcer (drug) is 
delivered every time a pre-selected number of operant responses (e.g. depression of 
a lever) are completed. Generally, an operant chamber may have two levers: 
depression of one lever results in drug delivery (active lever); whereas depression of 
the other may be noted, but has no pre-programmed response (inactive lever). 
Recording responses on the inactive lever can provide a measure of generalization of 
responding, and undirected behaviour. Significantly greater responding on the active 
lever, compared to the inactive lever, can then indicate that the self-administered 
compound acts as a reinforcer of the operant behaviour (lever press).  
 The most extensively used FR is FR1, also termed continuous 
reinforcement, where each response is reinforced by delivery of the drug. This 
schedule provides a simple association of the direct relationship between the operant 
behaviour and the subsequent effects of drug delivery, making this the easiest and 
fastest self-administration schedule to train. A drug self-administration paradigm 
23 
 
 
 
using a simple FR schedule of reinforcement can provide a quick and efficient 
indication of whether a compound will support self-administration behaviour, 
providing a measure of whether that compound possesses reinforcing properties and 
any potential for abuse.  
Weeks (1962) developed a chronically implanted IV catheter that, for the 
first time, provided a means of conducting long-term self-administration studies. 
First, experimenter-administered morphine sulphate injections were administered to 
rats in hourly doses, increasing in a 2.5% geometric progression from 2 to 40 mg/kg 
(122 doses in total), and the last dose being repeated for 1 to 2 days. This treatment 
regimen was suggested to produce physiological dependence. Next, a lever was 
inserted into the rat‟s cage, which, when pressed, produced a 10 mg/kg infusion of 
morphine sulphate. Following chance lever pressing producing the drug effects, 
lever pressing became regular, and response rates increased in a compensatory 
manner when the unit dose per infusion was reduced to 3.2 mg/kg/infusion (Weeks, 
1962). This indicated that morphine sulphate infusions were reinforcing, and that 
rats would perform an operant behaviour in order to obtain further infusions. 
Further, this study highlights the ease of training and acquisition of the operant 
behaviour using an FR1 schedule of reinforcement.  
Deneau and colleagues (1969) extended these findings by developing chronic 
indwelling catheters which permitted rhesus monkeys to voluntarily initiate IV self-
administration. The ability of drugs to support voluntary initiation of drug self-
administration is important in determining abuse liability, as it is possible that 
morphine self-administration following suggested physiological dependence 
(Weeks, 1962) was maintained by the negatively reinforcing amelioration of opiate 
withdrawal. CNS psychostimulants with abuse liability (e.g. MA), however, do not 
typically produce physiological dependence (Julien, 2001). A number of drugs 
(morphine, codeine, cocaine, d-amphetamine, pentobarbital, ethanol), however, 
induced and maintained voluntary self-administration behaviour (Deneau, et al., 
1969), indicating a potential liability for abuse, irrespective of their ability to 
produce physiological dependence. Importantly, a number of compounds that are not 
abused by humans, such as nalorphine, chlorpromazine, and physiological saline, did 
not support self-administration behaviour, suggesting they were not intrinsically 
reinforcing, and did not possess similar potential for abuse (Deneau, et al., 1969). 
The use of voluntary initiation and maintenance of drug self-administration in 
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animals is now well accepted as a test of predicting abuse liability in humans 
(Collins, et al., 1984). 
Voluntary initiation and maintenance of MA self-administration has 
subsequently been widely reported, in a number of animals, including rodents and 
non-human primates (Brady, McCallum, Glick, & O'Donnell, 2008; Clemens, 
Cornish, Hunt, & McGregor, 2006; Deneau, et al., 1969; Harrod, Dwoskin, Crooks, 
Klebaur, & Bardo, 2001; Johanson, Balster, & Bonese, 1976; Jun & Schindler, 2000; 
Kitamura, Wee, Specio, Koob, & Pulvirenti, 2006; Ranaldi & Poeggel, 2002; Yokel 
& Pickens, 1973). This supports the idea that it is positively reinforcing, and 
possesses potential for abuse and dependence. For instance, an early study 
demonstrated that experimentally naïve rats voluntarily initiated and maintained 
self-administration of MA under an FR1 schedule of reinforcement (Yokel & 
Pickens, 1973). When self-administration was limited to 6 hr/day, an increase in 
dose produced a decrease in rate of responding, and body weight and health was 
maintained in the rats. MA‟s immense potential for producing addictive-like 
behaviours was further demonstrated when animals given unlimited (24 h/day) self-
administration access showed substantial weight loss, body irritation and typically 
died within two weeks (Johanson, et al., 1976; Yokel & Pickens, 1973).  
The finding that an increase in the unit dose of self-administered MA 
resulted in a decrease in rate of responding (Yokel & Pickens, 1973) is typical of 
drug self-administration behaviour patterns reinforced according to an FR schedule. 
Drug self-administration is governed by the dose of self-administered drug, and the 
rate of operant responding is an inverse function of the unit dose per drug infusion. 
From the threshold unit dose (mg/kg/infusion) capable of supporting self-
administration behaviour at the peak of the dose-response curve, response rates 
decreased in accordance with increases of the unit dose, yielding a dose-response 
function resembling an inverted-U shape (Deneau, et al., 1969; Downs & Woods, 
1974; Goldberg, 1973; Markou, et al., 1993; Schuster & Thompson, 1969; 
Skjoldager, Winger, & Woods, 1991; Spealman & Goldberg, 1978; Wilson, et al., 
1971; Wilson & Schuster, 1972). For instance, the relationship between unit dose of 
drug infusion and rate of responding reinforced by both d- and l- isomers of MA and 
amphetamine resembled an inverted-U shape (Yokel & Pickens, 1973). The mean 
duration between operant responses was directly related to the unit dose per injection 
for each dose that maintained responding. This means there was an inverse 
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relationship between the unit dosage and rate of responding – as the self-
administered dose increased, response rates decreased (Yokel & Pickens, 1973). 
More recently, self-administration behaviour was maintained by three doses of IV 
MA (0.05, 0.1, 0.25 mg/kg/infusion), and maximum response rate was maintained 
by the lowest dose, followed by slower rates of responding as the unit dose increased 
(Jun & Schindler, 2000). The generated dose-response function comprised the 
descending limb of MA self-administration, and further dose increases would 
produce slower response rates. This relationship has been suggested to reflect an 
attempt at compensation by decreased responding following greater drug effects at 
higher unit doses (Yokel & Pickens, 1973), and changes in response rates may 
reflect an attempt to maintain a criterion amount of blood plasma drug level 
stimulation (Arnold & Roberts, 1997; Richardson & Roberts, 1996). 
Given that increasing the unit dose quickly resulted in lower response rates 
and fewer infusions, early drug self-administration studies found that total overall 
session drug intake remained relatively stable, independent of dose variations 
(Deneau, et al., 1969; Downs & Woods, 1974; Goldberg, 1973; Wilson, et al., 1971; 
Yokel & Pickens, 1973). Indeed, increasing the unit dose of MA, amphetamine, 
cocaine, pipradrol, methylphenidate, and phenmetrazine  produced slower response 
rates, and consequently, little change in overall session drug intake (Wilson, et al., 
1971; Yokel & Pickens, 1973). At doses that maintained self-administration 
behaviour, no significant differences were found between drug intake per session 
across doses for both amphetamine and MA (Yokel & Pickens, 1973). The most 
parsimonious explanation for dose-dependent responding is that lower rates of 
responding at higher doses reflect a compensatory mechanism to maintain optimum 
blood levels of drug – the magnitude of drug effect is maintained at a relatively 
constant level by increasing drug intake in the face of reduced drug impact and vice 
versa. In other words, drug self-administration on FR schedules is rapidly titrated in 
response to changes in dose, in a similar manner to peripheral mechanisms 
regulating self-administration of natural, non-drug reinforcers such as food and 
water (Gardner, 2000, 2008; Wilson, et al., 1971). Thus, rate of responding is a 
direct function of the unit dose being self-administered, whereas total drug intake 
per session remains relatively stable across doses. It should be emphasized, however, 
that one of the fundamental aspects of drug dependence is that drug intake can 
become uncontrollable and can lead to death by overdose (APA, 2000), even in 
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animals (Johanson, et al., 1976; Yokel & Pickens, 1973). Therein lies the distinction 
between „recreational‟ use, where intake is controlled, and abuse, where control has 
been lost. Figure 2 depicts the descending limb of a sample dose-response curve for 
active lever responding and overall total session drug intake as functions of self-
administered unit drug dose. 
 
 
Figure 2. Sample graph of mean (+SEM) number of responses per session (solid line) and mean drug 
intake per session (broken line) as functions of unit dosage of self-administered drug. 
The characteristic inverted U-shape of the dose-response curve for drug self-
administration, producing stable amounts of drug-intake across doses, can provide 
important insight into patterns of drug-taking behaviour. By plotting drug self-
administration across doses, changes in the dose-response curve may be suggestive 
of changes in the drug‟s pharmacological effects. Figure 2 shows that, on the 
descending limb of the dose-response curve, higher unit doses of self-administered 
drug produce lower rates of responding, whereas lower unit doses produce higher 
response rates, in a compensatory manner. The opposite is true for doses on the 
ascending limb – namely, increases in dose would produce increases in response 
rates. This suggests that on the descending limb lower response rates may reflect 
increased positive reinforcing effects and vice versa. This idea was supported by the 
finding that systemic partial DA blockade with low doses of pimozide or (+)-
butaclamol increased the rate of responding maintained by amphetamine, whereas 
pre-treatment with higher doses decreased response rates (Yokel & Wise, 1976). 
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Amphetamine‟s effects are mediated by non-exocytotic indirect agonism of the 
monoamines (DA, NE, 5-HT; Carlson, 2004; Julien, 2001) by blocking and 
reversing the action of membrane-bound monoamine transporters, in a similar 
mechanism to MA. Thus, pre-treatment with low doses of pimozide and/or (+)-
butaclamol, partially blocking amphetamine‟s effects at DA receptors, produced 
increased rates of responding suggesting a rightward shift in the dose-response curve 
(Yokel & Wise, 1976). This increase in response rate potentially compensated for a 
reduction in amphetamine‟s pharmacological efficacy. This idea was further 
supported by a cessation of responding at full blockade of DA receptors by higher 
doses of pimozide and (+)-butaclamol (Yokel & Wise, 1976), suggesting a complete 
blockade of the positive reinforcing effects of amphetamine. 
In terms of training drug self-administration in animals, responding on 
simple FR schedules of reinforcement represents the easiest method. As such, the 
voluntary initiation and acquisition of this behaviour can provide important insight 
into the potential abuse liability of a compound. Further, the maintenance of drug 
self-administration, across several unit doses of drug, can be used to generate a dose-
response curve to investigate patterns of drug-taking behaviour, and changes in a 
drug‟s reinforcing effects. With different doses producing different rates of 
responding, response rate being inversely related to unit dose, and overall drug-
intake remaining relatively stable across dose variations, dose-dependent responding 
likely reflects a compensatory mechanism to maintain a preferred level of drug 
stimulation. This is valuable for interpreting changes in rate of responding following 
experimental manipulations. Responding reinforced according to an FR schedule, 
however, does not tell us much in the way of the neurobiological mechanisms 
underlying the incentive motivation, or “drive”, for further drug reinforcement that 
is so characteristic of drug abuse and dependence. Further, one of the greatest 
obstacles to overcome in drug rehabilitation treatment is relapse to drug abuse, even 
following long periods of abstinence. Drug self-administration on other schedules of 
reinforcement has been used to address these aspects of drug-taking and drug-
seeking. 
3.2 Progressive ratio schedules of reinforcement 
Progressive ratio (PR) schedules of reinforcement were originally developed 
to measure the reinforcing efficacy of condensed milk solutions in rats (Hodos, 
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1961), and have since been exploited for drug self-administration studies (Bedford, 
Bailey, & Wilson, 1978; Gardner, 2000, 2008; Griffiths, Bradford, & Brady, 1979; 
Panlilio & Goldberg, 2007; Richardson & Roberts, 1996; Roberts, 1993; Sanchis-
Segura & Spanagel, 2006; Stafford, LeSage, & Glowa, 1998). The PR schedule of 
reinforcement as a measure of reinforcing efficacy has been used with all species of 
experimental animals including non-human primates, dogs, mice and rats. Under this 
schedule of reinforcement, the response requirements for each drug infusion increase 
according to a preset series, to the point where the operant behaviour is no longer 
performed, or does not meet the required response criterion within a stipulated 
timeframe (e.g. one hour). In this manner, the maximum response requirement that 
will support self-administration behaviour, termed the break-point (BP), can be 
established. The BP is intended to reflect the incentive motivation for further drug 
reinforcement, and can be interpreted as a measure of reinforcing efficacy of the 
self-administered drug. The BP measure has been demonstrated as stable over days 
and across studies. Different laboratories using a PR schedule of reinforcement have 
reported concordant findings – higher unit doses support higher BPs (Arnold & 
Roberts, 1997; Markou, et al., 1993; Panlilio & Goldberg, 2007; Richardson & 
Roberts, 1996; Roberts, et al., 2007; Sanchis-Segura & Spanagel, 2006). The 
completion of high ratios (e.g. > 1000) for a single drug infusion on a PR schedule 
of reinforcement has been compared to the extremely high motivation for further 
drug-taking seen in human drug users; corresponding to the DSM-IV-TR criteria for 
substance dependence of spending a great deal of time in activities necessary to 
obtain and/or use the substance (APA, 2000; Deroche-Gamonet, Belin, & Piazza, 
2004). 
In contrast to FR schedules of reinforcement, the dependent variable on a PR 
schedule of reinforcement is not related to the rate of responding, but rather is the 
absolute highest ratio completed – the time it takes to complete each ratio does not 
matter (within the temporal limits of the paradigm), just whether or not the ratio is 
completed. Because BPs are independent of the rate of responding, the BP can 
provide an effective measure of the reinforcing efficacy of a self-administered drug, 
and incentive motivation for further drug reinforcement, complementing 
interpretations of any changes in response rates observed under an FR schedule of 
reinforcement.  
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Hodos (1961) demonstrated that higher concentrations of condensed milk 
generated higher BPs, suggesting that the higher concentrations were more 
reinforcing. This effect has also been demonstrated for drugs of abuse – higher unit 
doses will support more persistent self-administration behaviour and sustain higher 
BPs, suggesting greater reinforcing efficacy. Dose-dependent responding reinforced 
according to a PR schedule generates a positive linear dose-response function. 
Indeed, BPs produced during MA self-administration in rats  (Brady, et al., 2008; 
Clemens, et al., 2006; Ranaldi & Poeggel, 2002; Roth & Carroll, 2004; Wee, Wang, 
Woolverton, Pulvirenti, & Koob, 2007), and rhesus monkeys (Wang & Woolverton, 
2007) were dose-dependent, with higher unit doses supporting higher BPs. Higher 
BPs indicate that the higher doses of MA are more reinforcing, and reflect a higher 
incentive motivation for further MA reinforcement (Arnold & Roberts, 1997; 
Markou, et al., 1993; Richardson & Roberts, 1996). Figure 3 depicts a sample dose-
response function of drug self-administration on a PR schedule of reinforcement. 
 
Figure 3. Sample graph of mean (+SEM) BPs reinforced by drug self-administration according to a PR 
schedule of reinforcement as a function of unit drug dose.  
The BP, as a reliable measure of reinforcing efficacy and incentive 
motivation, depends partly on the criterion time frame for completing each ratio. As 
stated above, BPs are measured independent of response rates, but they are still 
dependent on the allotted time frame for completion of each ratio within the 
paradigm. This means that if the criterion ratio period is too short relative to the 
inter-injection interval produced by the current unit dose of self-administered drug, 
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the BP may be biased toward lower values and vice versa (Markou, et al., 1993). 
Indeed, some studies have reported declining BPs at higher unit doses of MA, 
generating an inverted U-shape dose-response curve similar to those generated under 
FR schedules of reinforcement. For instance, PR responding was supported by four 
doses of MA (0.01, 0.03, 0.1, 0.3 mg/kg/infusion), with BPs increasing and reaching 
a peak when reinforced by the three lower doses, and decreasing when responding 
was reinforced by 0.3 mg/kg/infusion (Clemens, et al., 2006). It is possible that some 
higher doses of psychostimulants may be less positively reinforcing due to the 
unconditioned aversive subjective effects of the drug, experienced as being „over the 
top‟, thereby accounting for lower BPs at higher doses (Griffiths, et al., 1979; 
Roberts, et al., 2007; Stafford, et al., 1998; Wilson, et al., 1971). The reduction in 
BPs produced by the highest dose of self-administrated MA reported by Clemens et 
al. (2006), however, may reflect paradigmatic temporal limitations and should not be 
interpreted as a decrease in the reinforcing efficacy of MA, at first glance. It is 
possible that the criterion time for completion of each ratio may be responsible for 
lower BPs at higher doses, as the introduction of an inter-trial interval time-out (TO) 
period can eliminate the descending limb of a dose-response function on a PR 
schedule of reinforcement (Stafford, et al., 1998). For instance, cocaine self-
administration on a PR schedule of reinforcement generated a biphasic dose-
response curve (inverted U-shape), with lower BPs produced at higher doses 
(Rowlett, Massey, Kleven, & Woolverton, 1996). When longer inter-trial TO 
periods were introduced, however, dose-dependent responding remained a positive 
linear function of dose, reaching an asymptote and higher BPs at higher doses. This 
suggests that the reduction in BPs seen at higher doses of MA self-administration 
(Clemens, et al., 2006) may be more representative of the temporal limits imposed 
on completing each ratio, rather than a reduction in the reinforcing efficacy of MA at 
higher doses.  
The use of both FR and PR schedules of reinforcement to investigate the 
neurobiological mechanisms of drug-produced positive reinforcement can provide 
important complementary findings. Often, experimental manipulations, such as dose 
variations and pharmacological pre-treatments, produce inversely related effects on 
each schedule of reinforcement (McGregor & Roberts, 1993; Richardson & Roberts, 
1996). That is, as the self-administered unit dose of drug increases, BPs increase on 
a PR schedule of reinforcement; while response rates on an FR schedule of 
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reinforcement decrease. Indeed, self-administration of three doses of GBR 12909 
(0.375, 0.75, 1.5 mg/kg/infusion), a DAT inhibitor, on a FR1 schedule of 
reinforcement generated a dose-response curve with the lowest dose maintaining the 
highest rate of responding, and the highest dose producing the slowest response rates 
(i.e. the descending limb of the dose-response curve; Roberts, 1993). The same 
doses of GBR 12909 produced a positive linear dose-response function characterized 
by increasing BPs with increases in unit dose. These findings were compared to 
cocaine self-administration on the same schedules of reinforcement. The response 
rates for GBR 12909 on the FR1 schedule of reinforcement were approximately 
three times slower than for equivalent doses of cocaine, while BPs reinforced by 
equivalent doses of GBR 12909 and cocaine were comparable (Roberts, 1993). This 
indicated that GBR 12909 has a longer duration of action compared to cocaine, but 
possesses a similar reinforcing efficacy. Thus, using several unit doses of self-
administered drug and both paradigms to investigate changes in reinforcing efficacy 
as a function of unit dose can increase the convergent validity of any inferences 
made following experimental manipulations on either schedule.  
FR and PR schedules of reinforcement can be effectively used to 
complement conclusions based on findings from either paradigm. Changes on one 
schedule of reinforcement, however, may not necessarily be reflected in the other, 
emphasizing the importance of examining the impact of experimental manipulations 
on BP as well as rate of responding on a FR schedule of reinforcement. Indeed, 
systemic pre-treatment with SB-277011A (12.0, 24.0 mg/kg), a DA antagonist, 
significantly reduced BPs reinforced by MA self-administration (0.05 
mg/kg/infusion), but did not significantly affect MA self-administration reinforced 
by the same dose according to a FR2 schedule of reinforcement (Higley, et al., 
2011). A study only examining MA reinforced responding on an FR schedule of 
reinforcement may have erroneously concluded that SB-277011A pre-treatment did 
not affect MA self-administration behaviour. Complementing this finding with a 
reduction in MA reinforced BPs on a PR schedule of reinforcement following the 
same experimental manipulation provides a clearer picture of the dopaminergic 
mechanisms mediating the positively reinforcing effects of MA.  
Paradigmatic differences may account for the discrepancy in results between 
FR and PR schedules of reinforcement. For instance, animals responding on a PR 
schedule of reinforcement may receive more training, and therefore greater exposure 
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to the self-administered drug. This may produce neuroadaptations rendering PR self-
administration behaviour more, or less, susceptible to pharmacological 
manipulations. Further, the two schedules of reinforcement produced different levels 
of MA intake potentially influencing the effects of SB-277011A: total MA intake 
under the FR2 schedule of reinforcement averaged 2.5 mg, whereas total MA intake 
under the PR schedule averaged only 0.80 mg (Higley, et al., 2011). The greater 
levels of MA exposure during self-administration reinforced by an FR2 schedule 
may therefore have reduced the pharmacological efficacy of SB-277011A at DA 
receptors, rendering this manipulation ineffective. Thus, the use of both an FR and 
PR schedule of reinforcement provided a clearer picture of the dopaminergic 
mechanisms involved in MA self-administration. 
Further clarification of differential effects on PR and FR schedules of 
reinforcement may be achieved with pharmacological manipulations administered 
locally into brain tissue. Because anatomical specificity is not possible with systemic 
injections, a less selective behavioural effect may be produced. In contrast, specific 
intracerebral manipulations make possible the differentiation between 
neuroanatomical substrates and their contribution to drug self-administration 
behaviour. Indeed, local intra-striatal pre-treatment with SCH 23390 (0-2.0 µg/0.5 
µl/side), a DA antagonist, produced a dose-dependent increase in response rates 
maintained by IV cocaine self-administration (1.5 mg/kg/infusion) reinforced on an 
FR1 schedule, suggesting a decrease in cocaine‟s reinforcing efficacy (McGregor & 
Roberts, 1995). The same manipulation had no effect, however, on BPs reinforced 
with the same dose of cocaine under a PR schedule of reinforcement, suggesting this 
manipulation does not affect cocaine‟s reinforcing efficacy. Similarly, intra-
amygdala injections of SCH 23390 (0.1-2.0 µg/injection) produced significant 
increases in rate of responding supported by cocaine (1.5 mg/kg/infusion) under an 
FR1 schedule of reinforcement, while the same pharmacological pre-treatment had 
little effect on cocaine reinforced BPs under a PR schedule of reinforcement 
(McGregor & Roberts, 1993). The above findings suggest that BPs on a PR schedule 
of reinforcement and rate of responding on a FR schedule of reinforcement provide 
different information about drug self-administration behaviour. Not only may each 
dependent variable reflect distinct aspects of drug-produced positive reinforcement, 
but experimental manipulations may produce significant effects on one measure and 
not the other. Thus, investigating the influence of experimental manipulations on 
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BPs under a PR schedule of reinforcement and response rates under FR schedules of 
reinforcement may provide crucial insight into drug self-administration behaviour 
not attainable with either schedule alone (Arnold & Roberts, 1997; Gardner, 2000; 
Griffiths, et al., 1979).  
The PR schedule of reinforcement is not without limitations. Possibly the 
most problematic is that only a single data point is provided from an entire self-
administration session. When studying the effect of pharmacological manipulation 
on drug self-administration behaviour it is imperative that the effects of each drug 
coincide within the same timeframe. Thus, the effects of a drug with a short half-life 
that would be expected to decrease BPs might wear off before the effect on BP is 
observed. While some paradigms yield a stream of data during a session (e.g. 
assessing drug-produced locomotor activity in an open field), allowing the time 
course of drug action to be continuously assessed, PR schedules only provide a 
single measure of the incentive motivation for a further drug infusion – the BP.  
Ceiling and floor effects may also limit the sensitivity of a PR schedule of 
reinforcement. Because many drugs of abuse, possessing different mechanisms of 
action, show similar maximal BPs it may be difficult to detect differences between 
them. With that in mind, high BPs reflect a high incentive motivation and great 
reinforcing efficacy, potentially indicating a high abuse liability, so false positive 
determinations may not pose a problem. False negatives, however, may arise and 
because pharmacological history and route of administration can affect reinforcing 
efficacy (Carlson, 2004; Julien, 2001), using BPs to assess abuse liability requires 
that the drug is administered under optimal reinforcing conditions. Responding 
under a PR schedule of reinforcement also requires more training, and studies using 
this method typically take longer to complete than, for example, studies using FR 
schedules of reinforcement. This increases the risk of losing catheter patency in 
experimental animals, making reliable and valid data collection more difficult.  
Responding on a PR schedule of reinforcement represents an excellent 
method of determining changes in reinforcing efficacy of a self-administered drug, 
and provides a measure of incentive motivation for further drug-taking. Because the 
BP is a measure of reinforcing efficacy independent of rate of responding, any 
interpretational ambiguities inherent in changes in response rate on a FR schedule of 
reinforcement are ameliorated, and the two measures can be effectively used to 
complement inferences based on findings from either paradigm (Arnold & Roberts, 
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1997; Griffiths, et al., 1979; Richardson & Roberts, 1996; Stafford, et al., 1998). 
Thus, experimental manipulations on both a PR and FR schedule of reinforcement 
can tell us much more about drug self-administration than studying behaviour on 
either schedule alone, greatly increasing the convergent validity of any findings. 
These schedules of reinforcement have been extensively used to further our 
understanding of the neurobiological basis of drug self-administration.  
4 Neural mechanisms of drug self-administration 
Self-administration of drugs of abuse is based on operant theory, stipulating 
that a reinforcing stimulus will increase the likelihood of the behaviour that 
produced it recurring in the future. By demonstrating that laboratory animals 
voluntarily initiated and maintained self-administration of a number of drugs, across 
several drug classes, Deneau and colleagues (1969) established that drugs that are 
abused by humans are also positively reinforcing to laboratory animals. Since then, a 
great deal of research has been devoted to establishing the neurobiological 
mechanisms of drug abuse, its initiation, maintenance, relapse, and consequences. 
Drugs of abuse come from a variety of origins (synthetic, organic) and diverse 
classes (stimulants, depressants, narcotic analgesics), suggesting that their primary 
pharmacodynamics may vary substantially. These diverse primary mechanisms do 
not, however, preclude the possibility of a final common mechanism of drug-
mediated positive reinforcement. Various drugs of abuse have neither chemical nor 
pharmacological commonality, begging the questions of what these compounds have 
in common, and what distinguishes them from compounds that are not self-
administered? It appears that the answer to both of these questions resides in the 
universal ability of drugs of abuse to activate the dopaminergic system. There is a 
vast literature on other neurotransmitter mechanisms involved in the regulation of 
drug self-administration (e.g. 5-HT, NE, GABA, glutamate; Adinoff, 2004; Di 
Chiara, 1999; Di Chiara, et al., 2004; Gardner, 2000; Olive, 2005; Smith, Co, 
Freeman, & Lane, 1982; Sulzer, 2001), but review of these is beyond the scope of 
this thesis. For this reason, the common neurochemical substrates of drug produced 
positive reinforcement and mechanisms of drug self-administration investigated 
within this thesis will be discussed in greater detail. 
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Despite accounting for less than 1% of the brain‟s neuronal population 
(Marsden, 2006), DA systems have been suggested as the primary mechanism of 
reinforcement for drugs of abuse, including MA (Adinoff, 2004; Feltenstein & See, 
2008; Ikemoto, 2007; Sulzer, 2001; Wise & Bozarth, 1987; Wise & Rompre, 1989; 
Yokel & Wise, 1976). With very few exceptions, drugs self-administered by humans 
are self-administered by animals (Deneau, et al., 1969; Schuster & Thompson, 1969; 
Weeks, 1962; Wilson, et al., 1971; Yokel & Pickens, 1973) and drugs that are 
voluntarily self-administered by laboratory animals enhance brain reinforcement 
mechanisms  in the mesolimbic DA system (Gardner, 2000; Marsden, 2006; Wise & 
Rompre, 1989). These commonalities of self-administered drugs form the basis for 
the theory that drug self-administration is positively reinforcing through its effects 
on dopaminergic mechanisms. Indeed, in 1989 it was already suggested that 
“cocaine and amphetamine are rewarding because of their actions in dopaminergic 
synapses” (p. 214, Wise & Rompre, 1989). For instance, MA and many 
psychostimulants‟ primary action is to increase synaptic levels of the monoamines 
by blocking, and/or reversing membrane transporters (Camp, Browman, & Robinson, 
1994; Fischer & Cho, 1979; Julien, 2001; Sulzer, 2001; Sulzer, et al., 2005). The 
increase in extracellular levels of DA has been suggested to mediate the primary 
positive reinforcing properties of these drugs, while NE and 5-HT can modulate 
these effects (Di Chiara & Bassareo, 2007; Di Chiara, et al., 2004; Di Chiara & 
Imperato, 1988; Munzar, Baumann, Shoaib, & Goldberg, 1999). Opiates (e.g. 
morphine, heroin) primary mechanism is to stimulate the opioid receptors, 
particularly μ (mu) receptors (Cruickshank & Dyer, 2009; Julien, 2001; Martin, 
1983). Stimulation of these opioid receptors  inhibits GABA neurons in the VTA, 
preventing the tonic inhibition of dopaminergic neurons, thereby producing 
increased DA release in terminal regions (Martin, 1983; Shalev, Grimm, & Shaham, 
2002). Thus, diverse primary mechanisms of drugs of abuse may converge on a 
common secondary mechanism of increased DA activity.  
An increased level of DA activity appears to be the essential common 
neurochemical substrate of drug self-administration. Support for the idea that drugs 
of abuse increase dopaminergic neurotransmission has been obtained using brain 
microdialysis following experimenter-administered injections measuring 
extracellular synaptic DA concentrations in the NAc and caudate nucleus (dorsal Str) 
as an index of DA transmission in freely moving rats (Di Chiara & Imperato, 1988). 
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The results showed that drugs of abuse from diverse pharmacological classes, such 
as amphetamine, cocaine, morphine, methadone, ethanol and nicotine, increased 
extracellular DA concentrations in both regions, but more so in the NAc. These 
findings were extended to differentiate between the shell and core of the NAc in the 
increased extracellular DA release produced by various drugs of abuse. Brain 
microdialysis in freely moving rats showed that doses of cocaine, morphine and 
amphetamine that sustain self-administration behaviour increased synaptic DA 
concentrations preferentially in the shell, as opposed to the core of the NAc (Pontieri, 
Tanda, & Di Chiara, 1995). This effect is also seen following exposure to MA. For 
example, acute MA injections in both drug-naïve rats, and challenge injections in 
MA pre-treated rats, produced a significant increase in DA overflow in the Str 
(Hamamura, et al., 1991; Shuto, et al., 2006; Y. Zhang, Loonam, & Noailles, 2001). 
Thus, what drugs of abuse with diverse primary mechanisms may have in common 
is the ability to mediate the positive reinforcement necessary for their self-
administration through a common final mechanism – the dopaminergic system. 
With few exceptions, what most drugs of abuse have in common, and what 
differentiates them from drugs that are not abused, is the ability to activate the 
dopaminergic system. Specifically, drugs with aversive properties, such as κ opioid 
agonists (U-50.488, bremazocine, tifluadom; Mucha & Herz, 1985) reduced DA 
release, as measured by brain dialysis in freely moving rats (Di Chiara & Imperato, 
1988). Further, drugs that are not abused by humans, such as imipramine 
(antidepressant), atropine (muscranic antagonist) and diphenhydramine 
(antihistamine), did not alter synaptic DA concentrations in the Str or NAc  (Di 
Chiara & Imperato, 1988). Thus, the common denominator among most drugs of 
abuse appears to be the ability to increase dopaminergic neurotransmission. 
Together with the above findings, this provides in vivo evidence supporting the idea 
that the ability of drugs of abuse to reinforce the behaviour that delivers them is 
somehow linked with their ability to increase synaptic DA concentrations in the 
mesolimbic DA system.  
A wealth of preclinical research has suggested a crucial role for DA in the 
drug-produced positive reinforcement supporting self-administration behaviour. For 
instance, rodents self-administered both the dextro (d) and levo (l) isomers of MA 
and amphetamine, but lower doses of the d-, compared to l-isomer, were able to 
maintain self-administration behaviour (Yokel & Pickens, 1973). This indicates a 
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central dopaminergic mechanism may be the proximal cause of MA reinforcement, 
as each isomer is equipotent in autonomic, peripheral actions, but the d-isomer is 
more potent in central dopaminergic mechanisms (Wise & Rompre, 1989). Research 
examining DA levels during MA self-administration is somewhat lacking, however, 
increased DA levels were reported when cocaine was self-administered on a FR1 
schedule of reinforcement. Specifically, extracellular DA levels in the NAc were 
elevated by 200-800% during cocaine (2.0 mg/kg/infusion) self-administration, 
fluctuating within this range between operant responses (Wise, et al., 1995). There 
were larger increases in DA levels and a slower rate of responding following 
infusions of higher unit doses. These findings lend further support to the hypothesis 
that rate of responding for cocaine self-administration is titrated across doses for 
stable hourly drug intake, and that falling DA levels trigger successive responding 
for further cocaine infusions (Wise, et al., 1995).    
Selective pharmacological manipulation of dopaminergic systems producing 
altered patterns of operant behaviour has revealed further support for a role of DA in 
drug self-administration. Altered patterns of drug self-administration following 
selective pharmacological manipulation of the DA system have been reported for a 
wide range of addictive drugs, both psychostimulants and opiates (Bari & Pierce, 
2005; Barrett, Miller, Dohrmann, & Caine, 2004; Bergman, Kamien, & Spealman, 
1990; Botly, Burton, Rizos, & Fletcher, 2008; Brennan, Lake, et al., 2007; Caine & 
Koob, 1994; Caine, Negus, Mello, & Bergman, 1999; Daniela, Brennan, Gittings, 
Hely, & Schenk, 2004; David, Durkin, & Cazala, 2002; Higley, et al., 2011; Hubner 
& Moreton, 1991; McGregor & Roberts, 1995; McGregor & Roberts, 1993; Munzar, 
et al., 1999; Phillips, Robbins, & Everitt, 1994; Pulvirenti, Balducci, Piercy, & Koob, 
1998; Wilson & Schuster, 1972; Yokel & Wise, 1976; D. Zhang, et al., 2010). 
Specifically, pharmacological manipulations that decrease the reinforcing efficacy of 
the self-administered drug may increase response rates on an FR schedule of 
reinforcement in a compensatory manner, and decrease BPs on a PR schedule of 
reinforcement (similar to decreasing the unit dose of self-administered drug). This 
effect was demonstrated with chlorpromazine pre-treatment on drug self-
administration reinforced under a FR schedule. Chlorpromazine, the prototypical 
antipsychotic agent and DA antagonist, increased FR responding for cocaine, 
pipradrol, phenmetrazine, d-amphetamine, and methylphenidate in rhesus monkeys 
(Wilson & Schuster, 1972). Amphetamine self-administration reinforced according 
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to a PR schedule of reinforcement was also altered following selective manipulation 
of the DA system. Pre-treatment with the DA antagonists, raclopride, and eticlopride 
but not the 5-HT antagonist, ritanserin (Fletcher, 1998), dose-dependently reduced 
BPs maintained by amphetamine self-administration (Fletcher, 1998; Izzo, Orsini, 
Koob, & Pulvirenti, 2001). Further, pre-treatment with terguride, a partial DA 
agonist that functions as an agonist in conditions of low DA receptor occupancy, and 
an antagonist in conditions of high DA levels (such as during amphetamine self-
administration), significantly decreased amphetamine reinforced BPs on a PR 
schedule of reinforcement (Izzo, et al., 2001).  
Pharmacological manipulations that increase the reinforcing efficacy of the 
self-administered drug, on the other hand, may reduce response rates on a FR 
schedule of reinforcement and increase BPs (analogous to increasing the unit dose of 
self-administered drug on the descending limb of the dose-response curve). For 
instance, pre-treatment with the indirect DA agonist, phentermine, decreased MA 
self-administration reinforced according to a FR schedule (Munzar, et al., 1999), and 
pre-treatment with other DA agonists, such as amphetamine, quinelorane, 7-
hydroxy-dipropylaminotetralin (7-OH-DPAT) and GBR 12909, produced dose-
dependent left-ward shifts in the dose-response function for cocaine self-
administration (Barrett, et al., 2004; Caine, et al., 1999). Further, the indirect DA 
agonists, phentermine and GBR 12909, both generalized to cocaine and MA in a 
drug-discrimination task (Holtzman, 2001; Munzar, et al., 1999), and produced 
dose-dependent reductions in self-administration of either drug, analogous to a 
leftward shift in the dose-response curve  (Munzar, et al., 1999; Tella, 1995). The 
leftward shift in the dose-response function suggests an increase in cocaine‟s 
reinforcing efficacy. The idea of DA mediated positive reinforcement is further 
supported by the finding that GBR 12909 promoted voluntary initiation and 
maintenance of self-administration behaviour, under both FR and PR schedules 
(Roberts, 1993). Thus, selectively blocking DA reuptake is positively reinforcing. 
These findings suggest that self-administration behaviour in laboratory animals is 
supported by indirect DA agonists and is selectively altered by pharmacological 
manipulation of the DA system. 
Pharmacological manipulation that eliminates the reinforcing properties of 
the self-administered drug should produce a sequential change in responding 
characterized by an initial compensatory increase, followed by a decrease in 
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responding, before ceasing entirely. This typical extinction of responding was 
demonstrated following DA receptor blockade during both MA and amphetamine 
self-administration. Amphetamine self-administration was increased following pre-
treatment with low doses of the DA antagonists pimozide and (+)-butaclamol, and 
altered in a biphasic manner following high doses -  response rates initially increased 
before decreasing, and then ceasing entirely (Yokel & Wise, 1976). Similar findings 
were produced on MA self-administration which was attenuated by pre-treatment 
with the VMAT2 inhibitors lobeline, and lobelane (Harrod, et al., 2001; Neugebauer, 
2007; Nickell, et al., 2010). Lobeline and lobelane prevent the inhibition of MAO by 
MA and bind to the VMAT2, expelling DA into the presynaptic cytosol where it is 
metabolised to DOPAC, thereby preventing the reverse transport and increased 
release induced by MA (Dwoskin & Crooks, 2002; Nickell, et al., 2010; Wilhelm, 
Johnson, Eshleman, & Janowsky, 2008). These findings represent classic 
behavioural extinction in the face of a lack of reinforcement, as even with increased 
blood levels of amphetamine, responding ceased following full DA blockade (Yokel 
& Wise, 1976), and the lobeline-induced decrease in responding for MA was not 
surmounted by increasing the unit dose of MA (Harrod, et al., 2001). This suggests a 
non-specific rate decreasing effect, and a non-competitive mechanism of action for 
lobeline (Dwoskin & Crooks, 2002; Teng, Crooks, Sonsalla, & Dwoskin, 1997). 
Importantly, lobelane pre-treatment did not affect sucrose self-administration 
suggesting the decrease in responding produced by DA antagonism was selective to 
drug-produced positive reinforcement (Neugebauer, 2007). Further, while lobeline 
initially decreased responding for sucrose reinforcement, tolerance developed to this 
effect with repeated administrations, but the decrease in responding maintained by 
MA persisted (Harrod, et al., 2001), suggesting a more drug-selective effect. The 
support for enhanced DA neurotransmission in the reinforcing and addictive 
properties of drugs of abuse can be summarized by stating that an increase in 
extracellular DA levels follows exposure to all of the classically addictive drugs: DA 
receptor partial blockade increases drug self-administration, with cessation at full 
blockade; and drug self-administration is inhibited following DA synthesis blockade, 
or decreased catecholamine release by VMAT2 inhibition (Sulzer, 2001).  
Because many psychostimulants, including MA, produce substantial 
increases in 5-HT and NE neurotransmission (Julien, 2001; Raiteri, et al., 1979; 
Ricaurte, et al., 1980; Rothman, et al., 2001; Sulzer, et al., 2005), these monoamines 
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are also implicated in the neurobiological mechanisms of drug self-administration. 
Self-administration studies have demonstrated a limited role of NE in mediating 
psychostimulant reinforcement or supporting operant responding (Weinshenker & 
Schroeder, 2007), while serotonergic mechanisms may serve a modulatory role 
(Munzar, et al., 1999; Wise & Rompre, 1989). For instance, NE and 5-HT agonists 
did not significantly alter cocaine self-administration (Tella, 1995). Reducing NE 
synaptic transmission by systemic injection of the α-NE antagonist, phentolamine, or 
β-NE antagonist, l-propranolol, failed to alter amphetamine self-administration 
(Yokel & Wise, 1976). The DAT inhibitor, GBR 12909, supported voluntary 
initiation and maintenance of self-administration behaviour, under both FR and PR 
schedules (Roberts, 1993), indicating that blocking DA reuptake is positively 
reinforcing, while self-administration of NE reuptake inhibitors/agonists is not 
typically supported (Tessel & Woods, 1975; Wee, et al., 2006). These findings 
suggest that DA mediates the discriminative and reinforcing properties of 
psychostimulant self-administration, while NE systems may serve a limited role in 
this behaviour (Holtzman, 2001; Munzar, et al., 1999; Rothman & Baumann, 2006).  
5-HT mechanisms, on the other hand, can modulate psychostimulant self-
administration (Miszkiel, Filip, & Przegaliński, 2011; Müller, Carey, Huston, & De 
Souza Silva, 2007; Munzar, et al., 1999). A study of the relative reinforcing strength 
of MA to MDMA and its isomers found that MA maintained higher BPs on a PR 
schedule of reinforcement than the racemic, positive, or negative isomers of MDMA, 
with a reinforcing efficacy relationship of MA>(+)-MDMA>(±)MDMA>(-)MDMA 
(Wang & Woolverton, 2007). This relationship relates to each compound‟s 
monoamine releasing potency and the ratio of DA over 5-HT release is identical to 
the reinforcing efficacy of these compounds, as demonstrated by higher BPs reached. 
At initial exposure, MA releases roughly 30-fold more DA than 5-HT, whereas 
MDMA is about sevenfold more potent in releasing 5-HT than DA (Rothman, et al., 
2001).  Thus, the compound with the highest DA/5-HT ratio, MA, was the most 
effective reinforcer, compared to the weakest reinforcer, (-)MDMA, with the lowest 
DA/5-HT ratio (Rothman & Baumann, 2006; Wang & Woolverton, 2007). MDMA 
pre-treatment in rats that self-administered MA reinforced according to a PR 
schedule of reinforcement produced dose independent reductions of BPs, interpreted 
as a reduction in MA‟s reinforcing efficacy by the inhibitory effects of MDMA-
induced 5-HT release on dopaminergic mechanisms (Clemens, et al., 2006). 
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Systemic injections of the 5-HT agonist, fenfluramine, attenuated MA self-
administration on an FR schedule (Munzar, et al., 1999). Depleting forebrain 5-HT 
levels by injecting the neurotoxin 5,7-dihydroxy-tryptamine (5,7-DHT) into either 
the medial forebrain bundle, or amygdala, significantly increased BPs maintained by 
cocaine self-administration (Loh & Roberts, 1990). BPs maintained by amphetamine 
self-administration were reduced by the mixed DA and 5-HT antagonist risperidone, 
and the D2-like antagonist raclopride, while the 5-HT antagonist, ritanserin, did not 
significantly alter BPs (Fletcher, 1998). Further, in contrast to DAT inhibitors, 
SERT inhibitors do not support self-administration behaviour (Howell & Byrd, 1995; 
Tessel & Woods, 1975), indicating they do not mediate positive reinforcement and 
possess little potential for abuse. Taken together, these findings suggest that the 
reinforcing properties of psychostimulants supporting their self-administration are 
mediated primarily through DA pathways, and that 5-HT systems may play a 
modulating role in the mediation of psychostimulant self-administration and 
reinforcement (Holtzman, 2001; Munzar, et al., 1999; Rothman & Baumann, 2006).  
4.1 Dopamine receptors and drug self-administration 
Drugs of abuse increase extracellular levels of DA and pharmacological 
manipulation of the DA system produced significant changes in drug self-
administration patterns on both FR and PR schedules of reinforcement. The effects 
of DA stimulation and pharmacological manipulations of the DA system, however, 
depend on the specific type and the localisation of the receptor the 
neurotransmitter/drug binds to (Carlson, 2004; Missale, Nash, Robinson, Jaber, & 
Caron, 1998). Following the discovery that DA receptors could either stimulate or 
inhibit adenylyl cyclase (AC) activity, five DA receptor subtypes, which fall into 
one of two receptor categories, have been characterized (Missale, et al., 1998). DA 
D1-like receptors (D1 and D5) are positively coupled to AC, stimulating 3‟,5‟-cyclic 
monophosphate (cAMP) generation; whereas DA D2-like receptors either have no 
effect on AC, or are negatively coupled to AC, inhibiting cAMP formation 
(Kebabian, Blanchet, & Bedard, 1995; Self, 1998, 2004b; Self & Nestler, 1998). D1-
like receptors are more widely distributed, and can be located both pre- and 
postsynaptically with postsynaptic localization more frequently observed (Levey, et 
al., 1993; Missale, et al., 1998). D1-like receptors have also shown extrasynaptic 
localization (Gonon, 1997; Smiley, Levey, Ciliax, & Goldman-Rakic, 1994). D2-
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like receptors show frequent localization as both autoreceptors and postsynaptic 
receptors (Carlson, 2004; Levey, et al., 1993; Missale, et al., 1998). For instance, 
one of the most prominent regulators of DA neuron activity is the D2 autoreceptor. 
These receptors are found in the dendrites, soma and terminal buttons of DA neurons, 
and their localisation determines their effects. Specifically, activation of dendritic 
and somatic D2 autoreceptors produces hyperpolarization and decreases neural 
firing (Carlson, 2004). Activation of terminal button D2 autoreceptors, on the other 
hand, decreases the activity of an enzyme in the chain of DA biosynthesis, tyrosine 
hydroxylase (TH), thus decreasing DA production and finally its release (Carlson, 
2004). Thus, stimulation of D2 autoreceptors may down-regulate DA neuron activity, 
maintaining their activity within a stable rate of firing (Grace, 2002), whereas 
stimulation of postsynaptic D2 receptors may increase DA-mediated behaviours, 
such as drug self-administration (Missale, et al., 1998; Wise, Murray, & Bozarth, 
1990).  
In terms of drug self-administration, these receptors often mediate similar 
effects (Missale, et al., 1998; Self & Nestler, 1998; Waddington, et al., 1995). For 
instance, both receptor subtypes appear to mediate drug-produced positive 
reinforcement, as selective receptor agonists at both subtypes can substitute for 
cocaine and are self-administered (Self, Belluzzi, Kossuth, & Stein, 1996; Weed & 
Woolverton, 1995; Wise, et al., 1990). For instance, squirrel monkeys trained to 
lever press for IV cocaine reinforcement, maintained FR, and second-order fixed-
interval (FI) responding when infusions were replaced with agonists selective for the 
D1 (SKF 82958), and D2 (quinpirole) receptors, respectively (Grech, Spealman, & 
Bergman, 1996). Rats also self-administered agonists selective for each receptor, as 
SKF 82958 (Self, Belluzzi, et al., 1996), and the D2 agonist, bromocriptine (Wise, et 
al., 1990) both support IV self-administration. In addition, equimolar mixtures of the 
D1 agonist SKF 38393 and quinpirole, at concentrations that alone did not support 
intra-cranial self-administration, were self-infused at significant rates directly into 
the NAc shell (Ikemoto, Glazier, Murphy, & McBride, 1997). This suggests that 
concurrent activation of D1 and D2 receptors in the NAc shell had a synergistic 
effect on DA mediated reinforcement processes. Thus, selective activation of D1 
and/or D2 receptor subtypes produced positive reinforcement capable of maintaining 
self-administration behaviour. 
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Changes in drug self-administration patterns following pre-treatment with 
D1-like agonists and antagonists, further supports the role of DA and this receptor 
subtype in drug self-administration. For instance, pre-treatment with D1-like 
antagonists increased cocaine self-administration in rats on FR (Barrett, et al., 2004; 
Brennan, Lake, et al., 2007; Caine, Heinrichs, Coffin, & Koob, 1995; Caine & Koob, 
1994; Chang, Sawyer, Lee, & Woodward, 1994; Hubner & Moreton, 1991; 
McGregor & Roberts, 1995; McGregor & Roberts, 1993; Ranaldi & Wise, 2001), 
and second-order fixed interval (FI) schedules of reinforcement (Bergman, et al., 
1990). Intra-NAc self-administration of a D1 and D2 agonist combination (SKF 
38393 + quinpirole) on a FR schedule of reinforcement was abolished following D1-
like receptor antagonist pre-treatment, indicating a full blockade of positive 
reinforcement (Ikemoto, et al., 1997). Pre-treatment with D1-like antagonists 
reduced BPs reinforced by cocaine (Hubner & Moreton, 1991; McGregor & Roberts, 
1995; McGregor & Roberts, 1993; Ranaldi & Wise, 2001), methylphenidate (Botly, 
et al., 2008) and „speedball‟ infusions (cocaine and heroin combination; Cornish, 
Lontos, Clemens, & McGregor, 2005) on a PR schedule of reinforcement. D1-like 
antagonist pre-treatment increased N-benzylpiperazine (BZP; Brennan, Lake, et al., 
2007), MDMA (Daniela, et al., 2004), and methylphenidate (Botly, et al., 2008) self-
administration. Pre-treatment with the selective D1 agonists SKF 82958 and SKF 
77434 decreased cocaine self-administration (Barrett, et al., 2004; Caine, et al., 
1999). These findings suggest a critical role for DA D1-like receptor mechanisms in 
the self-administration of drugs of abuse. The effects of manipulating D1-like 
receptor mechanisms on measures of MA self-administration, however, have yet to 
be explored. 
Selective pharmacological manipulation of D2-like receptor mechanisms 
also altered drug self-administration patterns. Pre-treatment with D2-like antagonists 
produced an increase in cocaine self-administration in rats (Barrett, et al., 2004; 
Bergman, et al., 1990; Caine & Koob, 1994; Hubner & Moreton, 1991), or 
extinction of the operant behaviour following higher doses (Chang, et al., 1994). The 
D2-like antagonist, eticlopride, also produced a dose-dependent increase in cocaine 
self-administration in mice (Caine, et al., 2002). Self-administration of other drugs 
of abuse are also affected by selective D2-like antagonism, as pre-treatment with 
eticlopride produced an increase in methylphenidate (Botly, et al., 2008), and 
MDMA self-administration (Brennan, Carati, Lea, Fitzmaurice, & Schenk, 2009) in 
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rats. In addition, the direct D2 agonists, quinelorane and 7-hydroxy-
dipropylaminotetralin (7-OH-DPAT), both decreased cocaine self-administration in 
a manner similar to increasing the unit dose of cocaine (Barrett, et al., 2004; Caine, 
et al., 1999). Finally, intra-NAc self-administration of a D1 and D2 agonist 
combination (SKF 38393 + quinpirole) was attenuated following pre-treatment with 
the D2-like antagonist, sulpiride (Ikemoto, et al., 1997). 
Changes in the reinforcing efficacy of several drugs of abuse have also been 
suggested by selective manipulation of D2-like receptor mechanisms. Indeed, pre-
treatment with eticlopride reduced BPs on a PR schedule reinforced by cocaine (Bari 
& Pierce, 2005) and methylphenidate (Botly, et al., 2008) infusions. The D2-like 
antagonist raclopride, and mixed D2-like and 5-HT2 receptor antagonist, risperidone, 
both reduced BPs produced by amphetamine (Fletcher, 1998). D2 partial agonists 
reduced heroin (D. Zhang, et al., 2010), amphetamine (Izzo, et al., 2001), and 
cocaine (Pulvirenti, et al., 1998) reinforced BPs. Taken together, the above findings 
indicate a crucial involvement of DA D1- and D2-like receptor mechanisms in 
mediating the reinforcing properties of drugs of abuse and maintaining drug self-
administration behaviour. D2-like mechanisms have been implicated in the incentive 
motivation and reinforcing efficacy of MA, as BPs reinforced by MA on a PR 
schedule of reinforcement were attenuated following pre-treatment with the DA D3 
receptor antagonist, SB-277011A (Higley, et al., 2011), and the partial D2 agonist, 
aripiprazole (Wee, et al., 2007). Further, CJB090, a partial agonist at the D3 receptor, 
reduced extended (6 hr) access MA self-administration reinforced according to both 
an FR and PR schedule of reinforcement, while the D3 full antagonist, PG01037, 
reduced MA reinforced BPs on a PR schedule (Orio, Wee, Newman, Pulvirenti, & 
Koob, 2010). The contribution of D2-like mechanisms to the maintenance of MA 
self-administration, however, has not yet been further explored. 
5 Relapse and reinstatement of drug-seeking 
One of the greatest obstacles to the successful treatment of drug dependence 
is the high rate of relapse to drug abuse, even after prolonged periods of abstinence 
(APA, 2000; Degenhardt, et al., 2008; Eisinger, Wodarski, & Ferguson, 2009; 
Elkashef, 2008; Yahyavi-Firouz-Abadi & See, 2009). Relapse to drug-seeking and 
eventually drug-taking behaviour can be studied in the reinstatement paradigm of 
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drug self-administration (de Wit & Stewart, 1981). Reinstatement of drug-seeking is 
a measure that has been used to elucidate the neurobiological mechanisms 
responsible for the characteristic cyclical pattern of abstinence, drug craving and 
relapse to drug abuse. Following acquisition of drug self-administration, responding 
is extinguished by replacing drug infusions with vehicle (behavioural extinction), 
until a criterion level of responding is produced (e.g. < 20% of baseline number of 
responses). Extinguished responding can subsequently be reinstated by stimuli that 
have previously been reported to induce drug-craving and precipitate relapse in 
humans, namely: exposure to the drug or a drug with similar properties (drug-
priming; de Wit & Stewart, 1981), stress (Stewart, 2000), and/or drug-associated 
cues (Shaham & Stewart, 1996). There are two main dependent variables in 
reinstatement of drug-seeking: vehicle-reinforced responding on the previously 
drug-associated lever (active lever), interpreted as reflecting the magnitude of 
reinstated drug-seeking; and responses on the inactive lever, interpreted to reflect 
non-specific behavioural activation. 
The great intuitive appeal of the reinstatement paradigm is that it possesses 
substantial criterion, or face validity, as the variables that have produced 
reinstatement of drug-seeking behaviour in laboratory animals have also been 
reported to induce subjective reports of drug craving, and provoke relapse in humans 
(Epstein, Preston, Stewart, & Shaham, 2006; Katz & Higgins, 2003). A great 
number of studies have demonstrated that re-exposure to the drug of abuse, or a drug 
with similar subjective properties; exposure to drug-associated cues; and/or stress 
can evoke drug-seeking behaviour in laboratory animals and drug craving and 
relapse in humans (Epstein & Preston, 2003; Epstein, et al., 2006; Kalivas & 
McFarland, 2003; Shaham, Shalev, Lu, de Wit, & Stewart, 2003; Shalev, et al., 2002; 
Stewart, 2000; Volkow, et al., 2006). It should be pointed out that drug craving, 
however, cannot be reduced to an observable event, but rather can be conceived of 
as a motivational state in a causal sequential link with behaviour culminating in 
drug-seeking, and drug-taking. It is only the behavioural response that can be 
measured in animal studies of relapse and reinstatement of drug-seeking, whereas 
the subjective description of the cause for the behaviour can only be inferred 
(Epstein, et al., 2006; Katz & Higgins, 2003; Self & Nestler, 1998). Thus, the 
reinstatement paradigm of animal drug self-administration can be effectively used to 
explicitly measure extinguished drug-seeking behaviour, and we may infer that 
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craving may motivate some aspects of this behaviour, but drug-craving itself cannot 
be measured in animals.  
Each method of reinstating extinguished drug-seeking has been reliably 
demonstrated in laboratory animals trained to self-administer MA. MA-seeking 
behaviour was reinstated by priming injections of MA, presentation of discrete cues 
associated with self-administered MA delivery (Anggadiredja, Sakimura, Hiranita, 
& Yamamoto, 2004; Hiranita, Nawata, Sakimura, Anggadiredja, & Yamamoto, 
2006; Hiranita, Yamamoto, & Nawata, 2010; Moffett & Goeders, 2007; Rogers, et 
al., 2008; Shelton & Beardsley, 2008), and stress (Shepard, Bossert, Liu, & Shaham, 
2004). For instance, rats were trained to self-administer MA and subsequently 
underwent extinction training for 12 days either with, or without response contingent 
drug-paired cues (Shelton & Beardsley, 2008). Reinstatement of extinguished MA-
seeking behaviour was then induced by a priming injection of MA (1 mg/kg, IP) 
with and without contingent presentation of previously drug-paired cues. Further, 
response-contingent presentation of previously MA-paired cues alone, without MA-
priming, reinstated MA-seeking behaviour (Shelton & Beardsley, 2008). 
Extinguished MA-seeking was also reinstated by the experience of stress, induced 
through intermittent electric foot-shock, and pharmacologically, by systemic 
injections of the anxiogenic drug, yohimbine (Shepard, et al., 2004). 
A theoretical issue that has been raised regarding the reinstatement paradigm 
as a model of drug-seeking relapse to drug-taking is that the contingencies 
surrounding the reinstatement test itself differ between the animal model and human 
relapse. In drug-primed tests for reinstatement, the priming injections are given non-
contingently by the experimenter, whereas in cue-induced reinstatement, 
presentation of the discrete drug-associated cues typically depends on the operant 
behaviour of the animal (Shalev, et al., 2002). Conversely, relapse to drug abuse in 
humans typically involves contingent exposure to the drug, and/or noncontingent 
exposure to drug-related cues. For the human abuser, drug re-exposure is more often 
a consequence of a „lapse‟, rather than an initiator of relapse (Katz & Higgins, 2003). 
Thus, the drug priming-injection that precedes reinstatement of drug-seeking 
behaviour in the animal model is dissimilar from the self-imposed „lapse‟ that may 
precede full relapse in human users. Despite the discrepancy in the contingency of 
drug- and cue-exposure, the functional behaviour of drug-priming and drug cue-
induced reinstatement of drug-seeking in laboratory animals remain similar to the 
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behaviours of relapse in human drug abusers – that is, time spent obtaining (drug-
seeking) and taking the drug. 
Reinstatement of drug-seeking can be studied within-session, between-
session, or with a between-within-session variation of the procedure, depicted in 
table 1. Within-session reinstatement methods conduct tests of drug self-
administration, extinction training, and finally a test for reinstatement of drug-
seeking all within the same day (e.g. de Wit & Stewart, 1981). Between-session 
reinstatement studies conduct drug self-administration, extinction training, and 
reinstatement tests during different daily sessions, facilitating the investigation of the 
neurobiological mechanisms involved in relapse when the animal is free of self-
administered drug (e.g. Schenk, Gittings, & Colussi-Mas, 2011; Schenk, Hely, 
Gittings, Lake, & Daniela, 2008). Between-within-session reinstatement tests allow 
animals to self-administer a drug across several days followed by extinction training 
and reinstatement testing on the same day (e.g. Shaham, et al., 2003). These methods 
may employ different time frames for reinstatement testing, but they all measure the 
same behaviour – reinstatement of extinguished responding. For the purposes of this 
thesis, the between-session reinstatement method was used as animals are free of 
self-administered drug at the time of testing, and testing is not typically affected by 
the aversive symptoms of acute drug withdrawal (Shalev, et al., 2002). 
    
 Drug self-
administration 
Extinction 
training 
Reinstatement 
test 
Within Day 1 Day 1 Day 1 
    
Between-
within 
Day 1, 2 Day 3 Day 3 
    
Between Day 1, 2 Day 3, 4 Day 5 
    
Table 1. A depiction of sample timelines of within-session, between-within-session, and between-session 
reinstatement procedures. 
Some researchers, but by no means all, have suggested that the drug 
withdrawal period that may accompany drug abstinence may play a role in the 
mediation of relapse to drug abuse. According to this idea, the alleviation of the 
aversive subjective state of drug withdrawal (negative reinforcement) is thought to 
be one of the key reasons for compulsive drug use and repetitive relapse among 
drug-dependent individuals (Koob, 2005, 2006; Koob & Le Moal, 2001; Shaham, et 
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al., 2003). Studies on changes in the magnitude of the drug-seeking response as a 
function of the withdrawal period (i.e. the interval elapsed since a drug was last self-
administered), however, have revealed findings counterintuitive of the negative 
reinforcement theory. Reports indicate that reinstatement of drug-seeking behaviour 
in animals was greatest at time points well beyond the acute withdrawal period, and 
that the least reinstatement was observed following only one day of withdrawal, 
when the aversive effects of acute drug withdrawal would be expected to be their 
most pronounced (Epstein & Preston, 2003; Shaham, et al., 2003). For instance, 
compared to one day of abstinence, cocaine-seeking behaviour in rats was highest at 
one month of abstinence (Tran-Nguyen, et al., 1998), and extracellular DA levels 
were more elevated in the amygdala (Tran-Nguyen, et al., 1998), and NAc 
(Hollander & Carelli, 2007). This suggests that while withdrawal symptoms may 
contribute to further drug-seeking and –taking through negative reinforcement in 
humans users, drug withdrawal syndromes are not critical in relapse to drug-seeking 
in laboratory animals, as measured by the reinstatement paradigm. Rather, the 
duration of the withdrawal period following cessation of drug self-administration 
exerts profound quantitative effects on the magnitude of reinstatement, and 
extracellular DA levels. 
Reinstatement of extinguished drug-seeking behaviour represents an 
excellent paradigm for the investigation of the neurobiological mechanisms involved 
in relapse to drug-seeking and ultimately drug-taking. The paradigm has criterion, or 
face validity in the sense that the same variables that have been reported to induce 
subjective drug-craving and promote relapse to drug-seeking and drug-taking in 
abstinent human drug users also induce reinstatement of extinguished drug-seeking 
behaviour in laboratory animals (Katz & Higgins, 2003; Shaham, et al., 2003; 
Shalev, et al., 2002). These variables include exposure to the previously self-
administered drug, or a drug with similar interoceptive properties, exposure to 
environmental stimuli that have become associated with drug-taking behaviour, and 
experiencing stress. Reinstatement of extinguished MA-seeking behaviour has been 
demonstrated with each method. Preclinical studies on reinstatement of drug-seeking 
have confirmed clinical observations – that drug priming, or a single exposure to the 
relevant drug of abuse (e.g. the one draw on a MA pipe that precipitates a full binge), 
is the most potent trigger of relapse and drug-seeking behaviour (Adinoff, 2004). For 
the purposes of investigating the factors involved in reinstatement of drug-seeking 
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behaviour and which neural mechanisms are implicated, the reinstatement model 
arguably represents the most valid animal model of drug abuse relapse (Kalivas & 
McFarland, 2003). Studying reinstatement of drug-seeking behaviour using the 
between session paradigm can provide important information on the functional state 
of the neurobiological mechanisms involved in relapse at a time that may be beyond 
any effects of drug withdrawal, or short-term (e.g. 48 hrs) changes in those 
mechanisms, and when the animal is free of self-administered drug (Shalev, et al., 
2002). Thus, the reinstatement paradigm can be used to investigate one of the 
greatest obstacles to successful treatment of drug abuse and dependence.  
5.1 Dopamine and drug-seeking 
Relapse to drug abuse in humans, and reinstatement of drug-seeking in 
laboratory animals can be produced by presentation of drug-associated cues, 
exposure to stress, and by exposure to the drug itself (Katz & Higgins, 2003; Self, 
1998; Self & Nestler, 1998; Shaham, et al., 2003; Shalev, et al., 2002). Findings 
from studies using animal models of drug-seeking suggest relapse triggered by stress, 
drug-cues, and drug-priming are mediated by distinct neurochemical circuits, but 
converge on a final common pathway through dopaminergic systems (Kalivas & 
McFarland, 2003; Self, 1998; Stewart, 1984). For instance, during tests of drug-
seeking controlled by cocaine-associated cues, there were marked increases in 
dialysate DA levels in dorsal striatum (Ito, Dalley, Robbins, & Everitt, 2002), NAc, 
and amygdala (Weiss, et al., 2000). Correspondingly, cue-controlled drug-seeking 
under a second-order schedule was attenuated by local infusions of the non-selective 
DA antagonist, α-flupenthixol, into the dorsal Str (Vanderschuren, Di Ciano, & 
Everitt, 2005). In the reinstatement paradigm, drug-seeking triggered by drug-
associated cues was reduced by inhibition of midbrain (SN and VTA), and dorsal Str 
DA regions by local infusions of GABA agonists (baclofen + muscimol; See, Elliott, 
& Feltenstein, 2007), and by unilateral lesion of the DA rich NAc core and infusion 
of α-flupenthixol into the contralateral dorsal Str (Belin & Everitt, 2008). Further 
evidence for the involvement of the dopaminergic system in drug cue-produced 
reinstatement has been suggested by altered drug-seeking behaviour following pre-
treatment with DA agonists and antagonists selective for either D1- and/or D2-like 
receptors. For instance, cocaine-seeking reinstated by response-contingent 
presentation of a light + tone stimulus complex previously paired with cocaine 
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infusions was attenuated by pre-treatment with the direct D1 agonist, SKF 81297, 
and D1-like antagonist, SCH 23390 (Alleweireldt, Weber, Kirschner, Bullock, & 
Neisewander, 2002). Drug-cue produced heroin-seeking was also attenuated by both 
systemic and intra-NAc shell injections of SCH 23390 (Bossert, Poles, Ihbey, Koya, 
& Shaham, 2007). In addition, nicotine-seeking triggered by drug-associated cues 
was attenuated by pre-treatment with SCH 23390, and the D2-like antagonist, 
eticlopride (Liu, et al., 2010). Together, these findings indicate an important role for 
DA and D1- and D2-like receptor mechanisms in reinstatement of drug-seeking 
behaviour triggered by stimuli previously associated with drug-taking.  
Stress-induced relapse has been most often demonstrated in laboratory 
animals using a brief period of mild intermittent electric foot-shock, but has also 
been induced pharmacologically. For instance, previously extinguished MA-seeking 
behaviour was produced in rats by five minutes of intermittent (0.5 sec ON, mean 
OFF period of 40 sec, range 10-70 sec), inescapable, electric foot-shock (0.4, 0.6 
mA), delivered through a scrambler to the grid floor of the operant chambers 
(Shepard, et al., 2004).  Reinstatement of MA- (Shepard, et al., 2004) and cocaine-
seeking (Anker & Carroll, 2010) was also produced following systemic injections of 
the anxiogenic drug, yohimbine. Stress-induced reinstatement is mediated through 
dissimilar neurobiological pathways to drug- and cue-induced reinstatement (Kalivas 
& McFarland, 2003; Stewart, 2000),  but some studies have suggested the 
dopaminergic system may modulate this behaviour (Self, 1998; Shalev, et al., 2002). 
Indeed, pre-treatment with α-flupenthixol attenuated foot-shock induced heroin-
seeking (Shaham & Stewart, 1996). The PFC has also been implicated as infusions 
of SCH 23390 directly into the prelimbic cortex or obitofrontal cortex blocked foot-
shock-induced reinstatement of cocaine-seeking (Capriles, 2003). Conversely, 
selective antagonism of D1- or D2-like receptor mechanisms by systemic pre-
treatment with SCH 23390 or raclopride, had no significant effect on foot-shock 
induced reinstatement of heroin-seeking, but attenuated drug-primed reinstatement 
of heroin-seeking behaviour (Shaham & Stewart, 1996). Together, these findings 
indicate a secondary/indirect role of DA in foot-shock stress-induced reinstatement 
of drug-seeking (Shalev, et al., 2002). 
Drugs of abuse, across the pharmacological classes, have different primary 
sites of action, and psychostimulants increase synaptic levels of all the monoamines 
(DA, 5-HT, NE), but drug-primed reinstatement of drug-seeking appears to be 
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primarily mediated through dopaminergic mechanisms (Self, 1998, 2004b; Self & 
Nestler, 1998; Shaham, et al., 2003; Stewart, 1983, 2000). For instance, cocaine is a 
non-selective biogenic monoamine transporter inhibitor that binds with higher 
affinity to the SERT, than DAT or NET (Julien, 2001; Ritz, Cone, & Kuhar, 1990). 
Following extinguished cocaine self-administration, priming-injections of the DAT 
inhibitor, GBR 12909, but not the NET inhibitor, nisoxetine, nor the SERT inhibitor, 
fluoxetine, dose-dependently reinstated cocaine-seeking behaviour (H. D. Schmidt 
& Pierce, 2006). Infusions of morphine directly into the VTA reinstated previously 
extinguished cocaine- and heroin-seeking behaviour (Stewart, 1984), suggesting that 
DA activity in this region may facilitate the priming effects of both psychostimulants 
and opiates (Stewart, 1983). Further, intra-NAc shell injections of the DA antagonist, 
α-flupenthixol, attenuated GBR 12909-induced reinstatement of cocaine-seeking, 
suggesting a primary dopaminergic contribution to this behaviour (H. D. Schmidt & 
Pierce, 2006). Extinguished drug-seeking in rats previously trained to self-
administer heroin was also reinstated by priming-injections of GBR 12909 (De Vries, 
Schoffelmeer, Binnekade, Raasø, & Vanderschuren, 2002), and DA receptor 
antagonists attenuated drug-seeking produced by heroin priming-injections (Shaham 
& Stewart, 1996). Together, these findings suggest that an increase in extracellular 
DA, specifically in the NAc shell, is both necessary and sufficient for drug-induced 
relapse to psychostimulant- and opiate-seeking behaviour.  
Further evidence for the role of DA in drug-primed reinstatement of drug-
seeking comes from studies showing significant effects on this behaviour following 
selective pharmacological manipulation of D1- and D2-like receptor mechanisms. 
Although direct D1 and D2 agonists are both self-administered (Grech, et al., 1996; 
Ikemoto, et al., 1997; Self, Belluzzi, et al., 1996; Weed & Woolverton, 1995; Wise, 
et al., 1990), and pharmacological manipulations of D1- and D2-like receptor 
mechanisms produced similar effects on measures of drug-taking reinforced 
according to FR and PR schedules of reinforcement (Bari & Pierce, 2005; Barrett, et 
al., 2004; Brennan, et al., 2009; Brennan, Lake, et al., 2007; Caine, et al., 1995; 
Caine & Koob, 1994; Caine, et al., 1999; Daniela, et al., 2004), they may mediate 
qualitatively different aspects of drug-seeking (responding maintained in the absence 
of drug-reinforcement). Studies using the self-administration reinstatement model of 
relapse (de Wit & Stewart, 1981) have indicated that D1-like receptors may play a 
facilitative, or permissive, role in mediating the effects of D2-like receptor 
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stimulation on relapse to drug-seeking (Bergman, et al., 1990; Missale, et al., 1998; 
Phillips, et al., 1994; Self, Barnhart, Lehman, & Nestler, 1996). For instance, 
selective stimulation of D2 receptors has reinstated cocaine- (De Vries, et al., 2002; 
De Vries, Schoffelmeer, Binnekade, & Vanderschuren, 1999; Dias, Lachize, Boilet, 
Huitelec, & Cador, 2004; Khroyan, Barrett-Larimore, Rowlett, & Spealman, 2000; 
Self, Barnhart, et al., 1996), MDMA- (Schenk, et al., 2011) and heroin-seeking (De 
Vries, et al., 2002; De Vries, et al., 1999; Wise, et al., 1990). Conversely, selective 
stimulation of D1 receptors failed to reinstate these behaviours (De Vries, et al., 
1999; Dias, et al., 2004; Khroyan, et al., 2000; Schenk, et al., 2011; Self, Barnhart, et 
al., 1996), suggesting that D2 receptors play a primary role in inducing drug-seeking 
behaviour (Self, 2004b). Blockade of either D1- or D2-like receptor mechanisms, on 
the other hand, attenuated reinstatement of cocaine- (Alleweireldt, et al., 2002; 
Anderson, Bari, & Pierce, 2003; Capriles, 2003; Green & Schenk, 2002; Khroyan, et 
al., 2000; Khroyan, Platt, Rowlett, & Spealman, 2003; Milivojevič, Krisch, Sket, & 
Živin, 2004; Schenk & Gittings, 2003), heroin- (Bossert, et al., 2007; Shaham & 
Stewart, 1996), MDMA- (Schenk, et al., 2011), and nicotine-seeking behaviour (Liu, 
et al., 2010). Thus, because drug-seeking was produced by direct D2 agonists, but 
not by direct D1 agonists, and was attenuated by both selective D1- and D2-like 
antagonists, these findings suggest that stimulation of D1-like receptors alone is 
insufficient for reinstatement of drug-seeking, but may be necessary in enabling D2-
like receptor mediation of this behaviour. That is, D1-like receptor activation may 
play a permissive role in the expression of drug-seeking behaviour mediated by 
stimulation of D2-like receptor mechanisms. 
Reinstatement of extinguished MA self-administration in laboratory animals 
has been reliably demonstrated, and the dopaminergic system has been implicated in 
this behaviour, but compared to other drugs of abuse there is a relative paucity of 
studies on dopaminergic mechanisms of reinstatement of MA-seeking behaviour. 
Following extinguished MA self-administration (0.05 mg/kg/infusion) reinforced 
according to a FR2 schedule, MA-seeking was produced by a priming injection of 
MA (1 mg/kg, IP; Higley, et al., 2011). Pre-treatment with the DA D3 receptor 
antagonist, SB-277011A, significantly attenuated MA-seeking, suggesting that this 
behaviour can be altered through selective pharmacological manipulation of the 
dopaminergic system. Further, reinstatement of MA-seeking produced by MA-
associated cues, and MA-priming injections was attenuated following pre-treatment 
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with (−)-BPAP, a catecholaminergic enhancer, providing additional support for the 
idea of a dopaminergic mechanism of reinstatement of MA-seeking behaviour  
(Hiranita, et al., 2010). A wealth of research with other drugs of abuse has suggested 
crucial roles for both D1- and D2-like receptor mechanisms in the reinstatement of 
drug-seeking behaviour. The contributions of DA D1- and D2-like receptor 
mechanisms underlying reinstatement of MA-seeking, however, have yet to be 
further investigated. 
6 Summary and the present study 
Drug self-administration is an excellent tool for furthering our understanding 
of the neurobiological mechanisms of drug abuse and dependence. Self-
administration paradigms and the schedule of reinforcement they employ must be 
tailored, however, to accurately reflect the aspect of drug abuse that is under 
investigation – no single paradigm can answer all questions relevant to the study of 
drug abuse and dependence. Much research into the neurobiological mechanisms of 
drug self-administration has suggested that the dopaminergic system is crucial to the 
initiation of drug use, the transition to compulsive abuse and dependence, and to the 
maintaining cycle of drug-craving and relapse to drug abuse. The dopaminergic 
system also appears especially vulnerable to the neurotoxic effects of MA exposure, 
producing potentially debilitating functional deficits (Barr, et al., 2006; Camp, et al., 
1994; Fischer & Cho, 1979; Fischman & Schuster, 1974; Friedman, et al., 1998; 
NIDA, 2006; Tziortzis, Mahoney Iii, Kalechstein, Newton, & La Garza Ii, 2011; 
Volkow, et al., 2001). The majority of research into the potentially neurotoxic 
effects of MA, however, has utilized non-contingent exposure protocols, limiting the 
interpretation of MA-produced neuroadaptations following voluntary self-
administration. Studying the effects of repeated exposure to self-administered MA in 
laboratory animals can ameliorate these contingency issues.  
Like many other drugs of abuse, MA facilitates DA neurotransmission in 
terminal brain regions that comprise the mesocorticolimbic and nigrostriatal DA 
pathways (Barr, et al., 2006; Baumann, et al., 2002; Camp, et al., 1994; Cruickshank 
& Dyer, 2009; Julien, 2001). A great deal of research supports the idea that this 
effect is critical to drug self-administration. For example, DAT inhibitors, and direct 
D1 and D2 receptor agonists are self-administered (Grech, et al., 1996; Roberts, 
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1993; Weed & Woolverton, 1995), and pharmacological blockade of the DAT 
decreased self-administration (Barrett, et al., 2004). Further, pre-treatment with D1- 
and D2-like antagonists reduced BPs produced by drugs of abuse, and increased 
self-administration under FR schedules of reinforcement (Anderson, et al., 2003; 
Barrett, et al., 2004; Caine & Koob, 1994; Caine, et al., 2002). This suggests that 
DA D1- and D2-like receptor mechanisms mediate the preliminary positive 
reinforcement necessary for the initiation and maintenance of drug self-
administration, the reinforcing efficacy of the self-administered drug and incentive 
motivation for further drug-taking.  
As an animal model of relapse to drug abuse, the reinstatement model of 
drug-seeking (de Wit & Stewart, 1981) has indicated important roles for D1- and 
D2-like receptor mechanisms in this behaviour. Specifically, selective 
pharmacological blockade of D1- and D2-like receptors attenuated reinstatement of 
drug-seeking; and selective stimulation of D2 receptors reinstated drug-seeking 
behaviour (Self, 1998, 2004b; Self & Nestler, 1998; Shaham, et al., 2003; Shaham & 
Stewart, 1996; Stewart, 2000). 
Considering the epidemiologic status of MA abuse and dependence here in 
New Zealand, but also worldwide, there is a relative paucity of studies investigating 
the neurobiological mechanisms of MA self-administration. The vast majority of 
laboratory studies on the effect of pharmacological manipulation of DA receptors on 
psychostimulant self-administration have focused on cocaine as the drug of interest. 
Dopaminergic mechanisms of MA self-administration and reinstatement of MA-
seeking, specifically those mediated by D1- and D2-like receptor mechanisms, are 
less clear, and have yet to be thoroughly investigated. This warrants further analysis, 
as although cocaine and MA induce similar behavioural responses, they evoke 
different effects at the neurochemical level depending on the brain region 
studied(Camp, et al., 1994), duration of drug treatment (Y. Zhang, et al., 2001), and 
produce different subjective and cardiovascular effects in humans (Newton, et al., 
2005). In addition, divergent neuroadaptations following self-administration of 
cocaine vs. MA suggest that the effects of D1- and D2-like receptor manipulations 
might not extrapolate to MA self-administration. Specifically, rats exposed to self-
administered MA showed extensive reductions in D1- and D2-like receptor binding 
densities in the VTA and SN (Stefanski, et al., 1999). These neuroadaptations were 
not evident following exposure to self-administered cocaine under similar protocols 
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(Stefanski, et al., 2007). This raises the possibility that pharmacological 
manipulation of D1- and D2-like receptor mechanisms may have different effects on 
self-administration of MA.  
The aim of the present study was, therefore, to investigate the 
neurobiological mechanisms of MA self-administration, focusing on the 
dopaminergic system, and to determine the extent of any functional D1- and/or D2-
like receptor mechanism neuroadaptations at short (24 hr) or longer (72 hr – 7 day) 
withdrawal times. The following set of experiments aims to firstly determine the 
effect of exposure to chronically self-administered MA on dopaminergic and 
serotonergic markers of nerve terminal degeneration in the Str and FC, using high 
performance liquid chromatography (HPLC) with neurochemical detection. Any 
potential for neurochemical recovery will be assessed following a short (24 hr) and 
long (7 day) withdrawal period. In addition, the effect of contingency on these 
measures will be determined using a yoked model of self-administration. Because 
any potential DA reductions following MA self-administration may affect the 
response to manipulations of DA D1- and D2-like receptor mechanisms, the findings 
from this study will provide an indication of the functional status of the DA system 
during maintenance and reinstatement of MA self-administration in later 
experiments.  
Secondly, as neuroadaptations may take place throughout the dopaminergic 
system over the course of chronic drug abuse, it may be expected that D1- and D2-
like receptor mechanisms make differential contributions to MA self-administration 
throughout the course of drug abuse. Assessing different aspects of MA self-
administration with different schedules of reinforcement (FR vs. PR) and at different 
stages of MA abuse (maintenance vs. relapse) may provide a functional indication of 
the involvement of D1- and D2-like receptor mechanisms in this behaviour. To 
achieve this, the contribution of DA D1- vs. D2-like receptor mechanisms to the 
maintenance of MA self-administration will be determined under a schedule of 
continuous reinforcement (FR1) by pharmacological manipulation of these receptors. 
Further, D1- and D2-like receptor mediated mechanisms of the incentive motivation 
for MA reinforcement, and changes in the reinforcing efficacy of MA, will be 
determined by changes in BPs on a PR schedule of reinforcement following pre-
treatment with D1- and D2-like antagonists. Using both a FR and PR schedule of 
reinforcement will provide greater convergent validity indicating that behavioural 
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differences between manipulations likely reflect neuroadaptations as a function of 
MA self-administration, as opposed to procedural differences between each schedule. 
Assessing the effects of acute pre-treatment with a DA D1- or D2-like receptor 
antagonist on MA self-administration reinforced according to a FR and PR schedule 
will provide a functional assay of these receptor mechanisms complementing any 
neurochemical findings at the short withdrawal period obtained in the first 
experiment.  
Finally, the contribution of DA D1- and D2-like receptor mechanisms to 
relapse to MA abuse will be investigated through pharmacological manipulation of 
these receptor systems and the consequent effects on reinstatement of extinguished 
MA-seeking. Because the state of the dopaminergic system may be different during 
drug exposure as opposed to following abstinence, it may be expected that DA D1- 
and D2-like receptor mechanisms would contribute differentially to MA self-
administration at different stages (maintenance vs. relapse). Using the between-
session method of the reinstatement paradigm will allow a test of the contribution of 
these receptor mechanisms to this behaviour at a time when the animal is free of 
self-administered drug, providing further functional evaluation of these receptor 
mechanisms in the light of any neurochemical findings at the long withdrawal period 
from the first experiment.  
The first experiment examining changes in neurotransmitter tissue content as 
a function of MA self-administration at short (24 hrs) and long (7 days) withdrawal 
times will provide an important indication of the general neurochemical status of the 
dopaminergic system at these times. The findings from this experiment may then be 
complemented by functional assays of the dopaminergic system at different 
withdrawal times by acute selective pharmacological manipulation of D1- and D2-
like receptor mechanisms and the effects of this on MA self-administration, and on 
MA-seeking behaviour. The neurochemical findings at the short withdrawal time in 
the first study will be complemented by a functional assessment of DA D1- and D2-
like receptor mechanisms in MA self-administration at the same withdrawal time on 
an FR1 and PR schedule of reinforcement. The neurochemical findings at the long 
withdrawal time in the first study can then be complemented by a functional 
assessment of DA D1- and D2-like receptor mechanisms in the reinstatement of 
extinguished MA-seeking behaviour in the reinstatement paradigm.  
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General Methods 
7 Subjects 
Adult male Sprague-Dawley rats weighing approximately 300-350 g rats 
were used for all self-administration experiments. All rats were bred in the vivarium 
at Victoria University of Wellington and were housed in groups of four from 
weaning until they reached appropriate weights. They were then individually housed 
in standard polycarbonate cages in a temperature (21° C)- and humidity (77%)-
controlled room, and handled each day, three days prior to surgery. The colony was 
maintained on a 12-hr light/dark cycle (lights on at 0700), and all testing was 
conducted during the light portion of the cycle, beginning at 1400. Food and water 
were available ad libitum, except during testing. The colony was accredited by the 
Office of Laboratory Animal Welfare (OLAW), and principles of laboratory animal 
care were adhered to (NIH publication NO. 85-23, rev. 1985). All experimental 
procedures were approved by the Victoria University Animal Ethics Committee. 
8 Apparatus 
Self-administration training and testing were carried out in operant chambers 
(Med Associates, ENV 001, Georgia, Vermont, USA), enclosed in sound attenuating 
boxes. Each chamber had a plexiglass door, rear wall and ceiling; the lever mounted, 
and opposite wall were stainless steel; while the floor was grilled bars over a 
woodchip catch tray. The ceiling of each chamber had a hole in the centre to allow 
the passing of microbore tubing connected to a 20 ml syringe in an automatic pump 
(Razel Model A, 1 rpm motor, Georgia, Vermont, USA) into the chamber. Each 
chamber contained two levers and a stimulus light located above the right lever. 
Depression of the right lever (“active lever”) resulted in a 0.1 ml infusion delivered 
over 12 sec. Coincident with drug delivery was the illumination of the stimulus light 
located above the active lever, for the duration of the infusion. Depressions of the 
left lever (“inactive lever”) were recorded, but were without programmed 
consequence. Drug delivery and data recording were controlled by an interfaced 
microcomputer utilizing Med Associates software.  
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9 Procedures 
9.1 Surgery 
Catheters were constructed in-house using silastic tubing (0.51 mm [inner 
diameter] x 0.94 mm [outer diameter]) and a steel tip crafted from a 22 gauge 
needle. Silicon was applied to the join between tubing and steel tip, and to the 
proximal end of the catheter to be inserted into the vein to protect the tubing from 
any corrosion by superglue. Rats were implanted with chronic indwelling jugular 
vein catheters under deep anaesthesia produced by separate injections of xylazine (5 
mg/kg, IP) and ketamine (75 mg/kg, IP) given in their home cage. Anaesthesia was 
ascertained by foot pinch. Rats were then moved to the surgical suite, injected with 
the anti-inflammatory Carprofen® (5 mg/kg, SC, Pfizer Animal Health), their chests 
were shaved and cleaned with 85% ethanol, and iodine, and Lacrilube® was applied 
to their eyes to prevent drying out. A small incision was made in the chest and the 
right external jugular vein was isolated and tied off using surgical thread. Another 
incision was made on the top of the head from between the eyes to between the ears, 
the underlying tissue was removed using a scalpel blade to expose the skull, a 
topical antibiotic was applied, and the catheter was passed subcutaneously from this 
incision to the chest incision. A small cut was made in the jugular vein; the catheter 
was inserted and secured in place using surgical thread and super glue. The chest 
incision was closed with super glue and a topical antibiotic was applied. The rat was 
then placed in a stereotaxic and the steel-tipped distal end of the catheter was 
secured to the skull using acrylic dental cement adhered to four small jeweller‟s 
screws imbedded in the skull. Following surgery, Hartmann‟s sodium lactate 
solution (6ml each side of hindquarters, SC) was administered to replenish bodily 
fluids and electrolytes. Rats were then placed in a warmed recovery tray until the 
anaesthesia wore off, and finally returned to their home cage. 
Carprofen® (5 mg/kg, SC) was administered on each of the two days 
following surgery. During each of the five days comprising the recovery period, rats 
were weighed, and catheters were flushed with 0.1 ml of sterile 0.9% saline solution, 
containing heparin (30 IU/ml) and penicillin G potassium (250,000 IU/ml). At the 
start of the testing period, and every seven days thereafter, catheter patency was 
tested with a 0.1 ml infusion of sodium pentobarbital (5.0 mg/kg, IV). Catheter 
patency was confirmed by loss of the righting reflex within 5 sec. If catheter patency 
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was lost, a second catheter was inserted into the left jugular vein as described above 
and the rat was given a minimum of three days recovery time, during which no 
testing was conducted.  
9.2 Daily self-administration 
Training and experimental testing was conducted five days per week, 
Monday to Friday, during two hour daily sessions. At the start of each experimental 
session, the catheters were flushed with 0.2 ml of the 30 UI/ml heparin/penicillin 
solution. Immediately prior to each experimental session, rats were transferred from 
their home cages to the humidity (55%) and temperature (21ºC) controlled 
experimental room in a woodchip littered plastic carry box. The steel tip of each 
catheter was attached to the microbore tubing in the chamber connected to a 20 ml 
syringe in an automatic pump. The session began with an experimenter-delivered 
response on the active lever to clear the line of the heparin solution. Following each 
infusion there was a 30 sec timeout (TO) period during which responding on the 
active lever was without consequence. At the end of each self-administration 
session, catheters were again flushed with 0.2 ml of the 30 UI/ml heparin/penicillin 
solution, followed by 0.1 ml of a 30 IU/ml heparinised saline 0.9% solution 
containing 8000 IU/ml streptokinase to prevent the formation of fibroids. Rats were 
then returned to their home cages in the woodchip littered plastic carry box.  
9.3 Acquisition of self-administration 
During training, MA (0.1 mg/kg/infusion) was self-administered according to 
a FR1 schedule of reinforcement during daily two hour sessions. This dose was 
based on our preliminary work and that of other studies showing reliable self-
administration (Shelton & Beardsley, 2008; Stefanski, et al., 1999). Self-
administration was considered acquired when 1) there were at least 10 infusions 
earned per session; 2) the ratio of active lever to inactive lever presses during a 
session was at least 2:1; and 3) these criteria were met for at least three consecutive 
days with less than 20% variation in number of active lever responses.  
10 Drugs 
MA hydrochloride (ESR, Porirua, New Zealand) was dissolved in a 0.9% 
saline solution and administered via IP injection at a volume of 1 ml/kg, for acute 
dosing. For self-administration experiments, MA was dissolved in a 0.9% saline 
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solution containing 3 IU/ml heparin, and IV infusions were delivered in a volume of 
0.1 ml. All drug doses refer to the weight of the salt. 
11 Statistical analyses 
All analyses were conducted using the SPSS statistical package v.18, for 
Microsoft Windows. Specific analyses and experimental sample sizes are detailed in 
their relevant chapters and on figures.  
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Chapter 1: Effects of MA self-administration on 
monoamine and metabolite tissue concentrations 
12 Overview 
The aim of Chapter 1 was to investigate the effects of MA exposure on tissue 
levels of monoamines and metabolites and to determine whether the effects were 
persistent or transient. This was achieved using a typical experimenter-administered 
regime as well as a yoked method of self-administration which allowed effects of 
contingency to be dissociated from effects of experimenter-administered MA.  
An experimenter-administered exposure regime that has previously been 
shown to produce deficits in tissue levels of monoamines and neurotoxic effects 
(Chapman, Hanson, Kesner, & Keefe, 2001; Herring, et al., 2008; Quinton & 
Yamamoto, 2006) was administered. This treatment regime produced significant 
decreases in tissue levels of monoamines 24 hours (Pubill, et al., 2003), three days 
(Herring, et al., 2008), one week (Quinton & Yamamoto, 2006), three weeks 
(Chapman, et al., 2001) and seven weeks (Friedman, et al., 1998) following the last 
MA injection. In the present study, brain levels of monoamines and their metabolites 
in the Str and FC were measured following a short (24 hour) and longer (seven day) 
withdrawal period to determine the persistence of any effects. This experiment was 
intended to verify that the neurotoxic effects produced by this regime persisted 
throughout the seven day withdrawal period. Thus, this experiment served as a 
positive control of MA-induced neurotoxicity, rather than as a direct comparison to 
the effects of self-administered MA-exposure.  
The experimenter-administered regime comprising a series of acute, high 
dose injections administered to drug-naïve rats does not, however, reflect a typical 
exposure pattern of MA users (Cho, et al., 2001), and  several studies have suggested 
that differential neuroadaptations are produced when the drug is self-administered as 
opposed to when it is passively administered (Dworkin, et al., 1995; Jacobs, et al., 
2003; Stefanski, et al., 2004; Stefanski, et al., 1999; Stefanski, Lee, Yasar, Cadet, & 
Goldberg, 2002; Stefanski, et al., 2007). Drug self-administration in laboratory 
animals has substantial face and construct validity with regard to human drug-taking 
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behaviour (Gardner, 2008; Sanchis-Segura & Spanagel, 2006). Thus, drug self-
administration is a valid means of studying the effects of MA dependence on the 
brain (Stephens, et al., 2010). Therefore, the effects of self-administered MA-
exposure on tissue levels of monoamines and metabolites, comparing short and 
longer withdrawal times were investigated.  
A self-administration protocol that has previously shown effects of self-
administered MA on markers of DA neurotransmission was used (Stefanski, et al., 
1999). Because long-duration self-administration sessions may more accurately 
reflect effects of abuse (Kitamura, et al., 2006; Rogers, et al., 2008; Wee, et al., 
2007), acquisition of MA self-administration and response-escalation as a marker of 
dependence was examined in six hour sessions. Self-administration protocols similar 
to those reported by Stefanski (1999) produced smaller effects on the dopamine 
system (Schwendt, et al., 2009; Shepard, et al., 2006) than the more typical exposure 
regimens described above. Specifically, MA self-administration had no effect on 
DAT mRNA or TH protein levels in the VTA or substantia nigra, and no effect on 
striatal DA, or prefrontal 5-HT levels (Schwendt, et al., 2009). Self-administered 
MA produced decreases in DAT densities in both the striatum and prefrontal cortex, 
but no changes in typical markers of neurotoxicity (e.g. reduced TH levels, glial 
fibrillary acidic protein, calcium-binding adaptor molecule 1) in these regions 
(Schwendt, et al., 2009). 
These findings are consistent with the idea that MA self-administration does 
not produce the extensive neurochemical deficits and/or neurotoxicity seen 
following more stringent experimenter-administered treatment protocols. Tissue 
levels of monoamines were, however, only assessed at 14 days after the final MA 
self-administration session (Schwendt, et al., 2009). Most studies examining the 
effects of MA exposure on tissue levels of monoamines have assessed the effects at 
earlier withdrawal times, frequently 24 hours after the final MA exposure (Danaceau, 
et al., 2007; Graham, Noailles, & Cadet, 2008; O'Neil, et al., 2006; Shepard, et al., 
2006; Stefanski, et al., 1999). Assays conducted 24 hours and seven days following 
the final MA self-administration session will provide a comparison to other studies 
and may reveal changes in tissue level of monoamines produced selectively by MA 
self-administration.  
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12.1 Contingency of drug exposure 
High dose or repeated exposure to lower doses of MA produced 
neurotoxicity and neuroadaptations in dopaminergic and serotonergic neurons (Eisch, 
Schmued, & Marshall, 1998; Herring, et al., 2008; O'Dell & Marshall, 2005; Pubill, 
et al., 2003; Ricaurte, Guillery, Seiden, Schuster, & Moore, 1982; Sharma & 
Kiyatkin, 2009) and extensive decreases in DA and 5-HT across several brain 
regions (Quinton & Yamamoto, 2006). The striatum appears particularly susceptible 
to MA-induced decreases in DA and its metabolites (Bakit, et al., 1974; Chu, et al., 
2008; Friedman, et al., 1998; Thomas, Francescutti-Verbeem, & Kuhn, 2008; 
Wagner, et al., 1980). High dose MA administration also reduced 5-HT levels in the 
frontal cortex and hippocampus of rats (Graham, et al., 2008; Herring, et al., 2008). 
Because this exposure regime might not reflect effects produced in MA users (Cho, 
et al., 2001), however, several studies have attempted to more adequately model MA 
dependence. Methods include chronic exposure via osmotic minipumps (Davidson, 
et al., 2005), escalating dosing (ED) procedures (Cadet, et al., 2009; Graham, et al., 
2008; Segal, et al., 2003), pharmacokinetic modelling (Cho, et al., 2001; Herring, et 
al., 2008), and IV self-administration (Schwendt, et al., 2009; Shepard, et al., 2006; 
Stefanski, et al., 2004; Stefanski, et al., 1999; Stefanski, et al., 2002). 
ED and pharmacokinetic modelling might provide accurate approximations 
of dose and pattern of administration by MA users, but both paradigms require non-
contingent administration. Several studies have suggested that effects of drug 
exposure are dependent on the contingency of that exposure, and that differential 
neuroadaptations are produced when the drug is passively administered, rather than 
self-administered (Dworkin, et al., 1995; Jacobs, et al., 2003; Stefanski, et al., 2004; 
Stefanski, et al., 1999; Stefanski, et al., 2002; Stefanski, et al., 2007). For instance, 
in vivo microdialysis procedures showed greater levels of extracellular DA 
concentrations in the NAc during cocaine self-administration compared to during 
yoked cocaine delivery (Hemby, et al., 1997). As measured by in vitro quantitative 
autoradiography, five weeks of self-administered MA exposure produced a 
significant reduction in DA D1- (15% in NAc) and D2-like (34% in VTA; 31% in 
medial SN; 21% in dorsal SN) receptor levels, 24 hours post final MA self-
administration session (Stefanski, et al., 1999). No significant changes were reported 
on these measures following passive, yoked MA infusions (Stefanski, et al., 1999). 
Self-administered cocaine did not produce similar changes in DA D2-like receptor 
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densities. Rather, there was an increase in D2 receptor mRNA following cocaine 
self-administration, and a decrease in D2-like receptor densities following passive 
infusions, further emphasising the differential neurochemical consequences of 
passive administration versus active self-administration (Stefanski, et al., 2007). The 
changes in DA receptor density produced by self-administered MA exposure were 
transient (Stefanski, et al., 1999), and returned to control levels seven days following 
the final MA self-administration session (Stefanski, et al., 2002). Self-administered 
MA also failed to produce significant changes in striatal DA or prefrontal cortex 5-
HT tissue levels when measured following 14 days withdrawal (Schwendt, et al., 
2009). This finding is in contrast to the persistent neurochemical changes seen 
following experimenter-administered treatment regimes that have shown persistent 
reductions in DA levels at 3 weeks following the final MA treatment (Chapman, et 
al., 2001; Friedman, et al., 1998). 
A „yoked‟ procedure of drug self-administration allows one to differentiate 
neuroadaptations that are produced by the pharmacological effects of the drug alone 
from those that are involved, additionally, in active drug self-administration 
behaviour. Animals are grouped into triads; one self-administers the drug (response 
contingent; CM) and the two others receive either drug (yoked MA; YM) or vehicle 
(yoked vehicle; YV) infusions according to the behaviour of the self-administering 
subject. Figure 5 illustrates the basic mechanics of yoked drug self-administration.  
 
Figure 4. Triadic yoked MA self-administration. Contingent MA (CM; left) is delivered according to 
operant responding. Yoked MA (YM; centre) is delivered on the same frequency and pattern to the yoked 
rat dependent on responding of the rat receiving CM. Yoked vehicle (YV; right) infusions are delivered to 
the second yoked rat also dependent on CM delivery. A computer controlled syringe pump delivers all 
CM, YM and YV infusions. Image adapted from Haracz, Mash and Sircar (1999). 
By using a yoked method of drug self-administration, it is possible to 
distinguish between two types of drug-induced neuroadaptations: the 
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neurobiological consequences of drug exposure can be measured following YM 
exposure; compared to the effects involved in active drug self-administration 
behaviour, in addition to the pharmacological effects of the drug, measured 
following CM exposure; which can both be compared to any purely procedural 
effects following YV exposure.  
The present study investigated the effects of MA self-administration on 
striatal DA and prefrontal cortex 5-HT levels. A yoked-control procedure was used 
to compare the effects of self-administered and passively administered MA. It was 
hypothesized that any neurochemical deficits following chronic MA self-
administration would be less pronounced than those seen following previous studies 
that examined effects of experimenter-administered MA, and may show more rapid 
recovery. 
13 Subjects 
Male Sprague-Dawley rats weighing approximately 200-230g (n = 40) were 
used in the acute experiment (experiment 1), whereas larger 300-350g (n = 63) rats 
were used for self-administration experiments (experiment 2). Smaller rats were 
used in experiment 1 due to the high mortality rate of larger/older rats exposed to 
this treatment protocol (Xi, et al., 2009). Additionally, rats of a similar age and size 
to those used in experiment 1 were not suitable for experiment 2 as our laboratory 
has found that they do not recover as well following catheter implantation 
(unpublished observations). Rats in experiment 1 were housed in groups of three 
prior to MA treatment. On the MA treatment day, each rat was housed in an 
individual cage due to the possibility of MA facilitating defensive behaviour and 
attacks (Maeda, Sato, & Maki, 1985; Shintomi, 1975), and to minimize the effects of 
MA-produced hyperthermia (Askew, 1962). Individual housing conditions were 
maintained until brain tissue was harvested 24 hours, or seven days following 
treatment. Animals in experiment 2 were housed in groups of three to four prior to 
catheter implantation, and were then housed individually for the remainder of the 
experiment.  
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14 Experiment 1: MA self-administration 
14.1 Yoked methamphetamine self-administration 
Yoked rats were run in groups of three during a 20 day period. One rat in 
each triad self-administered MA on an FR1 schedule of reinforcement (CM). Each 
active lever press by the CM triggered an infusion of MA (YM) or heparinised 
(3UI/ml) saline 0.9% (YV). Daily self-administration sessions were six hours long. 
15 Experiment 2: Experimenter-administered MA regimen 
Intraperitoneal (IP) injections of either the saline 0.9% vehicle (n = 20) or 4 x 
10 mg/kg MA were administered in the home cage every two hours (n = 20). Four 
animals died following the MA exposure protocol, however, leaving a total of n = 16 
for this group.  
16 Neurochemical procedures 
16.1 Tissue extraction and preparation 
Rats were asphyxiated using C02, decapitated, and their brains were rapidly 
removed either 24 hours, or seven days following the final MA self-administration 
session. Brains were then placed in a stainless steel block for slicing into 1mm 
coronal sections (Heffner, Hartman, & Seiden, 1980) that were placed onto an ice-
chilled inverted petrie dish. The frontal cortex (FC; including prelimbic, cingulated 
and motor cortices) and striatum (Str; dorsal) were dissected out, immediately snap-
frozen by immersion in liquid nitrogen and weighed. These regions were assayed as 
previous studies have suggested they are susceptible to MA-induced neurotoxicity 
(Friedman, et al., 1998; Graham, et al., 2008; Herring, et al., 2008). Tissue samples 
were then stored at -80°C until further analyses were conducted. During storage, a 
Str sample from one control rat in the experimenter-administered group became 
compromised. Further, STR samples from one YV and one YM rat, and a FC sample 
from one YM rat in the self-administration groups became compromised. Data from 
these samples were excluded from analysis.  
16.2 Tissue analysis 
Tissue samples were homogenised in 0.1 N perchloric acid and centrifuged at 
10 000g for 30 mins at 4°C. The pellet was discarded, and the supernatant was 
filtered into vials. A 20 μl aliquot was injected into a high-pressure liquid 
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chromatography system with electrochemical detection (Agilent Eclipse EDB-C18, 
150 X 4.6 mm, 5 μm granulometry). The mobile phase (75 mM sodium dihydrogen 
phosphate, 1.7 mM octanesulphonic acid, 0.25 mM Na2EDTA, 100 μL/L 
triethylamine, 10% v/v acetonitrile, pH 3.0) was delivered at a constant flow rate of 
1.0 ml/min. Detection was performed using a coulometric detector (Coulochem III, 
ESA Inc., dual electrode detection cell, -175 and +400 mV; guard cell electrode, 
+450 mV). Detection limits were 28 pg for DA; 20 pg for 5-HT; 12 pg for HVA; and 
10 pg for 5-HIAA. Chromatograms were obtained using ChemStation software. 
Areas under the DA, 5-HT, HVA and 5-HIAA peaks for samples and for calibration 
standards were obtained. Concentrations of DA, 5-HT, HVA and 5-HIAA are 
expressed as ng/mg tissue, and were calculated according to the regression equations 
obtained with the calibration standards. Working external standards (500 – 15.125 
ng/ml in 0.1 N perchloric acid) were prepared fresh each day from external standard 
stock solutions.  
17 Statistical analyses 
The results from the experimenter-administered treatment regime were 
analyzed using 2 (condition: saline, MA) x 2 (withdrawal period: 24 hour, seven day) 
ANOVAs. Effects of withdrawal time were investigated using separate univariate 
ANOVAs.  
The results from the self-administration experiment were analyzed using 3 
(condition: CM, YM, YV) x 2 (withdrawal period: 24 hour, seven day) ANOVAs. 
Tukey‟s post-hoc analysis on effects of contingency was used when appropriate. 
Separate repeated measures ANOVAs (test day x lever) for each group (CM; YM; 
YV) were used to analyse differences in responding between active and inactive 
levers for the self-administration experiments. Separate univariate ANOVAs were 
used to determine significant differences between levers at each day. 
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18 Results 
18.1 Methamphetamine self-administration 
18.1.1 Yoked self-administration 
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Figure 5. Average number of responses (+SEM) on inactive and active levers for 0.1mg/kg/inf. MA during 
6-hour sessions over a 20 day period. A) The contingent MA group (CM; n = 16). B) The yoked MA group 
(YM; n = 16). C) The yoked vehicle group (YV; n = 16). *Significant difference between active and 
inactive levers (p < 0.05) 
Figure 5 (a: CM; b: YM; c: YC) shows the mean number of responses on the 
inactive and active levers during the 20 day self-administration period. The CM 
group rapidly acquired MA self-administration, as indicated by a preference for the 
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active lever, and active lever responding increased over the first 6 days (fig. 7a). A 
repeated measures ANOVA showed a main effect of lever [F(1, 30) = 52.81, p < 
0.0002], a main effect of day [F(19, 570) = 2.50, p = 0.00004], and an interaction 
between these factors [F(19, 570) = 1.96, p = 0.007]. Separate univariate ANOVAs 
revealed a significant difference between active and inactive levers from day 2 (p < 
0.05), with the exception of day 4. The YM group also showed a significant 
preference for the active lever [F(1, 30) = 6.39, p = 0.0351], but no effect of day 
[F(19, 532) = 0.92, p = 0.563], and no interaction between these factors [F(19, 570) 
= 0.72, p = 0.529]. Despite preferential responding on the active lever on some of 
the test days, the YM group did not fulfil criteria for MA self-administration 
acquisition because the preference for the active lever was erratic; separate 
univariate ANOVAs revealed that active lever preference was never maintained for 
three consecutive days (fig 7b). Finally, the YC group (fig. 7c) showed no 
preference for either lever [F(1, 30) = 0.44, p = 0.782]. There was a main effect of 
day [F(19, 570) = 5.50, p = 0.00078], but no interaction between these factors [F(19, 
570) = 1.15, p = 0.41]. 
18.2 Tissue concentrations of monoamines and metabolites 
18.2.1 Self-administered/yoked MA exposure 
ANOVA revealed that tissue levels of DA in the dorsal Str were reduced as a 
function of MA exposure, confirmed by a main effect of treatment group [F(2, 40) = 
7.34 , p = 0.002]. This reduction was transient and had returned to control levels by 
seven days, as demonstrated by a main effect of withdrawal period [F(1, 40) = 10.84, 
p = 0.002], but no interaction between these factors [F(2, 40) = 0.54, p = 0.586]. 
Tukey post-hoc tests showed no significant effect of contingency on striatal DA 
levels as CM and YM were not significantly different at either withdrawal period (p 
= 0.891). Because there was a main effect of withdrawal and treatment group, 
separate univariate ANOVAs were used to compare the CM and YM groups at both 
withdrawal times to the YV groups. Separate ANOVAs showed that DA levels in 
the CM [F(1, 14) = 5.486, p = 0.034], but not in the YM group [F(1, 14) = 3.324, p = 
0.09] were significantly reduced at 24 hours. The reduction in the CM group 
recovered over the withdrawal period, however, as there was no longer a significant 
difference from the YV group at seven days [F(1, 13) = 4.162, p = 0.062].  
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Self-administered and yoked exposure to MA did not alter tissue levels of 
HVA in the Str [F(2, 40) = 2.14, p = 0.131]. On the other hand, DA turnover was 
significantly increased in MA-exposed groups [F(2, 40) = 11.51, p = 0.000112], and 
there was a main effect of withdrawal [F(1, 40) = 6.94, p = 0.012], and an interaction 
between these factors [F(2, 40) = 4.99, p = 0.012]. Tukey‟s post hoc analysis showed 
no effect of contingency on DA turnover (p = 0.838). Because there was a main 
effect of withdrawal, separate ANOVAs were used to compare the CM and YM 
groups to YV groups. DA turnover was significantly elevated in both the CM [F(1, 
14) = 23.12, p = 0.00028] and YM [F(1, 14) = 20.86, p = 0.00048] groups at 24 
hours following the last self-administration session. This had returned to control 
levels at seven days, however, as neither CM [F(1, 13) = 1.71, p = 0.214], nor YM 
[F(1, 13) = 1.83, p = 0.201] groups were significantly different from YV groups.  
Tissue levels of 5-HT in the FC showed no effect of treatment group [F(2, 41) 
= 2.26, p = 0.118], or withdrawal time [F(1, 41) = 0.96, p = 0.333]. Equally, there 
were no significant effects of treatment group [F(2, 41) = 1.88, p = 0.166], or 
withdrawal time [F(1, 41) = 0.67, p = 0.417] on FC tissue levels of 5-HIAA, and no 
effect of treatment group [F(2, 41) = 2.14, p = 0.131], or withdrawal time [F(1, 41) = 
0.14, p = 0.713] on 5-HT turnover. Table 2 shows the effect of self-administered 
MA on tissue levels of DA, 5-HT and their respective metabolites in dorsal Str and 
FC for the contingent MA (CM), yoked MA (YM) and yoked vehicle group (YV). 
18.2.2 Experimenter-administered MA  
ANOVA (condition x withdrawal time) revealed that DA levels in the dorsal 
Str were significantly reduced in MA-exposed groups [F(1, 31) = 15.50, p = 
0.00045]. Effects at the 24 hour and seven day withdrawal periods were comparable 
and there was no significant effect of this variable [F(1, 31) = 2.80, p = 0.104], or an 
interaction between these factors [F(1, 31) = 0.25, p = 0.619]. ANOVA on tissue 
levels of homovanillic acid (HVA) failed to reveal an effect of condition [F(1, 31) = 
0.05, p = 0.822], withdrawal time [F(1, 31) = 0.20, p = 0.889], or an interaction 
between these factors [F(1, 31) = 0.62, p = 0.436]. DA turnover (HVA/DA) was, 
however, significantly increased in MA pre-treated groups, and there was a main 
effect of treatment group [F(1, 31) = 21.65, p = 0.00058], withdrawal time [F(1, 31) 
= 9.65, p < 0.004], and an interaction between these factors [F(1, 31) = 7.90, p < 
0.008]. Because there was a main effect of withdrawal, separate univariate ANOVAs 
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were used to compare the MA pre-treated groups at both withdrawal times to the 
saline pre-treated groups. ANOVA revealed that DA turnover was significantly 
elevated at the 24 hours [F(1, 16) = 19.215, p = 0.00046], but not the seven day 
withdrawal period [F(1, 15) = 3.431, p = 0.084].  
Analysis of tissue levels of 5-HT in the FC revealed a significant depletion 
among MA exposed groups [F(1, 32) = 5.47, p = 0.026], that was persistent as there 
was no effect of withdrawal period [F(1, 32) = 1.36, p = 0.252], and no interaction 
between these factors [F(1, 32) = 1.24, p = 0.274]. There were no effects on 5-
hydroxyindoleacetic acid (5-HIAA) as a function of treatment group [F(1, 32) = 3.14, 
p = 0.086], or withdrawal time [F(1, 32) = 2.20, p = 0.148], and no interaction 
between these factors [F(1, 32) = 2.94, p = 0.096]. There were also no effects on 5-
HT turnover (5-HIAA/5-HT) as a function of MA exposure [F(1, 32) = 0.18, p = 
0.675], or withdrawal time [F(1, 32) = 0.02, p = 0.885], nor an interaction between 
these factors [F(1, 32) = 4.09, p = 0.051]. Table 3 shows the effect of the high-dose 
treatment of MA on tissue levels of DA, 5-HT and their respective metabolites in 
dorsal Str, and FC, respectively, following either a 24 hour (MA24hr) or seven day 
(MA7day) drug-free period.  
 
 
 
  
 
Table 2. Average (±SEM) monoamine and metabolite levels (ng/mg tissue) for the yoked vehicle (YV) groups contingent MA (CM) groups, and yoked MA (YM) 
groups at 24 hours and seven days following final self-administration session. Symbols show a significant difference relative to YV group: *(p < 0.05); ‡ (p < 
0.001). 
Region   DA  HVA  HVA/DA 
  24 hours 7 days 24 hours 7 days 24 hours 7 days 
Striatum YV 15.55 ± 0.92 17.75 ± 0.97 1.01 ± 0.09 1.23 ± 0.08 0.06 ± 0.00 0.07 ± 0.00 
 CM 12.56 ± 0.89* 15.32 ± 0.72 1.27 ± 0.11 1.22 ± 0.07 0.10 ± 0.01‡ 0.08 ± 0.00 
 YM 13.74 ± 0.39 14.93 ± 0.47 1.43 ± 0.11 1.19 ± 0.10 0.10 ± 0.01‡ 0.08 ± 0.01 
   5-HT  5-HIAA  5-HIAA/5-HT 
  24 hours 7 days 24 hours 7 days 24 hours 7days 
Frontal Cortex YV 0.47 ± 0.03 0.52 ± 0.04 0.48 ± 0.04 0.46 ± 0.02 1.04 ± 0.09 0.91 ± 0.08 
 CM 0.41 ± 0.05 0.44 ± 0.01 0.42 ± 0.03 0.42 ± 0.03 1.12 ± 0.12 1.03 ± 0.06 
 YM 0.49 ± 0.03 0.49 ± 0.04 0.39 ± 0.02 0.44 ± 0.03 0.82 ± 0.04 0.95 ± 0.12 
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Table 3. Average (±SEM) monoamine and metabolite levels (ng/mg tissue) for the saline and methamphetamine (MA) pre-treated groups. Symbols show a 
significant difference relative to saline groups: *(p < 0.05); †(p < 0.01); ‡(p < 0.001). 
   DA  HVA  HVA/DA 
  24 hours 7 days 24 hours 7 days 24 hours 7 days 
Striatum Saline 11.85 ± 0.57 13.05 ± 0.65 1.14 ± 0.06 1.22 ± 0.07 0.10 ± 0.01 0.09 ± 0.00 
 MA 7.27 ± 1.83† 9.51 ± 0.83† 1.21 ± 0.23 1.09 ± 0.08 0.22 ± 0.03‡ 0.12 ± 0.02 
   5-HT  5-HIAA  5-HIAA/5-HT 
  24 hours 7 days 24 hours 7 days 24 hours 7days 
Frontal Cortex Saline 0.39 ± 0.01 0.40 ± 0.01 0.37 ± 0.02 0.44 ± 0.02 0.98 ± 0.08 1.14 ± 0.06 
 MA 0.33 ± 0.03* 0.37 ± 0.02* 0.37 ± 0.02 0.37 ± 0.03 1.19 ± 0.10 1.00 ± 0.10 
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19 Discussion 
19.1 Behavioural results 
19.1.1 Yoked self-administration tests 
MA self-administration was rapidly acquired by the contingent MA group 
(CM), as demonstrated by preferential responding on the active lever from day 2, 
and throughout the 20 day experiment, apart from day 4. The yoked MA group 
(YM) also showed a significant preference for the active lever. However, the 
preference was sporadic and never met the criteria for acquisition of self-
administration behaviour. CM and YM groups were exposed to a daily average of 4-
5 mg/kg MA. Our laboratory has previously demonstrated increased stereotypy and 
locomotor activity at doses of 2 mg/kg MA (Brennan, Johnstone, Fitzmaurice, Lea, 
& Schenk, 2007), suggesting the increased lever pressing in the YM group may 
reflect elevated general behaviour activation as a result of MA intoxication. 
However, this does not explain the preference for the active lever. Rather, this may 
be clarified by an association between the stimulus light paired with each drug 
infusion and the subjective drug effects. During the yoked experiment, whenever the 
CM responded on the active lever to deliver an infusion of MA, the stimulus light 
above this lever was illuminated in each chamber of the triad. This pairing between 
light illumination and drug infusion may have produced a conditioned drug-
association for the stimulus light, engendering approach behaviours in the YM 
toward the stimulus light and active lever (right corner of test chamber). Stereotyped 
head-bobbing (as observed upon video recording of the test chambers), produced by 
MA intoxication, in the right corner of the test chamber would produce the erratic, 
rather than focused, active lever presses. The MA-produced behavioural activation 
in concert with a conditioned preference for the right corner of the test chamber may 
explain the sporadic preference for the active lever. 
19.2 Neurochemical results 
19.2.1 Chronic self-administration exposure 
Self-administered MA produced transient decreases in striatal DA in addition 
to a transient increase in DA turnover. These findings are consistent with results 
from another study on the neurochemical effects of self-administered MA. 
75 
 
 
 
Decreased striatal and prefrontal cortex DAT densities, but no changes in striatal DA 
or prefrontal cortex 5-HT levels, or any changes in typical markers of neurotoxicity 
(e.g. tyrosine hydroxylase levels, loss of terminal fibres, silver staining, glial 
fibrillary acidic protein, or calcium-binding adaptor molecule 1 levels) were reported 
following a 14-day withdrawal period (Schwendt, et al., 2009). Longer session 
durations have produced more extensive reductions in monoamine tissue levels, as 
15 hours of access to self-administered MA for eight days, produced persistent 
reductions in DA and DAT levels up to 14 days following the final session 
(Krasnova, et al., 2010). Nonetheless, changes in monoamine levels following MA 
self-administration do not necessarily equate to neurotoxic damage and appear less 
pronounced compared to the persistent reductions in DA levels following 
experimenter-administered MA regimes at three (Chapman, et al., 2001) and up to 
seven weeks (Friedman, et al., 1998) following MA exposure. Together, these 
findings suggest that MA self-administration under the current conditions did not 
produce extensive neurotoxicity and/or any lasting neurochemical disruption. 
However, the transient DA reductions and increase in DA turnover found in the 
present study, and the lasting decreases in DAT densities (Schwendt, et al., 2009), 
and more persistent reductions in DA and DAT levels following a longer session 
duration (Krasnova, et al., 2010) suggest that both short-term and enduring 
alterations in the regulation of DA neurotransmission occur as a consequence of self-
administered MA exposure. 
These changes in DA regulation may have functional implications. Indeed, 
exposure to psychostimulants at doses that only produce transient monoamine 
reductions, in the absence of any markers of neurotoxic damage, may have persistent 
effects on behaviour and cognition (Baumann, Wang, & Rothman, 2007; Dalley, et 
al., 2007). For instance, six hours access to MA self-administration produced an 
impairment in a novel object recognition task 10 days after the final session, 
enhanced MA-primed reinstatement of drug-seeking (Rogers, et al., 2008), and an 
increase in MA self-administration compared to one hour access (Kitamura, et al., 
2006). Furthermore, eight hours access to self-administered MA produced 
significant impairment (i.e. accuracy reduction, omissions, disturbed response 
latency and increased impulsivity) on a five-choice serial reaction time task up to 
two weeks following the final self-administration session (Dalley, et al., 2007). This 
would suggest that prolonged access to contingent MA may increase cognitive 
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deficits, impulsivity, and motivation for MA-seeking, impair attention and 
perpetuate an increase in MA self-administration. Indeed, MA users who had 
experienced a discrete period of unrestricted access to MA in the past reported 
greater motivation for continued MA use (more days of use per week, greater use 
per day, and greater total use per week), compared to MA users with no experience 
of unrestricted access (Culbertson, De La Garza II, Costello, & Newton, 2009). 
Conversely, self-administered MA failed to alter tissue levels of 5-HT, 5-
HIAA, or rate of 5-HT turnover in the FC. These results are not entirely unexpected 
since the experimenter-administered treatment protocol produced more substantial 
depletions of striatal DA tissue levels compared to cortical 5-HT levels. Given that 
striatal dopaminergic systems have been suggested to be the most sensitive to MA-
produced neurochemical perturbations (Chu, et al., 2008; J. E. Hanson, et al., 2009; 
Quinton & Yamamoto, 2006; Thomas, et al., 2008; Wagner, et al., 1980) it was 
expected that greater effects would be seen here as opposed to cortical regions. 
Further, a reduced density of DATs in the striatum and prefrontal cortex following 
self-administered MA occurred in the absence of any changes to SERT in these 
regions (Schwendt, et al., 2009). These findings are consistent with the idea that MA 
self-administration produces predominantly dopaminergic effects.  
19.2.2 Yoked self-administration exposure 
A yoked self-administration protocol was used to investigate the effect of 
contingency on brain chemistry. There was no difference between contingent (CM 
group) and yoked delivery (YM group) of MA on tissue levels of monoamines and 
metabolites, or turnover rates. The present lack of significant difference between 
exposure protocols may relate to the mode of action of MA and the present 
neurochemical assay. Studies of experimenter-administered MA have shown that 
MA functions as a DA uptake blocker, a potent releaser of DA, decreases striatal 
DAT activity and reduces DA tissue levels (Bakit, et al., 1974; Cruickshank & Dyer, 
2009; Fleckenstein, et al., 2000; Julien, 2001; Krasnova & Cadet, 2009; Suzuki, et 
al., 1980). More specifically, MA enters the presynaptic terminal button via the DAT, 
and binds with the VMAT-2, reversing its action and expelling DA in the cytosol, 
where it is pumped into the synaptic cleft via MA-induced reverse transport through 
the DAT (Barr, et al., 2006; Cruickshank & Dyer, 2009; Kish, 2008). Moreover, MA 
also limits monoamine metabolism by inhibiting MAO, further increasing the pool 
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of DA available for reverse transport into the synapse and duration for receptor 
activation (Cruickshank & Dyer, 2009; Elkashef, 2008; Julien, 2001; Suzuki, et al., 
1980). These combined effects contribute to a drastic increase in synaptic 
monoamine levels, and the longer elimination half-life (11-12 hrs in humans) than 
most other psychostimulants, such as cocaine (1-2 hours; Newton, et al., 2005). The 
present transient reductions in DA tissue levels and increased rate of DA turnover 
seen in rats exposed to both contingent and yoked MA infusions, may, therefore, 
reflect the purely pharmacological effects of chronic MA exposure per se, rather 
than the differences between the motivated process of active MA-taking behaviour 
and passive MA exposure. Other studies have also shown neuroadaptational 
differences in rats exposed to contingent and yoked drug infusions, compared to 
yoked controls. DA D1-like receptor densities, for instance, were reduced in rats 
receiving response contingent as well as yoked infusions of cocaine (De Montis, Co, 
Dworkin, & Smith, 1998). Furthermore, the maximum number of D1 receptor 
binding sites (Bmax), and DA stimulated adenylyl cyclase activity (Vmax) was 
similarly reduced in rats exposed to both contingent and yoked cocaine infusions 
(De Montis, et al., 1998). That these neuroadaptations occurred in rats receiving both 
contingent and yoked cocaine infusions suggests they reflect the purely 
pharmacological effects of self-administered cocaine exposure, rather than cognitive 
processes involved in drug-taking.  
Given the relatively non-specific nature of monoamine tissue content 
analysis using HPLC with neurochemical detection, the lack of significant 
differences between contingent and yoked MA exposure is not unexpected. For 
instance, this neurochemical assay does differentiate between intracellular and 
extracellular DA levels, and the purely pharmacological effects of MA may render 
differences in exposure contingency on the present measures undetectable. Indeed, 
many studies showing differences between contingency of drug exposure have 
examined different measures, such as changes in receptor density, receptor binding, 
and gene expression, or used in vivo microdialysis to detect changes in monoamine 
levels during drug self-administration.  For instance, in vivo microdialysis revealed 
greater increases in DA levels in rats actively self-administering cocaine, compared 
to yoked littermates (Hemby, et al., 1997). Quantitative autoradiography showed that 
only contingent access to self-administered MA reduced DA D1- and D2-like 
receptor densities (Stefanski, et al., 1999), whereas only yoked cocaine infusions 
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produced a reduction in D2-like receptor densities (Stefanski, et al., 2007). 
Furthermore, in situ hybridization analysis revealed that only contingent cocaine 
increased D2 receptor mRNA levels, with no corresponding changes in D2-like 
receptor binding density, compared to yoked littermates (Stefanski, et al., 2007). 
These findings suggest that behaviourally contingent drug exposure produces 
different neurobiological consequences, as measured by changes in receptor 
disposition and gene expression, to those seen following passive exposure, and 
emphasize the importance of using appropriate behavioural models when 
investigating the consequences of MA dependence.  
There is a relative paucity of studies using self-administered MA to 
investigate neurobiological consequences of this exposure, whereas ED protocols are 
more prolific. ED protocols have been used to provide a greater approximation of 
the escalation in dose and pattern of MA exposure seen in MA dependence, than 
typical single-day acute high dose exposure, but still require non-contingent MA 
administration. Indeed, rats that underwent ED regimes were exposed to comparable 
and greater amounts of total MA than in the present study (Cadet, et al., 2009; 
Danaceau, et al., 2007; Fischman & Schuster, 1974; Graham, et al., 2008; O'Neil, et 
al., 2006; Segal, et al., 2003), yet displayed no changes in striatal DA levels or DA 
turnover at 24 hours following the final treatment (Danaceau, et al., 2007; Graham, 
et al., 2008; O'Neil, et al., 2006). The divergence between passively-administered 
and actively self-administered neurochemical consequences of MA exposure may 
best be explained by the relatively low starting doses of MA that are typically 
employed in ED regimes. It has previously been suggested that the typical low doses 
of an ED regimen may allow a tolerance to the DA-depleting effects of MA to 
develop (Cadet, et al., 2009; Danaceau, et al., 2007; Fischman & Schuster, 1974; 
O'Neil, et al., 2006; Segal, et al., 2003). On the other hand, the rats self-
administering MA in the present study were exposed to comparatively high initial 
doses of MA, due to the rapid acquisition of MA self-administration and escalation 
in responding over the first six days (fig. 5a). Indeed, self-administration session 
duration has determined the amount of daily MA intake, where two hour sessions 
resulted in circa 1-2 mg/kg (Stefanski, et al., 1999), six hour sessions 4-5 mg/kg 
(present findings), nine hour sessions 6 mg/kg (Shepard, et al., 2006), and 15 hour 
sessions approximately 14-15 mg/kg (Krasnova, et al., 2010) of daily MA intake. In 
addition, longer session duration facilitates acquisition of MA self-administration 
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(Kitamura, et al., 2006; Rogers, et al., 2008), and the rapid acquisition and escalation 
of responding in the present study permitted a higher initial MA dose exposure that 
may account for the transient striatal DA deficits.  
19.2.3 Experimenter-administered MA exposure 
The persistent reductions of DA and 5-HT that occurred following the MA 
„binge‟ treatment regime are consistent with the findings of other studies (Chapman, 
et al., 2001; Friedman, et al., 1998; Fuller & Hemrick-Leuke, 1980; J. E. Hanson, et 
al., 2009; Herring, et al., 2008; Hotchkiss & Gibb, 1980; Hotchkiss, et al., 1979; 
Quinton & Yamamoto, 2006). Because MA-produced hyperthermia exacerbates 
neurotoxicity and DA depletions, and ambient temperature affects the degree of 
MA-produced hyperthermia (Imam & Ali, 2001; Krasnova & Cadet, 2009), the 
experimenter-administered treatment regime was administered in a temperature-
controlled housing room. Nonetheless, the high MA dose (4 x 10 mg/kg) was lethal 
to 20% of the rats. 
DA turnover (HVA/DA) was transiently elevated in MA-exposed animals, 
whereas other studies have shown more persistent elevations in DA turnover (Cadet, 
et al., 2009; Davidson, et al., 2005; Friedman, et al., 1998). The more transient effect 
seen here may be explained by the use of relatively young rats in this group, as MA-
produced DA deficits and changes in DA regulation are more pronounced in older 
rats. Indeed, high dose MA injections (40 mg/kg x 1; 10 mg/kg x 4 every 2 hrs) 
caused death in the majority of adult rats at similar weights to those used in the 
present self-administration study (275-300 g; Xi, et al., 2009). A single high dose of 
MA (40 mg/kg, IP) caused 100% mortality in 12-month-old rats, whereas no deaths 
occurred in one or six month old rats (Imam & Ali, 2001). Furthermore, there was an 
age-related increase in the reduction of DA and its metabolites in the Str following 
40 mg/kg MA (IP), and following 5 mg/kg MA (IP) there was no effect observed in 
one month old rats, whereas the effect was significant in rats aged six and 12 months 
(Imam & Ali, 2001). These age-related differences may be attributed to more 
efficient DA neurotransmission in younger rats (Thomas, et al., 2008; Volz, 
Farnsworth, Rowley, Hanson, & Fleckenstein, 2009). More specifically, younger 
(postnatal day 38-42) compared to older (postnatal day 88-92) rats appear to have 
kinetically up-regulated VMAT-2 and higher levels of functionally active DAT 
(Volz, et al., 2009). In the presence of MA, this may enable greater cellular efflux of 
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DA from the cytoplasm, thereby preventing cytoplasmic DA rising to neurotoxic 
levels after drug administration.  
Because tissue levels of HVA were not affected by MA treatment in the 
present study, increased DA turnover could be interpreted as a simple depletion of 
DA in the absence of any change in HVA levels. As DA levels in the striatum were 
greatly reduced, however, and because HVA is a catabolite of DA, it is possible that 
the rate of DA breakdown was increased as a consequence of MA exposure. Indeed, 
the enzymes responsible for breaking DA down to HVA were up-regulated under 
conditions of increased microglial activity (Helkamaa, et al., 2007; Thomas, et al., 
2008), such as that following MA exposure (Herring, et al., 2008; Krasnova & Cadet, 
2009; Krasnova, et al., 2010). The increased DA turnover could augment the 
production of free radical intermediates, such as the potentially toxic compounds 
hydrogen peroxide, ammonia, and aldehyde (Holshneider & Shih, 2000), thereby 
increasing the risk of further oxidative injury (Hauptmann, Grimsby, Shih, & 
Cadenas, 1996; Wei, Yeung, Jurma, & Andersen, 1996). This suggests that, in the 
short-term, the MA-induced increase in DA turnover seen here could potentiate 
striatal neuronal damage.  
The experimenter-administered treatment regime also produced a persistent 
depletion of 5-HT levels in the frontal cortex. A report of rapid recovery of 
significant 5-HT depletions (>80%) two hours following high-dose MA treatment 
(Graham, et al., 2008), suggests that neurochemical assay at an earlier time point 
may have revealed even more substantial deficits than those seen here. In addition, 
5-HIAA levels and 5-HT turnover were not affected in the present study, suggesting 
that experimenter-administered MA did not produce lasting changes in frontal cortex 
serotonergic neurotransmission. Taken together, these results suggest that dorsal 
striatal dopaminergic systems are more susceptible to neuronal damage produced by 
MA-exposure, than frontal cortical serotonergic systems (Chu, et al., 2008; J. E. 
Hanson, et al., 2009; Quinton & Yamamoto, 2006; Thomas, et al., 2008; Wagner, et 
al., 1980). 
In conclusion, the present study makes a significant contribution to drug 
dependence research by presenting an extended-access yoked-animal model that is 
more representative of human MA dependence. The findings presented here 
revealed that the striatal dopaminergic deficits produced by MA self-administration 
were comparatively mild, because they were no longer evident at seven days. This is 
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consistent with previous studies suggesting that exposure to self-administered MA 
does not produce the extensive reductions in monoamine tissue levels and 
neurotoxicity observed following experimenter-administered high-dose MA 
treatment regimes. Specifically, self-administered MA produced a transient 
reduction of striatal DA tissue levels, and increase in DA turnover that may suggest 
a disruption of DA neurotransmission and regulation in the dorsal striatum that 
recovers over time. There was no effect of contingency on these measures as 
comparison between contingent and yoked self-administration groups revealed no 
significant differences. This suggests that divergent neuroadaptations following 
dissimilar chronic MA regimens may be for the most part due to varying levels and 
time course of MA exposure.  
Chapter 2: Effects of D1-like and D2-like receptor 
antagonists on MA self-administration 
20 Overview 
MA self-administration during six hour sessions reduced DAT densities, that 
persisted up to 14 days (Schwendt, et al., 2009), increased DA turnover rates, and 
produced transient reductions in tissue levels of DA (Chapter 1). MA self-
administration during two hour sessions, also produced a reduction in D1- and D2-
like receptor binding densities 24 hours, but not seven days, following the last self-
administration session (Stefanski, et al., 1999; Stefanski, et al., 2002). These 
transient neuroadaptations may have functional implications for MA dependence 
because D1- and D2-like receptor mechanisms have been suggested to mediate 
crucial aspects of drug self-administration (Martinez, et al., in press; Missale, et al., 
1998; Self, 1998).  Pharmacological manipulations targeting D1- and D2-like 
receptor subtypes provide a means of investigating the role of these receptor 
mechanisms in MA self-administration.  
Most studies on the effect of DA receptor antagonists in the maintenance of 
psychostimulant self-administration and their reinforcing effects have studied 
cocaine self-administration, and both D1- and D2-like receptor subtypes have been 
implicated (Barrett, et al., 2004; Hubner & Moreton, 1991; McGregor & Roberts, 
1995; Self, 2004b). For instance, when cocaine self-administration was maintained 
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by simple FR schedules of reinforcement, both D1- and D2-like receptor antagonists 
shifted the dose-response curve downward and to the right (Caine & Koob, 1994; 
Caine, et al., 1999). Further, the reinforcing efficacy of, and incentive motivation for 
cocaine, as measured by BPs on a PR schedule of reinforcement, was reduced by 
D1- (McGregor & Roberts, 1995; Ranaldi & Wise, 2001) and D2-like receptor 
antagonists (Bari & Pierce, 2005; Hubner & Moreton, 1991). A small number of 
studies suggest a role of DA in MA self-administration as responding on both FR 
and PR schedules of reinforcement has been altered by pre-treatment with DA 
antagonists (Wee, et al., 2007; Yokel & Wise, 1976). The selective contribution of 
D1- vs. D2-like receptor mechanisms to self-administration of MA, however, is not 
understood.  
The aim of Chapter 2 was, therefore, to investigate the contribution of DA D1- and 
D2-like receptors to MA self-administration. This was achieved in the third 
experiment by analyzing changes in the number of responses maintained by an FR1 
schedule of reinforcement following pre-treatment with a D1- or D2-like receptor 
antagonist. The fourth experiment generated a dose-response curve of BPs under a 
PR schedule of reinforcement. The MA dose that generated the highest BP was then 
used for further investigation of the contribution of D1- and D2-like receptors to 
MA‟s reinforcing efficacy. SCH 23390 and eticlopride are highly selective 
antagonists at DA D1- and D2-like receptors, respectively (Bourne, 2001; Martelle 
& Nader, 2008), and were used to investigate the contribution of these receptor 
subtypes to the maintenance of MA self-administration under both the FR and PR 
schedules of reinforcement. Because two hour MA self-administration sessions 
produced down-regulated D1- and D2-like receptor densities, but no effects on DAT 
and TH levels (Stefanski, et al., 1999), the present experiments used a two hour 
session duration in order to minimize dopaminergic deficits and neurotoxicity due to 
MA self-administration, and elucidate the functional implications of DA receptor 
down-regulation. Two hour MA self-administration sessions produced greater 
reductions in D2- over D1-like receptor binding densities (Stefanski, et al., 1999), 
suggesting D2-like receptor mechanisms may be less responsive to pharmacological 
manipulations. It was, therefore, hypothesized that greater effects on MA self-
administration would be observed following D1-like antagonist pre-treatment.  
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21 Subjects 
Adult male Sprague-Dawley rats were used for self-administration 
experiments in accordance with the general methods (n = 22 for FR experiments; n = 
18 for PR experiments). 
22 Experiment 3: Effects of D1- and D2-like Receptor 
Antagonists on Methamphetamine Self-administration on an 
FR1 Schedule of reinforcement 
Following acquisition, tests were conducted to assess the effects of SCH 
23390 and eticlopride on responding maintained by a range of MA (0.05-0.2 
mg/kg/infusion) doses. SCH 23390 (0.01-0.02 mg/kg, SC, n = 10) was administered 
in the home cage 15 min prior to the onset of the self-administration test session. 
These doses and pre-treatment times were based on previous studies from our 
laboratory on the effects of SCH 23390 on MDMA (Daniela, et al., 2004), and 
cocaine (Brennan, Lake, et al., 2007) self-administration. Tests of the effect of 
eticlopride (0.0-0.05 mg/kg, IP, n = 12) on responding maintained by MA were 
conducted in a separate group of rats. Procedures were identical to those used for 
SCH 23390 tests, except that eticlopride was administered in the home cage 30 min 
prior to the onset of self-administration testing. These doses and pre-treatment times 
were based on previous studies from our laboratory on MDMA self-administration 
(Brennan, et al., 2009) and reinstatement (Schenk & Gittings, 2003). 
A recurring series of tests comprised of baseline and test days ensued. 
Antagonists were only administered when there were at least two prior consecutive 
baseline test days during which responding on the active lever did not vary by more 
than 20%. 
The initial test dose of MA was 0.05 mg/kg/infusion. Once the effect of all 
doses of the antagonist, administered in random order, on responding maintained by 
this dose had been determined, the dose was increased to 0.1 or 0.2 mg/kg/infusion 
for individual rats, and testing of the antagonist on responding maintained by this 
dose commenced. Only   
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23 Experiment 4: Effects of D1- and D2-like Receptor 
Antagonists on Methamphetamine Self-administration on a PR 
Schedule of reinforcement 
23.1 Training 
Following acquisition of self-administration, an FR2 schedule of 
reinforcement was imposed until there was less than 20% variation across three days. 
The reinforcement requirements were then increased to FR5 for a minimum of five 
days. Once responding was stable (< 20% variation across the last three days) the 
schedule of reinforcement was changed to PR, and the 30 sec TO period was omitted. 
One experimenter triggered infusion was delivered to clear the catheter line of the 
heparinised solution at the start of each daily session. The next infusion was 
delivered contingent on a single active lever response. Thereafter, the number of 
responses required to obtain subsequent infusions was increased according to the 
following progression: 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, 50, 62, 77, 95, 118, 145, 178, 
219, 268, 328, 402, 492, 603, 737, 901, 1102, 1347, 1647, 2012. This PR series was 
derived from the following equation:  
Response ratio (rounded to nearest integer) = [5e
(injection number x 0.2)
] – 5 
This series was used because it has been used extensively in studies of cocaine and 
MA self-administration (Brebner, Phelan, & Roberts, 2000; Richardson & Roberts, 
1996; Roberts, et al., 1996).  
The ratio continued to increase within session until it failed to be completed 
within a one hour period. If any individual session continued for more than six hours, 
a water spout was inserted into the experimental chamber for the remainder of the 
session. If any individual session continued for longer than 12 hours, testing was 
omitted the following day. BP was defined as the last ratio completed during a 
session. Inactive lever responding for the PR experiments was not recorded.  
23.2 Effects of D1- and D2-like antagonism 
The dose response curve for MA self-administration was generated across 
days. The first dose tested was 0.1 mg/kg/infusion. Tests of this dose continued for 
at least five days, or until there were three consecutive days during which ranked BP 
did not vary by more than 20%. The dose of MA for each individual rat was then 
changed to 0.05, or 0.2 mg/kg/infusion. This procedure was repeated until all rats 
had been tested on each dose of MA (n = 12). Some rats failed to meet the 
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responding stability criteria and were excluded from the study. Tests of the effects of 
SCH 23390 (0.0-0.04 mg/kg, SC, n = 6), and eticlopride (0.0-0.05 mg/kg, IP, n = 6) 
on self-administration of the dose of MA that generated the highest BPs (0.2 
mg/kg/infusion) were then conducted. 
For these tests, a recurring series comprised of baseline and test days ensued. 
A minimum of two baseline testing days, in which there was less than 20% variation 
in number of infusions obtained, were given between tests of antagonist effects. 
SCH 23390 and eticlopride administration was identical to that in the FR 
experiments. Doses were administered in random order.  
24 Drugs 
SCH 23390 and eticlopride (Sigma Aldrich, Australia) were dissolved in a 
sterile 0.9% saline solution, and injected in a volume of 1 ml/kg. All drug doses refer 
to the weight of the salt.  
25 Statistical analyses 
Effects of the D1- and D2-like receptor antagonists on MA self-
administration reinforced according to the FR1 schedule were analysed using 
separate ANOVAs (antagonist dose x MA dose) to determine the effect of each 
antagonist, with Tukey‟s post-hoc analyses conducted where appropriate. Further, 
two-way ANOVAs (antagonist dose x lever) were used to determine the effects of 
each antagonist on active vs. inactive lever responding. The dose response curve for 
MA self-administration reinforced according to the PR schedule was analyzed using 
a repeated measures ANOVA, and t-tests to determine differences between doses. 
Separate repeated measures ANOVAs, with post hoc t-tests where appropriate, were 
used to determine the effect of each antagonist on BPs maintained by MA on the PR 
schedule of reinforcement.  
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26 Results 
26.1 Responding on the FR1 schedule of reinforcement 
26.1.1 Effects of SCH 23390 
 
Figure 6. Effects of two doses of SCH 23390 [A) 0.01; B) 0.02 mg/kg] on lever responding maintained by 
various doses of MA (0.05, 0.1, 0.2 mg/kg/infusion). Symbols represent mean number of responses 
(+SEM). *Significant difference between vehicle and SCH 23390 pre-treated groups (p < 0.05). 
Figure 6 shows the effects of SCH 23390 on MA self-administration 
according to an FR1 schedule of reinforcement. SCH 23390 pre-treatment produced 
significant changes in responding maintained by MA infusions: 0.01 mg/kg 
decreased responding maintained by 0.05 mg/kg/infusion MA; whereas the 0.02 
mg/kg decreased responding maintained by 0.05 and 0.2 mg/kg/infusion MA. A 
two-way ANOVA (SCH 23390 x MA) revealed a significant main effect of SCH 
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23390 dose [F(2, 200) = 12.45, p = 0.0008], a main effect of MA dose [F(2, 200) = 
6.040, p = 0.00058], and an interaction between these factors [F(3, 200) = 5.51, p = 
0.00031]. Tukey post hoc tests confirmed that 0.02 mg/kg SCH 23390 decreased 
MA (0.05, 0.2 mg/kg/infusion, p = 0.0003) maintained responding, and the 0.01 
mg/kg dose decreased responding for MA 0.05 mg/kg/infusion (p = 0.003). A two-
way ANOVA was conducted to clarify the effects of SCH 23390 on active vs. 
inactive lever responding. Active lever responding was significantly decreased by 
SCH 23390 pre-treatment [F(2, 87) = 17.23, p = 0.0005], but inactive lever 
responding was not significantly affected [F(2, 87) = 2.54, p = 0.084]. 
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26.1.2 Effects of eticlopride 
 
Figure 7. Effects of three eticlopride doses [A) 0.0125 mg/kg; B) 0.025 mg/kg; C) 0.05 mg/kg] on lever 
responding maintained by various doses of MA (0.05, 0.1, 0.2 mg/kg/infusion). Symbols represent the 
mean number of responses (+SEM). 
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Figure 7 shows the effects of eticlopride pre-treatment on MA self-
administration reinforced according to an FR1 schedule of reinforcement. 
Eticlopride pre-treatment failed to significantly alter MA self-administration. 
ANOVA (eticlopride dose x MA dose) revealed a significant main effect of MA 
dose [F(2, 299) = 11.85, p = 0.0023], but no significant effect of eticlopride dose 
[F(3, 299) = 1.21, p = 0.307], or interaction between MA and eticlopride dose [F(5, 
299) = 0.45, p > 0.847]. A two-way ANOVA was conducted to investigate effects of 
eticlopride on active vs. inactive lever responding. Neither active lever [F(3, 135) = 
1.18, p = 0.320], nor inactive lever [F(3, 135) = 0.44, p = 0.724] responding was 
significantly affected by eticlopride pre-treatment. There appeared to be a trend 
toward an increase in responding on both levers across each dose of eticlopride, 
although this did not reach significance. 
26.2 Responding on the PR schedule of reinforcement 
26.2.1 Dose-response effects of MA 
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Figure 8. Mean (+SEM) BPs maintained by various doses of MA (0.05, 0.1, 0.2 mg/kg/infusion). 
*Significantly different from vehicle maintained BPs (p < 0.05). 
Figure 8 illustrates the effect of MA dose on BPs reinforced according to a 
PR schedule of reinforcement. Repeated measures ANOVA revealed that BP 
increased with increasing dose [F(3, 27) = 20.974, p = 0.00032], and t-tests 
confirmed that the BP for each MA dose was significantly higher than for vehicle 
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infusions (p = 0.008). The BP produced by 0.2 mg/kg/infusion MA was the highest 
and was used for subsequent testing of the effects of D1- and D2-like antagonists on 
MA self-administration.  
26.2.2 Effects of SCH 23390 
SCH 23390 dose (mg/kg)
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Figure 9. The effect of pre-treatment with various doses of SCH 23390 (0.01, 0.02, 0.04 mg/kg) on mean 
BPs (+SEM) maintained by MA (0.2 mg/kg/infusion). *Significantly different to vehicle pre-treatment (p < 
0.05). 
Figure 9 shows the effect of SCH 23390 pre-treatment on BPs maintained by 
0.2 mg/kg/infusion MA. ANOVA revealed that SCH 23390 produced a dose-
dependent decrease in BP [F(3, 15) = 6.27, p = 0.006], and post hoc t-tests 
confirmed that the BP was significantly attenuated by the 0.02 and 0.04 mg/kg doses 
(p = 0.043).  
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26.2.3 Effects of eticlopride 
 
Figure 10. The effect of pre-treatment with various doses of eticlopride (0.0125, 0.025, 0.05 mg/kg) on 
mean BPs (+SEM) maintained by MA (0.2 mg/kg/infusion). 
Figure 10 depicts the effect of eticlopride pre-treatment on the MA-produced 
BP. Catheter patency was lost for two of the rats prior to completion of the full dose-
response curve, and therefore, data from these rats were excluded from analysis 
(final n = 4). Repeated measures ANOVA revealed that there was no significant 
change in BP as a function of eticlopride pre-treatment [F(3, 9) = 0.52, p = 0.678].  
27 Discussion 
Self-administration was produced according to both the FR and PR schedule 
of reinforcement. Responding under both schedules of reinforcement was dose-
dependent: rate of responding decreased with increased dose according to the FR 
schedule; and BPs increased with increased dose according to the PR schedule. 
These findings reflect typical aspects of MA self-administration under these 
schedules, and are characteristic of dose manipulations on each schedule (Arnold & 
Roberts, 1997; Richardson & Roberts, 1996; Roberts, et al., 2007). Under FR 
schedules of reinforcement, rate of responding changes, within certain dose limits, 
so that a relatively constant level of drug intake is maintained. Accordingly, as the 
unit dose per infusion is increased, rate of responding decreases in a compensatory 
manner, characteristic of the descending limb of the dose-response curve. On the 
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other hand, under PR schedules, the final ratio completed increases with increasing 
dose. It has been suggested that the BP reflects a measure of reinforcing efficacy, or 
incentive motivation for further reinforcement (Arnold & Roberts, 1997; Hodos, 
1961; Richardson & Roberts, 1996). Hence, as the unit dose per infusion was 
increased, higher BPs were maintained, suggesting greater reinforcing efficacy and a 
higher incentive motivation for continued MA reinforcement. 
When responding was reinforced according to the FR1 schedule, SCH 23390 
pre-treatment produced significant changes in MA self-administration: 0.01 mg/kg 
decreased responding maintained by 0.05 mg/kg/infusion MA; whereas the 0.02 
mg/kg decreased responding maintained by 0.05 and 0.2 mg/kg/infusion MA. In 
contrast, eticlopride pre-treatment failed to significantly alter MA self-
administration at any dose. Similar results were produced when responding was 
reinforced according to the PR schedule. Under these conditions D1-like receptor 
blockade produced a reduction in BPs, whereas D2-like receptor blockade had no 
significant effect. Due to two rats losing catheter patency prior to completing the full 
dose range of eticlopride pre-treatment, the results from this experiment may be 
considered preliminary. It is possible that increasing the number of rats in this 
experiment may have revealed more pronounced effects of eticlopride pre-treatment.  
Nonetheless, this finding, together with the results from the experiment using the 
FR1 schedule of reinforcement suggest a preferential role of DA D1-, over D2-like, 
receptors in the maintenance of MA self-administration, and in the incentive 
motivation for further MA reinforcement. 
Pharmacological blockade of DA receptors often produces non-specific 
motor impairments that might explain the decrease in MA self-administration (Grace, 
2002; Missale, et al., 1998). SCH 23390 pre-treatment, however, did not 
significantly affect inactive lever responding in the FR experiments. The 0.02 mg/kg 
dose of SCH 23390 has previously been shown to increase operant responding 
reinforced by some doses of both MDMA (Daniela, et al., 2004), and cocaine 
(Brennan, Lake, et al., 2007) in our laboratory. Furthermore, responding on the PR 
schedule of reinforcement reached BPs of roughly 200 following pre-treatment with 
0.01 mg/kg SCH 23390, equivalent to over 1000 cumulative responses. It is, 
therefore, unlikely that the decrease in responding produced by D1-like receptor 
blockade reflects an inability to perform the lever press operant. SCH 23390 is also 
an agonist at the 5-HT2c receptor, which may have affected MA self-administration 
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(Munzar, et al., 1999), but the doses required are 10-fold higher than those required 
for D1-like receptor blockade (Bourne, 2001; Millan, Newman-Tancredi, Quentric, 
& Cussac, 2001). The most parsimonious explanation of the data is that D1-like 
receptors are critical for MA self-administration. The current failure of eticlopride to 
alter MA self-administration is not likely due to inadequate dosage since MDMA 
self-administration was increased by these doses when administered under almost 
identical conditions to those used in the present study (Brennan, et al., 2009). Tests 
with higher doses of eticlopride were not conducted because they have been shown 
to produce non-specific generalized decreases in motor activity (Green & Schenk, 
2002; Schenk & Gittings, 2003).  
The effect of SCH 23390 on MA self-administration is consistent with 
studies that have suggested an important role of this receptor subtype in the self-
administration of other drugs with abuse potential. For instance, pre-treatment with 
D1-like antagonists altered self-administration of MDMA (Daniela, et al., 2004); 
heroin (Gerrits, Ramsey, Wolterink, & Ree, 1994); N-benzylpiperazine (BZP; 
Brennan, Lake, et al., 2007); methylphenidate (Botly, et al., 2008) and cocaine (Bari 
& Pierce, 2005; Barrett, et al., 2004; Caine, et al., 1995; Caine & Koob, 1994; 
Hubner & Moreton, 1991; McGregor & Roberts, 1995; Ranaldi & Wise, 2001) on 
FR schedules of reinforcement. Furthermore, BPs on PR schedules of reinforcement 
maintained by methylphenidate (Botly, et al., 2008); „speedball‟ (cocaine + heroin 
combination; Cornish, et al., 2005); and cocaine (Bari & Pierce, 2005; Hubner & 
Moreton, 1991; McGregor & Roberts, 1995; Ranaldi & Wise, 2001) were reduced 
following pre-treatment with D1-like antagonists. Together, these findings suggest 
that D1-like receptor mechanisms are crucial for the self-administration of drugs of 
abuse, including MA. 
The failure of D2-like receptor blockade to decrease MA self-administration 
is in contrast to other reports of the effects of D2-like receptor antagonists on opiate 
and psychostimulant self-administration (Botly, et al., 2008; Caine & Koob, 1994; 
Caine, et al., 1999; Hubner & Moreton, 1991; D. Zhang, et al., 2010). The D2 partial 
agonist
2
 terguride, for example, dose-dependently reduced heroin self-administration 
on a FR schedule of reinforcement (D. Zhang, et al., 2010) and reduced BPs 
                                               
2
 Partial agonists bind to DA receptors with high affinity and low intrinsic 
activity, acting as functional agonists during low dopaminergic tone, and antagonists 
during high dopaminergic tone, such as during drug self-administration. 
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produced by heroin and amphetamine self-administration (Izzo, et al., 2001; D. 
Zhang, et al., 2010). Eticlopride pre-treatment increased methylphenidate (Botly, et 
al., 2008) and MDMA self-administration (Brennan, et al., 2009) on a FR schedule 
of reinforcement, and reduced BPs maintained by methylphenidate self-
administration (Botly, et al., 2008). Pre-treatment with eticlopride also produced 
rightward shifts in the dose-response function in cocaine self-administration (Barrett, 
et al., 2004) on an FR schedule of reinforcement. Other D2-like antagonists have 
produced similar alterations in cocaine self-administration. Spiperone pre-treatment 
increased responding reinforced by smaller doses on an FR schedule of 
reinforcement, and decreased responding maintained by higher doses (Hubner & 
Moreton, 1991). Self-administration on an FR5 timeout (TO) 20-sec schedule of 
reinforcement was increased following spiperone pre-treatment, and decreased on an 
FR15 TO 2-min multiple schedule (Caine & Koob, 1994).  
The experiment using the FR1 schedule of reinforcement enabled a 
comparison of the effects of the DA antagonists on cocaine and MDMA self-
administration previously investigated in our laboratory. Under these experimental 
conditions, MA self-administration was preferentially altered by manipulation of 
D1-like receptor mechanisms, with no significant effect of D2-like manipulations, 
whereas MDMA (Brennan, et al., 2009; Daniela, et al., 2004) and cocaine (Brennan, 
Lake, et al., 2007) self-administration were significantly altered by manipulations of 
both receptor mechanisms. These discrepancies may relate to the divergent 
consequences of chronic drug exposure on DA neurochemistry and synaptic 
transmission. 
Following a progressively increasing dose regimen of experimenter 
administered IV infusions of MA, a greater reduction in D2-like receptor binding, 
compared to D1-like receptor binding, was found in the striatum of rats (Segal, et al., 
2005). Similar findings have been reported following self-administered MA 
exposure. For instance, following approximately 25 daily two hour MA self-
administration sessions, under conditions almost identical to the current study, there 
were greater decreases in D2-like (21-34%), over D1-like receptor binding densities 
(15%; Stefanski, et al., 1999). A greater effect of D1- over D2-like antagonists, on 
MA self-administration might, therefore, be expected. Cocaine self-administration 
under similar protocols did not produce any comparable changes in DA receptor 
binding densities (Stefanski, et al., 2007), potentially explaining why both D1- and 
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D2-like receptor antagonists decreased cocaine self-administration (Botly, et al., 
2008; Brennan, Lake, et al., 2007; Caine, et al., 2002). The present results extend the 
finding of reduced D1- and D2-like receptor binding densities following MA self-
administration (Stefanski, et al., 1999), to suggest a functional disruption in D2-like 
receptor mediated mechanisms. Further, the current findings show similar effects of 
D1- and D2-like antagonism when MA self-administration was reinforced according 
to both the FR and PR schedules. This suggests that these results reflect 
neuroadaptations as a function of self-administered MA exposure, rather than 
procedural differences in the schedules of reinforcement. Taken together, these 
findings suggest that novel neuroadaptations may take place following MA self-
administration, compared to self-administration of other psychostimulants, rendering 
D2-like receptor mechanisms less responsive to selective pharmacological 
manipulation.  
The present data suggest that following chronic MA self-administration DA 
D1- and D2-like receptor mechanisms contribute differentially to MA self-
administration, with a greater role of D1- over D2-like mechanisms. This finding is 
in contrast to the results of previous studies on the effects of D1- and D2-like 
receptor blockade on drug self-administration, but is consistent with reports on the 
different neuroadaptations that result from chronic self-administration of other 
psychostimulants, particularly cocaine. On the basis of these results, it seems that 
MA self-administration, through novel neuroadaptations not seen following self-
administration of other psychostimulants, becomes preferentially dependent on DA 
D1-like, over D2-like, receptor mechanisms. It will be of interest to investigate how 
pharmacological manipulation of these receptor mechanisms influences other 
behavioural indices of MA self-administration.  
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Chapter 3: Role of D1- and D2-like receptor 
mechanisms in drug-seeking following MA self-
administration 
28 Overview 
Drug abusers reported great difficulty in controlling their drug use despite a 
strong desire to do so (Cadet, et al., 2003; Julien, 2001), and the high rate of relapse 
to drug abuse is a critical obstacle to effective long-term treatment (Copeland & 
Sorensen, 2001; N. K. Lee, Pohlman, Baker, Ferris, & Kay-Lambkin, 2010; N. K. 
Lee & Rawson, 2008; Shaham, et al., 2003; Shalev, et al., 2002). MA users run a 
particularly high risk of relapse (Copeland & Sorensen, 2001) and persistent drug 
craving can lead to relapse even after long periods of abstinence (Epstein & Preston, 
2003; Epstein, et al., 2006; Hartz, et al., 2001). This emphasizes the importance of 
research that identifies the relevant neurobiological mechanisms of relapse to MA-
seeking and MA-taking behaviour.  
Self-administration procedures have been effectively used to study 
reinstatement of drug-seeking and relapse following abstinence. One model in 
particular is able to determine factors that can reinstate responding following 
extinguished drug self-administration (de Wit & Stewart, 1981), such as exposure to 
the previously self-administered drug, drug-associated stimuli, or stress (Epstein, et 
al., 2006; Shaham, et al., 2003). Drug-seeking has often been attributed to 
dopaminergic mechanisms (Green & Schenk, 2002; Marinelli, Cooper, Baker, & 
White, 2003; Schenk, et al., 2011; H. D. Schmidt & Pierce, 2006; Self, 2004b), as 
following extinguished drug self-administration, priming injections of DA agonists, 
including the previously self-administered drug, reinstated drug-seeking behaviour 
(De Vries, et al., 1999; H. D. Schmidt & Pierce, 2006; Shaham & Stewart, 1996; 
Stewart, 2000). Further, DA D1- and D2-like receptor mechanisms appear critical 
for this response as priming injections of selective D2 receptor agonists reinstated 
cocaine- and heroin-seeking (De Vries, et al., 2002; Self, 2004b), and cocaine- and 
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heroin-seeking behaviour was attenuated by selective D1- and D2-like receptor 
antagonists (Self, 1998, 2004b; Self & Nestler, 1998; Shaham & Stewart, 1996). 
Reinstatement of drug-seeking has also been demonstrated following 
extinguished MA self-administration (Anggadiredja, et al., 2004; Hiranita, et al., 
2010; Moffett & Goeders, 2007; Rogers, et al., 2008; Shelton & Beardsley, 2008; 
Shepard, et al., 2004), but the contribution of DA D1- and D2-like mechanisms to 
this behaviour have yet to be thoroughly investigated. The finding that 
pharmacological blockade of DA D1-like receptor mechanisms decreased MA self-
administration on an FR1 and PR schedule of reinforcement (Chapter 2) is consistent 
with an important role of this receptor in the maintenance of MA abuse and the 
reinforcing efficacy of MA, and other drugs of abuse (Bari & Pierce, 2005; Le 
Merrer, Gavello-Baudy, Galey, & Cazala, 2007; Ranaldi & Wise, 2001). 
Conversely, the lack of effect of a D2-like receptor antagonist on these measures 
(Chapter 2) is different from the vast body of literature showing a role of D2-like 
mechanisms in self-administration of other drugs of abuse (Botly, et al., 2008; Caine 
& Koob, 1994; Caine, et al., 1999; Hubner & Moreton, 1991; D. Zhang, et al., 2010). 
Because the maintenance of MA self-administration was differentially responsive to 
pharmacological manipulations of D1- and D2-like receptor mechanisms (Chapter 2), 
it is possible that reinstatement of MA-seeking is also preferentially altered by 
pharmacological manipulation of D1-like receptor mechanisms. Self-administered 
MA during two hour sessions produced a greater reduction of DA D2-like receptor 
densities when measured after 24 drug free hours (Stefanski, et al., 1999), but this 
effect was transient and the binding measure was comparable to control levels after 
seven drug free days (Stefanski, et al., 2007). Self-administered MA during six hour 
sessions, on the other hand, also produced transient reductions in striatal DA levels 
following 24 hours withdrawal; the deficits were also no longer observed following 
seven drug free days (Chapter 1). Therefore, the present experiments used two hour 
self-administration sessions, similar to Stefanski‟s protocols (1999; 2002), to 
investigate the contribution of DA D1- and D2-like receptor mechanisms to the 
reinstatement of extinguished MA-seeking behaviour. This may provide an 
indication of the functional status of these receptor mechanisms at withdrawal times 
when receptor densities may be returning to control levels (Stefanski, et al., 2002), 
in the absence of persistently reduced DA levels (Chapter 1).  
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Considering this, the aim of Chapter 3 was to determine the involvement of 
dopaminergic mechanisms in reinstatement of MA-seeking behaviour. A role of DA 
was investigated in two ways: by comparing the effects of either a D1- or D2-like 
receptor antagonist on drug-seeking produced by MA-priming injections; and by 
comparing the effects of priming injections of a DAT inhibitor, and selective DA D1 
and D2 receptor agonists on drug-seeking. The results from Chapter 2 suggest that 
D1-like receptor mechanisms might play a significant role in reinstatement of MA-
seeking. Due to the recovery of both D1 and D2 receptor density reductions seven 
days following MA self-administration (Stefanski, et al., 2002), it was of particular 
interest to examine the involvement of D2-like receptor mechanisms in this 
behaviour. 
The effects of various doses of experimenter-administered MA on drug-
seeking were determined in the fifth experiment. Two doses of MA were tested to 
establish a baseline measure of MA-produced reinstatement of drug-seeking. The 
dose that generated the highest number of drug-seeking responses was then used for 
subsequent experiments investigating the selective involvement of D1- and D2-like 
receptors in relapse to MA-produced drug-seeking behaviour. 
In the sixth experiment, the effects of acute pre-treatment with various doses 
of either the D1-like antagonist, SCH 23390, or the D2-like antagonist, eticlopride, 
on MA-primed drug-seeking were investigated. For comparison, the effect of 
pharmacological blockade of D1- and D2-like receptors on MA-seeking produced by 
cocaine-priming injections was also investigated. Cocaine-primed reinstatement of 
drug-seeking has previously been attenuated by pre-treatment with both D1- and D2-
like antagonists (Anderson, et al., 2003; Khroyan, et al., 2000; Schenk & Gittings, 
2003). The purpose of this experiment was, therefore, to determine if there would be 
any differential effects between MA and cocaine priming-injections and D1- or D2-
like antagonist pre-treatment, or if a history of MA self-administration had produced 
neuroadaptations that rendered pre-treatment with the D2-like antagonist ineffective. 
That is, if the findings between drug primes are similar, this would suggest the 
effects of D1- or D2-like antagonist pre-treatment are reflective of changes taking 
place in DA receptor mechanisms as a function of MA self-administration. 
Furthermore, the effect of eticlopride pre-treatment on MDMA-produced drug-
seeking in rats experienced with MDMA self-administration was also investigated. 
Previous research suggests a significant role of D2-like receptor mechanisms in 
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relapse to drug-seeking, with D2-like antagonist pre-treatment attenuating drug-
primed reinstatement (Khroyan, et al., 2000; Schenk & Gittings, 2003; Shaham & 
Stewart, 1996). This experiment was, therefore, conducted as a positive control of 
the effects of eticlopride pre-treatment on reinstatement of drug-seeking behaviour 
following psychostimulant self-administration. 
Finally, the seventh experiment further investigated the role of DA in 
reinstatement of MA-seeking behaviour by measuring drug-seeking following 
priming injections of various doses of the DAT inhibitor, GBR 12909 (Andersen, 
1989), a direct D1 agonist, SKF 81297 (Self, Belluzzi, et al., 1996), and a direct D2 
agonist, quinpirole (Malmberg & Mohell, 1995). In view of previous findings of 
dopaminergic involvement of drug-seeking following self-administration of other 
drugs of abuse, it was hypothesized that the indirect DA agonists (MA, cocaine, 
GBR 12909) would reinstate MA-seeking behaviour. Direct stimulation of D1 
receptors has previously failed to potentiate drug-seeking (Alleweireldt, et al., 2002; 
Khroyan, et al., 2000; Khroyan, et al., 2003; Self, Barnhart, et al., 1996), and 
blocking both D1- and D2-like receptors attenuated drug-seeking (Bossert, et al., 
2007; Green & Schenk, 2002; Khroyan, et al., 2000; Schenk & Gittings, 2003; 
Shaham & Stewart, 1996), while direct stimulation of D2 receptors has reinstated 
extinguished drug-seeking behaviour (De Vries, et al., 2002; De Vries, et al., 1999; 
Khroyan, et al., 2000; Schenk, et al., 2011; Self, Barnhart, et al., 1996; Wise, et al., 
1990). Considering the preferential effect of D1-, over D2-like antagonism on 
maintenance of MA self-administration (Chapter 2), however, it was predicted that 
D1-, but not D2-like, antagonism would attenuate MA-seeking, while direct 
stimulation of neither D1- nor D2-like receptor mechanisms would potentiate MA-
seeking.  
29 Subjects 
Adult, male Sprague-Dawley rats (n = 43) were used according to the general 
methods. 
30 MA & MDMA Self-administration 
Daily MA self-administration took place as in the general methods. 
Following at least 10 days of MA self-administration and the fulfilment of 
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acquisition criteria, the schedule of reinforcement was increased to FR2 until there 
was a minimum of three consecutive days of stable responding (< 20% variation in 
number of active lever responses), and finally to FR5 for a minimum of 10 days.  
 Acquisition of MDMA self-administration was conducted during daily six 
hour sessions. Each depression of the active lever (FR1) produced an infusion of 
MDMA 1.0 mg/kg/infusion. Infusion volume and duration remained the same as for 
MA self-administration, but the 30 sec TO period was omitted. This session-time 
and dose of MDMA was chosen based on previous studies from our laboratory 
(Colussi-Mas, Wise, Howard, & Schenk, 2010; Schenk, Gittings, Johnstone, & 
Daniela, 2003; Schenk, et al., 2007). Acquisition criteria for MDMA self-
administration remained the same as for MA. Due to the low responding maintained 
by this dose of MDMA (Daniela, et al., 2004; Schenk, et al., 2003), the dose was 
decreased to 0.5 mg/kg/infusion once the acquisition criteria had been met. 
Responding was then reinforced according to a FR1 schedule until active lever 
responding varied by less than 20% for three consecutive days. Response 
requirements were then increased to FR2 for a minimum of three days, and then to 
FR5. The FR5 schedule was maintained for at least five days before tests of drug-
seeking commenced. 
31 Drug-seeking 
Following stable responding maintained by the FR5 schedule of 
reinforcement, operant behaviour was extinguished by replacing the drug with a 
heparinzed (3 IU/ml) saline solution, and disconnecting the light stimulus that had 
previously been paired with self-administered drug infusions. The vehicle solution 
was delivered according to an FR5 schedule. Once the number of active lever 
presses decreased to < 20% of baseline, tests of drug-seeking were conducted. On 
these days, antagonists were administered in the home cage, and agonists were 
administered in the testing room immediately prior to the start of the test. 
Responding was reinforced according to an FR5 schedule by the delivery of the 
vehicle solution and the illumination of the light stimulus, previously paired with 
self-administered drug infusions during training. The 30 sec TO period was 
maintained for MA-seeking experiments, but was omitted in MDMA-seeking tests.  
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31.1 Experiment 5: MA-produced drug-seeking 
Initial tests determined the effects of various doses of experimenter-
administered MA (0.0, 1.0, or 2.0 mg/kg, IP, n = 8) on drug-seeking behaviour 
following extinction of MA self-administration. All doses of MA were administered 
to all rats in a random order. Repeated tests were conducted during a recurring series 
of drug self-administration (Phase 1; minimum two days), extinction (Phase 2; 
minimum two days), and reinstatement tests (Phase 3; one day) until all rats had 
been tested with all three doses of MA. 
31.2 Experiment 6: Effects of D1- and D2-like antagonism on drug-
primed drug-seeking 
On the basis of the MA dose-response data obtained in experiment 5, 
subsequent groups were tested with 2.0 mg/kg MA. Effects of either the D1-like 
antagonist, SCH 23390 (0.0-0.04 mg/kg, SC, n = 5), or the D2-like antagonist, 
eticlopride (0.0-0.05 mg/kg, IP, n = 7), on drug-seeking produced by a priming 
injection of MA (2.0 mg/kg, IP) was measured. Pre-treatments were administered in 
the home cage 15 (SCH 23390), or 30 (eticlopride) minutes prior to the MA 
priming-injection. These pre-treatment times and doses were based on previous 
studies from our laboratory (Brennan, et al., 2009; Brennan, Lake, et al., 2007; 
Daniela, et al., 2004; Schenk & Gittings, 2003).  
Cocaine-primed MA-seeking tests were conducted to investigate whether the 
effects of pre-treatment with a D1- or D2-like antagonist were similar to previous 
studies of cocaine-primed reinstatement of drug-seeking (Anderson, et al., 2003; 
Khroyan, et al., 2000; Schenk & Gittings, 2003). Similar effects between drug 
primes may then suggest DA receptor mechanism changes following MA self-
administration. SCH 23390 (n = 4), and eticlopride (n = 6) pre-treatment procedures 
were identical to those used for MA-primed reinstatement, except that a cocaine (20 
mg/kg, IP) priming-injection was administered immediately prior to placing the rats 
in the experimental chambers. This dose of cocaine was chosen based on previous 
studies of drug-seeking from our laboratory (Schenk & Gittings, 2003; Schenk, et 
al., 2008). Doses of the antagonists were administered in random order and tests 
were conducted according to the recurring series outlined above.  
MDMA-primed MDMA-seeking tests were conducted as a positive control 
of the effects of D2-like antagonism on reinstated drug-seeking following self-
administration of another psychostimulant, MDMA. Procedures were identical to the 
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other tests on the effects of eticlopride on drug-seeking behaviour, except an 
MDMA (10.0 mg/kg, IP, n = 5) priming-injection was administered immediately 
prior to placing the rats in the experimental chambers. This dose of MDMA was 
chosen based on previous studies demonstrating MDMA-seeking in our laboratory 
(Colussi-Mas, et al., 2010; Schenk, et al., 2008). 
31.3 Experiment 7: DA agonist-primed MA-seeking 
Tests of drug-seeking produced by the DAT inhibitor, GBR 12909 (0.0, 1.0, 
10.0 mg/kg, IP, n = 4), the selective D1 agonist, SKF 81297 (0.0-4.0 mg/kg, IP, n = 
4), and the selective D2 agonist, quinpirole (0.0, 1.0 mg/kg, IP, n = 6), were 
measured as above. Drug doses were administered in random order in the 
experimental room immediately before placing the rat in the experimental chamber. 
These doses are based on preliminary work and previous studies on the effects of 
DA agonists on drug-seeking (De Vries, et al., 2002; H. D. Schmidt & Pierce, 2006; 
Self, Barnhart, et al., 1996).  
31.4 Drugs 
MDMA hydrochloride was obtained from ESR (Porirua, New Zealand) and 
was dissolved in a sterile solution of heparinised (3 IU/ml) physiological saline 
solution for self-administration. GBR 12909 was dissolved in distilled water, while 
all other drugs (Sigma Aldrich, Australia) were dissolved in a 0.9% saline solution. 
Systemic injections were in a volume of 1.0 ml/kg. All drug doses refer to the 
weight of the salt.  
31.5 Data analysis 
The dose-response curve for MA-primed MA-seeking, effects of the D1- and 
D2-like antagonists on drug-primed drug-seeking, and drug-seeking produced by the 
DA agonists were analyzed using separate repeated measures analysis of variance 
(ANOVA: drug dose x lever). Simple contrasts were used to determine differences 
between drug doses and vehicle treatment. A number of rats were included in several 
drug-seeking tests. Extent of MA exposure can influence the magnitude of reinstated 
MA-seeking (Kitamura, et al., 2006; Rogers, et al., 2008; Shalev, et al., 2002), and, 
consequently, the ability of DA agonists and antagonists to influence this behaviour. 
Therefore, separate analyses taking into account the amount of each individual rat‟s 
self-administered MA exposure over and above their first drug-seeking test were 
included in subsequent assays of dopaminergic manipulation of MA-seeking as a 
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covariate in analysis of covariance (ANCOVA: drug dose x lever x MA exposure). 
For illustrative purposes, separate repeated measures ANOVAs only on rats‟ first 
reinstatement test (i.e. excluding animals with additional exposure to self-
administered MA, where n ≥ 4), and ANOVAs without MA exposure as a covariate, 
were also conducted. 
32 Results  
32.1 Self-administration and extinction responding 
32.1.1 MA self-administration 
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Figure 11. Average (+SEM) responding for MA self-administration on active (black bars), and inactive 
(grey bars) levers during two days of maintenance (Phase 1), and the last two days of extinction (Phase 2; 
FR5; n = 10). 
Figure 11 shows the average number of responses on the active and inactive 
levers during two days of MA self-administration (Phase 1) and the last two days of 
extinction responding (Phase 2), prior to the start of the reinstatement tests (Phase 3). 
Responding was high during drug self-administration. When the drug was replaced 
with vehicle solution and the stimulus light was disconnected, active lever 
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responding decreased. The average number of days to reach extinction criteria was 
3.3 (± 0.15) days. Repeated measures ANOVA revealed a significant main effect of 
condition (Phase 1 vs. Phase 2; [F(1,9) = 38.18, p = 0.0002]), lever (active vs. 
inactive; [F(1, 9) = 51.87, p = 0.0005]), and a significant interaction between these 
factors [F(1, 9) = 32.51, p = 0.0002]. A repeated measures ANOVA was conducted 
to examine the effect of vehicle priming injections, and the illumination of the 
stimulus light previously paired with MA-infusions on reinstatement of MA-seeking. 
Vehicle-priming and the illumination of the previously drug-paired stimulus light 
reinstated MA-seeking as demonstrated by a main effect of lever [F(1, 7) = 25.75, p 
= 0.001], a main effect of condition (Phase 2 vs. Phase 3; [F(1, 7) = 9.15, p = 0.019], 
and an interaction between these factors [F(1, 7) = 7.60, p = 0.028].  
32.1.2 MDMA self-administration 
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Figure 12. Average (+SEM) responding for MDMA self-administration on active (black bars), and 
inactive (grey bars) levers during two days of maintenance (Phase 1), and the last two days of extinction 
(Phase 2; FR5; n = 10). 
Figure 12 shows the average number of responses on active and inactive 
levers during two days of MDMA self-administration (Phase 1) and the last two 
days of extinction responding (Phase 2), prior to the start of the reinstatement tests 
(Phase 3). Responding was high during drug self-administration, and rapidly 
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decreased when the drug was replaced with vehicle solution and the stimulus light 
was omitted. Repeated measures ANOVA revealed a significant main effect of lever 
[F(1, 4) = 643.20, p = 0.0001], condition (Phase 1 vs. Phase 2; [F(1, 4) = 254.85, p = 
0.00009], and an interaction between these factors [F(1, 4) = 335.06, p = 0.00005]. 
32.2 Experiment 5: MA-produced drug-seeking 
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Figure 13. Average responding (+SEM) in drug-seeking tests elicited by various doses of MA (0; 1.0; 2.0 
mg/kg). *Significantly different to vehicle dose (p < 0.05) 
Figure 13 shows the effect of MA (0.0 – 2.0 mg/kg, IP) on drug-seeking 
behaviour. MA-priming injections dose-dependently reinstated previously 
extinguished drug-seeking behaviour. Repeated measures ANOVA revealed a main 
effect of lever [F(1, 7) = 34.16, p = 0.0006], MA-prime [F(2, 14) = 5.509, p = 0.017] 
and a significant interaction between MA-prime and lever was observed [F(2, 14) = 
4.897, p < 0.024]. Simple contrasts revealed that both doses of the MA-prime 
significantly increased active lever responding compared to vehicle priming 
injections (p = 0.025). 
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32.3 Experiment 6: Effects of D1- and D2-like antagonism on drug-
primed drug-seeking 
32.3.1 MA-primed MA-seeking 
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Figure 14. Effects of SCH 23390 [A) 0.0; 0.01; 0.02; 0.04], and eticlopride [B) 0.0; 0.0125; 0.025; 0.05 
mg/kg] on drug-seeking produced by MA (2.0 mg/kg) priming. *Significantly different compared to 
vehicle (p < 0.05) 
Figure 14 illustrates the effect of pre-treatment with a D1- or D2-like 
antagonist on drug-seeking produced by MA (2.0 mg/kg, IP). Pre-treatment with 
SCH 23390 dose-dependently attenuated MA-produced drug-seeking. Repeated 
measures ANOVA revealed a main effect of lever [F(1, 4) = 21.77, p = 0.01], a main 
effect of SCH 23390 dose [F(3, 12) = 9.15, p = 0.002], and an interaction between 
lever and SCH 23390 dose [F(3, 12) = 6.71, p = 0.007]. Simple contrasts confirmed 
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that the 0.02 and 0.04 mg/kg doses significantly decreased drug-seeking behaviour 
(p = 0.0049).  
Eticlopride did not significantly reduce MA-produced drug-seeking 
behaviour. A repeated measures ANCOVA, failed to show a significant effect of 
eticlopride pre-treatment on MA-produced drug-seeking [F(3, 15) = 1.641, p = 
0.222]. This was corroborated by repeated measures ANOVA on drug-seeking 
behaviour among rats in their first reinstatement test alone [F(3, 9) = 1.17, p = 
0.375], and among all rats tested with eticlopride without MA-exposure as a 
covariate [F(3, 18) = 2.04, p = 0.144], both showing no significant effect of 
eticlopride. 
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32.3.2 Cocaine-primed MA-seeking 
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Figure 15. Effects of SCH 23390 [A) 0.0; 0.01; 0.02; 0.04], and eticlopride [B) 0.0; 0.0125; 0.025; 0.05 
mg/kg] on MA-seeking produced by cocaine (20.0 mg/kg) priming. *Significantly different compared to 
vehicle (p < 0.05) 
Figure 15 shows cocaine-produced (20.0 mg/kg, IP) MA-seeking and the 
effect of DA D1- and D2-like antagonist pre-treatment on reinstated responding. 
Pre-treatment with SCH 23390 reduced cocaine-produced MA-seeking. Repeated 
measures ANCOVA revealed a main effect of lever [F(1, 2) = 18.91, p = 0.049], 
SCH 23390 dose [F(3, 6) = 4.91, p = 0.047], and an interaction between these 
factors [F(3, 6) = 14.30, p = 0.004]. The effect of D1-like antagonist pre-treatment 
was supported by repeated measures ANOVA without MA-exposure as a covariate 
showing a main effect of SCH 23390 pre-treatment [F(3, 9) = 16.44, p = 0.001]. 
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Simple contrasts confirmed that all doses of SCH 23390 were effective in reducing 
MA-seeking behaviour (p = 0.033).  
Eticlopride failed to reduce cocaine-produced MA-seeking. Repeated 
measures ANCOVA revealed that pre-treatment with eticlopride did not 
significantly decrease drug-seeking behaviour [F(3, 12) = 0.46, p = 0.188], 
supported by repeated measures ANOVA without MA-exposure as covariate, 
showing no significant effect of eticlopride [F(3, 15) = 1.689, p = 0.212]. 
32.3.3 MDMA-primed MDMA-seeking 
 
Figure 16. Effect of eticlopride (0.0; 0.0125; 0.025; 0.05 mg/kg) on drug-seeking produced by 
MDMA (10.0 mg/kg) priming. 
Figure 16 illustrates the effect of eticlopride pre-treatment on drug-seeking 
produced by MDMA (10.0 mg/kg, IP) priming-injections. Eticlopride pre-treatment 
dose-dependently reduced drug-primed MDMA-seeking behaviour. Repeated 
measures ANOVA exposed a significant main effect of lever [F(1, 4) = 30.10, p = 
0.006], eticlopride dose [F(3, 12) = 3.51, p = 0.049], and an interaction between 
these factors [F(3, 12) = 4.34, p = 0.026]. Simple contrasts revealed that the two 
larger doses of eticlopride significantly attenuated MDMA-seeking behaviour (p = 
0.049). 
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32.4 Experiment 7: DA agonist-primed MA-seeking 
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Figure 17. Effect of priming injections of various DA agonists [A) quinpirole (0.0, 1.0 mg/kg), B) 
GBR 12909 (0.0, 1.0, 10.0 mg/kg), C) SKF 81297 (1.0, 2.0, 4.0 mg/kg)] on MA-seeking behaviour. 
Figure 17 shows the effect of priming-injections of quinpirole (A: 0-1.0 
mg/kg, IP), GBR 12909 (B; 0.0-10.0 mg/kg, IP), and SKF 81297 (C; 0.0-4.0 mg/kg, 
IP) on drug-seeking behaviour. Priming injections of GBR 12909 dose-dependently 
increased drug-seeking behaviour. Repeated measures ANCOVA revealed a main 
effect of lever [F(1, 4) = 148.65, p = 0.0002], a main effect of GBR 12909 [F(2, 8) = 
16.82, p = 0.001], and an interaction between these factors [F(2, 8) = 27.75, p = 
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0.0002]. The effect of the GBR 12909 priming-injections was confirmed by repeated 
measures ANOVA on drug-seeking behaviour among rats in their first reinstatement 
test alone [F(2, 6) = 14.23, p = 0.005] and among all rats tested with GBR 12909 
without MA-exposure as a covariate [F(2, 10) = 29.326, p = 0.00006]. Simple 
contrasts confirmed that the increase in active lever responding was produced by the 
10.0 mg/kg dose (p < 0.003). 
Priming-injections of quinpirole did not significantly reinstate MA-seeking 
behaviour [F(1, 4) = 3.92, p = 0.119]. This was verified by a repeated measures 
ANOVA on drug-seeking behaviour among rats in their first reinstatement test alone 
[F(1, 4) = 3.92, p = 0.119] and among all rats tested with quinpirole without MA-
exposure as a covariate [F(1, 5) = 5.92, p = 0.059]. 
SKF 81297 priming-injections also failed to reinstate MA-seeking behaviour 
[F(3, 6) = 0.83, p = 0.523], further supported by a repeated measures ANOVA 
without MA-exposure as a covariate, also showing no significant effect of SKF 
81297 [F(3, 9) = 2.81, p = 0.1]. 
33 Discussion 
The results of this study support the idea that dopaminergic mechanisms are 
important for reinstatement of MA-seeking, and further suggest an important role of 
D1-, but not D2-like receptor mechanisms. Prior to the first reinstatement test, rats 
received substantial exposure to self-administered MA during training (32.4-93.9 
mg/kg over an average of 32 days). When MA was replaced with the vehicle and the 
drug-paired light stimulus was omitted, responding decreased to less than 20% of 
baseline levels.  MA-seeking was produced by priming-injections of the DAT 
inhibitor, GBR 12909, cocaine, and MA indicating an important role for DA in 
relapse to MA-seeking. However, selective stimulation of DA D1 and D2 receptors 
by priming-injections of SKF 81297 and quinpirole, respectively, did not reinstate 
MA-seeking behaviour. Only one dose of quinpirole was tested in the present study 
and it is possible that a greater dose range may have revealed different effects. The 
present dose, however, is larger than and equivalent to doses that have reinstated 
drug-seeking in rats previously self-administering cocaine (De Vries, et al., 2002; De 
Vries, et al., 1999; Self, Barnhart, et al., 1996), heroin (De Vries, et al., 2002) and 
MDMA (Schenk, et al., 2011). Dopaminergic mechanisms also appear to play an 
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important role in reinstatement of MDMA-seeking behaviour, because; in contrast to 
MA-seeking, the D2-like antagonist, eticlopride, significantly reduced drug-primed 
MDMA-seeking. The different findings between the present studies and previous 
research on the effects of pharmacological manipulation of D2 receptors  may be 
explained by the effects of MA on D2-like receptor mechanisms (Segal, et al., 2005; 
Stefanski, et al., 1999), discussed in greater detail below.  
33.1 D1- and D2-like antagonist effects on MA-seeking 
SCH 23390 dose-dependently decreased MA-seeking produced by both 
cocaine and MA priming-injections. A large number of other studies have reported 
similar effects of SCH 23390, and other D1-like antagonists, consistent with an 
important role of this receptor in drug-seeking behaviour (Self, 1998, 2004b; Self & 
Nestler, 1998; Shaham, et al., 2003; Shalev, et al., 2002). For instance, cocaine-
seeking produced by stress (foot schock; Capriles, 2003) and drug-associated cues 
(Alleweireldt, et al., 2002; Bossert, et al., 2007; Liu, et al., 2010) was attenuated by 
pre-treatment with D1-like antagonists. Heroin- (Bossert, et al., 2007) and nicotine-
seeking (Liu, et al., 2010) produced by exposure to drug associated cues was also 
reduced by D1-like antagonist pre-treatment. Cocaine-seeking produced by priming 
injections of caffeine (Green & Schenk, 2002), WIN 35,428 (Schenk & Gittings, 
2003), and cocaine (Anderson, et al., 2003; Khroyan, et al., 2000; Schenk & Gittings, 
2003) was reduced by pre-treatment with DA D1-like receptor antagonists. Further, 
D1-like antagonist pre-treatment also attenuated drug-primed heroin- (Shaham & 
Stewart, 1996) and MDMA-seeking behaviour (Schenk, et al., 2011). These findings 
indicate that, similar to reinstatement of drug-seeking following self-administered 
exposure to other drugs of abuse, DA D1-like receptor mechanisms appear critical 
for relapse to MA-seeking behaviour. 
The smallest dose of SCH 23390 attenuated cocaine-produced (fig. 15a), but 
not MA-produced (fig. 14a) drug-seeking. This may relate to the different 
mechanisms of action of MA and cocaine, their duration of action and subjective 
effects (Julien, 2001; Krasnova & Cadet, 2009; Newton, et al., 2005). It has been 
suggested that reinstatement of drug-seeking is produced by drugs that share 
discriminative stimulus properties that generalize to the reinforcing effects of the 
previously self-administered drug (Schenk & Partridge, 1999; Shaham, et al., 2003; 
Stewart, 2000). Amphetamine, methylphenidate and caffeine priming-injections, for 
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instance, reinstated extinguished cocaine-seeking behaviour (Green & Schenk, 2002; 
Schenk & Partridge, 1999), suggesting they generalized to cocaine‟s reinforcing 
effects. Drugs from other pharmacological classes, such as 
Δ
9THC, morphine and 
nicotine, on the other hand, failed to reinstate cocaine-seeking (Schenk & Partridge, 
1999), suggesting they did not produce discriminative stimulus properties that 
generalized to cocaine‟s reinforcing effects. Indeed, GBR 12909 and MA 
generalized to cocaine in a drug-discrimination task (Holtzman, 2001), and GBR 
12909 and cocaine reinstated MA-seeking in the present study, indicating they share 
discriminative stimulus properties relating to the reinforcing effects of MA.  
Nonetheless, cocaine and MA have been reported to produce different subjective 
effects, with MA having a slower onset and longer effects than cocaine (Newton, et 
al., 2005),  and the combined pharmacological mechanism of MA produces a longer 
elimination half-life (11-12 hours) than that of cocaine (1-2 hours; Julien, 2001). It 
is, therefore, possible that while cocaine‟s discriminative stimulus effects 
generalized sufficiently to reinstate MA-seeking, the more potent effect of the lower 
dose of SCH 23390 in reducing cocaine-primed drug-seeking may reflect the more 
rapid peak and decline, and the different subjective effects, compared to the MA-
prime. 
Eticlopride failed to significantly alter the drug-seeking response following 
the MA- and cocaine-priming injections. Comparisons between cocaine- and MA-
primes were made because cocaine-primed drug-seeking has previously been 
reduced by pre-treatment with both D1- and D2-like antagonists (Anderson, et al., 
2003; Khroyan, et al., 2000; Schenk & Gittings, 2003). It is, therefore, possible that 
cocaine-priming may have produced differential effects following D1- and D2-like 
antagonist pre-treatment, compared to the MA-prime. The lack of effect of 
eticlopride on drug-seeking following both MA- and cocaine-priming injections, 
however, suggests that this finding reflects changes taking place in DA receptor 
mechanisms following a history of MA self-administration. This finding is unusual 
since many other studies have shown an attenuation of drug-seeking behaviour 
following administration of eticlopride and other D2-like receptor antagonists 
(Khroyan, et al., 2000; Schenk & Gittings, 2003; Self, 1998, 2004b; Self, Barnhart, 
et al., 1996; Shaham & Stewart, 1996). Cocaine-seeking behaviour in monkeys, for 
example, was dose-dependently attenuated by pre-treatment with the D2-like 
antagonists eticlopride and nemonapride (Khroyan, et al., 2000), and in rats by pre-
114 
 
 
 
treatment with the novel D1 agonist/D2 antagonist LEK-8829 (Milivojevič, et al., 
2004). Reinstatement of heroin-seeking behaviour was attenuated by the D2-like 
antagonist, raclopride, suggesting that D2-like receptors also contribute to heroin-
induced relapse (Shaham & Stewart, 1996). Furthermore, following cocaine self-
administration under almost identical protocols as the present study, eticlopride 
attenuated cocaine-, WIN 35,428- (Schenk & Gittings, 2003), and caffeine-produced 
cocaine-seeking (Green & Schenk, 2002). It is unlikely that the lack of eticlopride 
effect seen here is due to an inadequate dose as the current doses are comparable to 
effective doses used in cocaine-primed reinstatement studies (e.g. Khroyan, et al., 
2000; Schenk & Gittings, 2003). Higher doses were not tested because they have 
been shown to produce non-specific generalized decreases in motor activity (Green 
& Schenk, 2002; Schenk & Gittings, 2003). In addition, pre-treatment with the same 
doses of eticlopride significantly attenuated MDMA-seeking behaviour in the 
present study. This suggests that the dose range was behaviourally effective and 
demonstrates successful attenuation of extinguished drug-seeking behaviour 
following psychostimulant self-administration with eticlopride.  
This lack of effect following D2-like antagonist pre-treatment may relate to 
the substantial exposure to self-administered MA in the present study, and the 
consequential neuroadaptations in DA receptor mechanisms following MA self-
administration. Indeed, previous findings showed that 25 days exposure to self-
administered MA produced roughly a two-fold greater reduction in D2-, over D1-
like receptors (Stefanski, et al., 1999). The present study utilized almost identical 
protocols to the Stefanksi et al. (1999) study, suggesting that a preferential effect of 
D1-, over D2-like antagonism might, therefore, be expected. The failure of 
eticlopride to attenuate both MA- and cocaine-primed reinstatement of MA-seeking 
is consistent with the finding that eticlopride failed to significantly alter the dose-
response curve for MA self-administration on an FR1 schedule of reinforcement, 
and reduce BPs on a PR schedule of reinforcement (Chapter 2). Further, these 
findings suggest that D2-like receptor mechanisms are not critical for the 
reinstatement of MA-seeking behaviour.  
33.2 DA agonist effects on MA-seeking 
Priming injections of MA, cocaine and the DAT inhibitor, GBR 12909, dose-
dependently reinstated MA-seeking behaviour, consistent with previous research 
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indicating an important role of DA in reinstatement of previously extinguished drug-
seeking (H. D. Schmidt & Pierce, 2006; Shaham, et al., 2003; Shalev, et al., 2002). 
MA is a potent releaser of 5-HT and NE, in addition to DA (Cruickshank & Dyer, 
2009; Julien, 2001; Rothman, et al., 2001), but there is a relative paucity of research 
into the effects of 5-HT and/or NE agonists on MA-seeking behaviour. The effect of 
priming-injections of DA, 5-HT, and NE agonists on their ability to reinstate 
previously extinguished drug-seeking following self-administration of other drugs of 
abuse, however, has been investigated. A DAT inhibitor (GBR 12909), but not a 
SERT (fluoxetine) or NET inhibitor (nisoxetine), dose-dependently reinstated 
cocaine-seeking behaviour, which was subsequently attenuated by pre-treatment 
with a DA antagonist (H. D. Schmidt & Pierce, 2006). Reinstatement of heroin- (De 
Vries, et al., 1999) and MDMA-seeking behaviour (Schenk, et al., 2011) was also 
induced by priming-injections of GBR 12909. Priming injections of 5-HT receptor 
agonists (DOI, mCPP), however, failed to reinstate MDMA-seeking, while a SERT 
inhibitor (clomipramine) attenuated drug-seeking behaviour produced by MDMA-
associated cues, suggesting a modulating role for 5-HT in this behaviour (Schenk, et 
al., 2011). Taken together, these findings indicate a primary role of DA in drug-
primed reinstatement of previously extinguished drug-seeking and the present results 
extend this idea to reinstatement of MA-seeking behaviour. 
Priming-injections of the direct D1 agonist, SKF 81297, did not reinstate 
MA-seeking. These results are supported by previous studies on the effect of direct 
D1 agonists on reinstatement of previously extinguished responding, suggesting 
selective stimulation of this receptor did not reinstate drug-seeking behaviour (Self, 
2004b; Self & Nestler, 1998). For instance, priming-injections of the D1 agonists 
SKF 81297 (Khroyan, et al., 2000), and SKF 82958 (De Vries, et al., 1999; Dias, et 
al., 2004; Khroyan, et al., 2000; Self, Barnhart, et al., 1996) failed to reinstate 
cocaine- and heroin-seeking (De Vries, et al., 1999) behaviour. Priming-injections of 
low doses (0.3, 1.0 mg/kg) of SKF 81297 produced mild reinstating effects on 
cocaine-seeking in one study, but these effects were eliminated following higher 
dose (3.0 mg/kg) primes (Alleweireldt, et al., 2002). The dissociation between D1- 
and D2-like receptors on reinstatement of drug-seeking is intriguing as both 
receptors mediate reinforcing stimuli (Missale, et al., 1998; Self, Belluzzi, et al., 
1996; Wise, et al., 1990) and may indicate that D1- and D2-like receptors mediate 
qualitatively different aspects of drug-seeking. Indeed, it has been suggested that 
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D1-like receptors may play a facilitative or „permissive‟ role in reinstatement of 
drug-seeking behaviour (Missale, et al., 1998; Self, 1998, 2004b; Self, Barnhart, et 
al., 1996; Self & Nestler, 1998). That is, although selective stimulation of D1-like 
receptors failed to reinstate drug-seeking (Alleweireldt, et al., 2002; Dias, et al., 
2004; Khroyan, et al., 2000; Self, Barnhart, et al., 1996), significant attenuation of 
reinstated drug-seeking is produced following pre-treatment with D1-like 
antagonists (Alleweireldt, Kirschner, Blake, & Neisewander, 2003; Alleweireldt, et 
al., 2002; Brennan, et al., 2009; Daniela, et al., 2004; Khroyan, et al., 2000; Khroyan, 
et al., 2003; Schenk & Gittings, 2003; Shaham & Miczek, 2003; Shaham, et al., 
2003; Shalev, et al., 2002). Thus, because drug-seeking was not produced by direct 
D1 receptor agonists, but was attenuated by pre-treatment with D1-like antagonists, 
these findings suggest that stimulation of D1-like receptors alone is insufficient for 
reinstatement of drug-seeking, but may be necessary in „permitting‟ drug-seeking 
behaviour induced by other stimuli (e.g. exposure to similar drugs, stress, or drug-
associated cues).  Nonetheless, the doses of SKF 81297 that previously produced 
mild drug-seeking (Alleweireldt, et al., 2002), did not reinstate MA-seeking in the 
present study, nor cocaine-seeking in a previous study (Khroyan, et al., 2000). 
Together, these findings suggest selective stimulation of D1-like receptor 
mechanisms does not reinstate drug-seeking behaviour (Self, 1998, 2004b; Self & 
Nestler, 1998), and the present results extend this idea to reinstatement of MA-
seeking behaviour. 
Priming injections of the direct D2 agonist, quinpirole, failed to reinstate 
MA-seeking. This finding is atypical because previous studies have reported 
reinstated drug-seeking behaviour following D2 agonist priming injections in rats 
(De Vries, et al., 2002; De Vries, et al., 1999; Dias, et al., 2004; Self, Barnhart, et al., 
1996; Wise, et al., 1990) and monkeys (Khroyan, et al., 2000), following self-
administration of psychostimulants (De Vries, et al., 2002; De Vries, et al., 1999; 
Dias, et al., 2004; Khroyan, et al., 2000; Schenk, et al., 2011; Self, Barnhart, et al., 
1996; Wise, et al., 1990), and opiates (De Vries, et al., 2002; Wise, et al., 1990). 
These findings indicate an important role for D2 receptor activation in the 
reinstatement of drug-seeking behaviour (Self, 1998, 2004a, 2004b; Self & Nestler, 
1998; Shaham, et al., 2003; Shalev, et al., 2002; Stewart, 2000). Quinpirole, 
specifically, reinstated drug-seeking behaviour in animals previously self-
administering cocaine (De Vries, et al., 2002; De Vries, et al., 1999; Khroyan, et al., 
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2000; Self, Barnhart, et al., 1996) and heroin (De Vries, et al., 2002), while the 
direct D2 agonists bromocriptine and quinelorane reinstated heroin- (Wise, et al., 
1990), and cocaine-seeking (Dias, et al., 2004; Wise, et al., 1990), respectively. Only 
a single dose of quinpirole was tested in the present study, however, and the 
limitations inherent in using a single dose suggest that testing with higher doses may 
have produced greater effects. Nonetheless, the dose of quinpirole used in the 
present study is identical to reinstatement-producing doses in previous studies on 
cocaine- (De Vries, et al., 2002; Self, Barnhart, et al., 1996), and MDMA-seeking 
behaviour (Schenk, et al., 2011). The failure of a D2 agonist to induce MA-seeking 
behaviour is consistent with the finding that a D2-like antagonist failed to alter 
responding for MA reinforced under both an FR1 and PR schedule (Chapter 2); and 
MA- and cocaine-primed reinstatement of MA-seeking (above); and lends further 
support to the hypothesis that D2-like receptor mechanisms undergo 
neuroadaptations as a function of MA self-administration, rendering them less 
responsive to pharmacological manipulation, than D1-like receptor mechanisms. 
The failure of eticlopride to attenuate, and quinpirole to induce MA-seeking 
behaviour, respectively, may be explained by the novel effects of repeated MA 
exposure on DA neurotransmission. Reduced levels of DA and D2-like receptor 
availability is a consistent finding in human drug abusers, including those with a 
history of MA abuse (B. Lee, et al., 2009; Martinez, et al., 2009; Volkow, et al., 
2001). Rodents self-administering MA for six hours/day presented no changes in 
monoamine levels in PFC or NAc (Schwendt, et al., 2009), transient reductions in 
striatal DA levels (Chapter 1), and a persistent decrease in DAT protein levels in 
PFC and dorsal Str (Schwendt, et al., 2009). Increasing session duration to 15 
hours/day, however, produced transient changes in NE and 5-HT levels, with 
persistent dose-dependent reductions in DA, DAT and TH levels in the Str and 
cortex (Krasnova, et al., 2010). More extensive testing, using longer duration self-
administration sessions, may, therefore, reveal neurochemical consequences that are 
not apparent following shorter sessions, as in the current study.  
As previously noted, reduced levels of both D1- and D2-like receptor 
availability have been demonstrated in laboratory animals following experimenter-
administered MA infusions, but there were greater reductions in D2- over D1-like 
receptor binding densities (Segal, et al., 2005). Self-administered MA, under 
protocols almost identical to the current study, also produced more substantial 
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decreases in DA D2-, over D1-like, receptor binding (Stefanski, et al., 1999). 
Greater reductions in D2-, than D1-like, receptor binding densities, as a function of 
self-administered MA exposure, may therefore explain the preferential effect of 
SCH 23390 on MA-seeking behaviour. Comparable effects on DA D2-like receptor 
binding densities have not always been observed following exposure to other drugs 
of abuse. Following cocaine exposure, for example, the findings have been 
somewhat ambiguous, where decreases (Nader, et al., 2002), increases (Peris, et al., 
1990), or no change in D2-like receptor binding (D. R. Wallace, Mactutus, & Booze, 
1996) have been reported. Indeed, exposure to self-administered cocaine (2–6 hr 
sessions) failed to produce persistent changes in D2-like receptor binding densities 
(Ben-Shahar, et al., 2007; Briand, Flagel, Seeman, & Robinson, 2008; Laurier, 
Corrigall, & George, 1994; Stefanski, et al., 2007). This could explain why drug-
seeking following cocaine self-administration was susceptible to pharmacological 
manipulation of both D1- and D2-like receptor mechanisms, whereas drug-seeking 
following MA self-administration in the present study was only susceptible to 
pharmacological antagonism of D1-like receptors.  
These results are consistent with the idea that MA self-administration may 
produce neuroadaptations in the dopaminergic system not seen following self-
administration of other drugs of abuse. The findings that eticlopride failed to alter 
responding for MA self-administration under an FR1 and a PR schedule of 
reinforcement, together with the present results, suggests that under the current 
protocols, DA D2-like receptor mechanisms may undergo novel neuroadaptations as 
a function of self-administered MA exposure, rendering these behaviours more 
susceptible to pharmacological manipulations of DA D1-like receptor mechanisms.  
General discussion 
The aim of this thesis was to understand the neurobiological mechanisms and 
consequences of MA self-administration, focusing on the dopaminergic system. In 
particular, a focus was to determine whether there are persistent changes in striatal 
DA and frontal cortex 5-HT levels following self-administered MA exposure and 
whether these changes have functional implications for MA self-administration and 
reinstatement of MA-seeking. These objectives were accomplished in three ways. 
First, two drug free periods were chosen (24 hours vs. seven days) to determine 
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whether was recovery of DA and 5-HT levels, their respective metabolites and rates 
of turnover, following self-administered MA exposure. The effects on contingency 
on these measures were determined using a yoked-control self-administration 
protocol. Second, the effects of selective pharmacological manipulation of DA D1- 
and D2-like receptor mechanisms on the maintenance of MA self-administration 
were determined under an FR1 schedule of reinforcement. For comparison, the 
effect of these manipulations on changes in the reinforcing efficacy and incentive 
motivation for further MA reinforcement was determined using a PR schedule of 
reinforcement. Finally, the contribution of DA and DA D1- and D2-like receptor 
mechanisms to relapse to MA-seeking behaviour was investigated using the 
reinstatement paradigm. The current experiments were used to evaluate the above 
questions and the results can be briefly summarised as follows. 
1. Self-administered MA does not produce neurotoxicity in rats, but does produce 
transient neurochemical disruption and changes in DA regulation. 
2. MA exposure produces neuroadaptations predominantly in dopaminergic, 
rather than serotonergic systems and the striatum appears highly susceptible to 
MA-produced reductions in tissue levels of DA. 
3. These changes likely represent the purely pharmacological effects of exposure 
to self-administered MA as there were no significant differences between self-
administered MA and passive (yoked) MA infusions on neurochemical 
measures.  
4. DA D1- and D2-like receptor mechanisms contribute differentially to the 
maintenance of MA self-administration. A greater role of D1- over D2-like 
mechanisms was suggested since there were significant changes in MA self-
administration maintained by both FR1 and PR schedules of reinforcement 
following pre-treatment with a selective D1-, but not a selective D2-like 
receptor antagonist.  
5. Similar to other drugs of abuse, dopaminergic mechanisms appear crucial for 
relapse to MA-seeking. This was suggested by reinstatement of MA-seeking 
behaviour following priming injections of the indirect DA agonists cocaine, 
GBR 12909, and MA.  
6. DA D1- and D2-like receptor mechanisms contribute differentially to 
reinstatement of MA-seeking behaviour. MA-seeking was attenuated by pre-
treatment with a selective D1-like receptor antagonist, but drug-seeking was 
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not potentiated by a direct D1 agonist. MA-seeking behaviour was not 
significantly attenuated by selective D2-like receptor antagonist pre-treatment, 
and was drug-seeking was not potentiated by priming injections of a selective 
D2 agonist. 
In Chapter 1, a typical experimenter-administered exposure regime produced 
persistent reductions of DA and 5-HT, in the dorsal Str, and FC, respectively, and 
transient increases in DA, but not 5-HT, turnover. Similar findings have been 
produced in other studies utilizing an experimenter-administered MA regime 
(Friedman, Castañeda, & Hodge, 1998; Herring, Schaefer, Gudelsky, Vorhees, & 
Williams, 2008; Pubill, et al., 2003; Quinton & Yamamoto, 2006). The effects of 
chronically self-administered MA on these measures were less pronounced, however, 
and only transient decreases in striatal DA levels and elevated rates of DA turnover 
in the dorsal Str were produced. This finding provided an important basis for 
subsequent experiments by providing a means with which to assess the functional 
status of DA D1- and D2-like receptors in the absence of substantial and persistent 
changes in tissue monoamine levels and toxicity. In line with these results, two hour 
MA self-administration sessions using almost identical parameters to the 
experiments in Chapters 2 and 3 produced no substantial changes in monoamine 
neurotransmission or toxicity, but produced greater reductions in D2-, over D1-like 
receptor densities (Stefanski, et al., 1999; Stefanski, et al., 2002). 
Because the rats in the experimenter-administered and self-administering 
groups were of different ages it was not possible to make direct comparisons 
between effects of the two exposure regimens. Self-administered MA, however, 
produced smaller and more transient neurochemical changes. This might reflect 
differences in susceptibility to neurotoxicity as a function of age (J. E. Hanson, et al., 
2009; Imam & Ali, 2001; Volz, et al., 2009). A test of this possibility would require 
measuring effects of self-administered MA in younger rats. Regardless, self-
administration is generally considered a valid means of determining effects of drug 
dependence (Gardner, 2000, 2008; Lynch, et al., 2010; Markou, 2009; Markou, et al., 
1993; Panlilio & Goldberg, 2007; Sanchis-Segura & Spanagel, 2006), and because 
self-administered MA failed to produce comparable and persistent deficits in the 
various neurochemical measures, the data suggest that acute high-dose 
experimenter-administered MA treatment should not be used to model the effects of 
chronic MA dependence. 
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Other studies have also reported less pronounced and/or less persistent 
changes in various neurochemical markers following self-administered MA. For 
example, increased TH mRNA and protein levels were reported 1 day, but not 30 
days, following 10 days of MA self-administration (Shepard, et al., 2006). 
Decreased DAT densities in the striatum and pre-frontal cortex were produced 14 
days following the last MA self-administration session, but there were no changes in 
DA and 5-HT tissue levels, or SERT densities (Schwendt, et al., 2009). Following 
longer self-administration sessions there were reductions in DA levels (30%) that 
persisted for up to 14 days (Krasnova, et al., 2010). Experimenter-administered MA 
produced greater and more persistent reductions in DA (Friedman, et al., 1998). 
Taken together with the present results, this suggests that MA self-administration 
does not produce the extensive neurotoxicity and/or lasting neurochemical 
disruption that has been observed following high-dose, experimenter-administered 
treatment regimes (Chapman, et al., 2001; Friedman, et al., 1998).  
A small number of studies assessing effects of DA antagonists have 
suggested that dopaminergic mechanisms underlie the maintenance of MA self-
administration (Higley, et al., 2011; Orio, et al., 2010; Wee, et al., 2007; Yokel & 
Wise, 1976). The relative contribution of D1- and D2-like receptor mechanisms, 
however, has not been thoroughly investigated. Accordingly, Chapter 2 determined 
effects of selective antagonists on MA self-administration reinforced by an FR1, and 
a PR schedule of reinforcement. Consistent with findings from studies of cocaine 
and other drug self-administration (Bari & Pierce, 2005; Botly, et al., 2008; Brennan, 
et al., 2009; Caine, et al., 1995; Caine & Koob, 1994; Cornish, et al., 2005; Hubner 
& Moreton, 1991; McGregor & Roberts, 1995; Phillips, et al., 1994; Ranaldi & Wise, 
2001), D1-like antagonism attenuated MA self-administration. In contrast to the 
majority of research on effects of DA antagonists on self-administration of other 
drugs of abuse (Bari & Pierce, 2005; Botly, et al., 2008; Brennan, et al., 2009; Caine 
& Koob, 1994; Caine, et al., 1999; David, et al., 2002; Hubner & Moreton, 1991; 
Izzo, et al., 2001; Phillips, et al., 1994; D. Zhang, et al., 2010), the D2-like receptor 
antagonist, eticlopride, failed to significantly alter MA self-administration. Pre-
treatment with compounds selective for the D3 receptor, however, have been shown 
to reduce extended access MA self-administration reinforced according to both an 
FR and PR schedule. These manipulations, however, had lesser effects following 
limited access. Pre-treatment with the partial D3 agonist, CJB090, reduced MA self-
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administration reinforced according to an FR1 schedule and lowered BPs during six 
hour access (Orio, et al., 2010). During one hour access only the highest dose 
reduced BPs, with no effect on responding reinforced according to an FR1 schedule. 
Further, pre-treatment with the D3 antagonist, PG01037, only reduced BPs in the 
extended access group, with no effect in the limited access group (Orio, et al., 2010). 
This suggests that MA self-administration may be more sensitive to pharmacological 
manipulation of D2-like receptor mechanisms following extended access. It is, 
therefore, possible that two hour sessions may have been insufficient to observe the 
effects of eticlopride pre-treatment in the present study. 
Because most studies on the effects of DA antagonists on self-administration 
make use of simple FR schedules, the contribution of D1- and D2-like receptors to 
MA self-administration reinforced according to a PR schedule was also assessed. 
Because BPs on a PR schedule of reinforcement are independent of the rate of 
responding, the BP can provide an effective measure of the incentive motivational 
properties of MA, complementing changes in response rate observed under the FR1 
schedule of reinforcement. This greatly increases the convergent validity of any 
findings and may provide crucial insight into the contribution of DA receptor 
mechanisms to MA self-administration behaviour, not attainable with either 
schedule alone. Similar findings were produced regardless of whether the FR1 or PR 
schedule was applied. Thus, the data suggest that both the positively reinforcing 
effects and incentive motivational properties of MA are decreased following D1-, 
but not D2-like receptor blockade. 
The findings from Chapter 2 raised the question of how DA D1- and D2-like 
receptor mechanisms contribute to other indices of MA dependence. The 
reinstatement paradigm of extinguished drug self-administration is a measure that 
has been used to show that the same variables that can induce subjective reports of 
drug craving and provoke relapse to drug dependence in humans (i.e. exposure to the 
drug of abuse or similar drugs, drug-associated cues and/or stress) also produce 
reinstatement of drug-seeking in laboratory animals (Epstein & Preston, 2003; 
Epstein, et al., 2006; Shaham & Miczek, 2003; Shaham, et al., 2003; Shalev, et al., 
2002; Volkow, et al., 2006). For this reason, Chapter 3 used the reinstatement 
paradigm to assess the role of dopaminergic mechanisms in relapse to MA 
dependence, as has been demonstrated following self-administration of other drugs 
of abuse (Anker & Carroll, 2010; de Wit & Stewart, 1981; Dias, et al., 2004; Kalivas 
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& McFarland, 2003; Neisewander, O'Dell, Tran-Nguyen, Castañeda, & Fuchs, 1996; 
Schenk, et al., 2011; Shaham, et al., 2003; Stretch & Gerber, 1973). The D1-like 
antagonist, SCH 23390, produced a dose-dependent reduction in the magnitude of 
drug-seeking produced by priming injections of both MA- and cocaine, and priming 
injections of a direct D1 agonist did not reinstate MA-seeking behaviour. These 
findings are consistent with previous studies on drug-seeking (Alleweireldt, et al., 
2002; Anderson, et al., 2003; Botly, et al., 2008; Khroyan, et al., 2000; Liu, et al., 
2010; Milivojevič, et al., 2004; Schenk, et al., 2011; Self, Barnhart, et al., 1996) and 
have led to the suggestion that D1- like receptor mechanisms may play a facilitative 
role in the DA mediated effects on relapse to drug-seeking (Missale, et al., 1998; 
Self, 1998, 2004b; Self & Nestler, 1998). That is, direct stimuluation of D1 receptors 
has previoulsy failed to potentiate reinstatement of drug-seeking (De Vries, et al., 
1999; Dias, et al., 2004; Khroyan, et al., 2000; Schenk, et al., 2011; Self, Barnhart, et 
al., 1996), but pre-treatment with D1-like antagonists attenuated drug-seeking 
behaviour (Alleweireldt, et al., 2003; Alleweireldt, et al., 2002; Brennan, et al., 2009; 
Daniela, et al., 2004; Khroyan, et al., 2000; Khroyan, et al., 2003; Schenk & Gittings, 
2003; Shaham & Miczek, 2003; Shaham, et al., 2003; Shalev, et al., 2002). This 
suggests that direct stimulation of D1 receptors alone does not produce relapse to 
drug-seeking, but may be a necessary component in relapse produced by exposure to 
drugs, drug associated cues, or stress. The present findings extend the idea of a 
central dopaminergic mechanism in reinstatement of drug-seeking to reinstatement 
of extinguished MA-seeking, and further indicate an important role for D1-like 
mechanisms in the reinstatement of MA-seeking behaviour.  
Pre-treatment with the D2-like antagonist, eticlopride, failed to attenuate 
MA-seeking produced by priming injections of either MA- or cocaine-priming 
injections, and the selective D2 agonist, quinpirole, failed to produce drug-seeking. 
These findings are in contrast to studies on reinstatement of drug-seeking following 
self-administration of other drugs of abuse. For instance, both psychostimulant- and 
opiate-seeking was attenuated following pre-treatment with D2-like antagonists  
(Khroyan, et al., 2000; Schenk & Gittings, 2003; Self, 1998, 2004b; Self, Barnhart, 
et al., 1996; Shaham & Stewart, 1996). Further, drug-seeking behaviour following 
extinguished cocaine and heroin self-administration was produced following priming 
injections of direct D2 agonists (De Vries, et al., 2002; De Vries, et al., 1999; Dias, 
et al., 2004; Khroyan, et al., 2000; Self, Barnhart, et al., 1996; Wise, et al., 1990). 
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These findings are consistent with the findings of Chapter 2; D1-like mechanisms 
play a more significant role than D2-like mechanisms in MA dependence.  
A possible explanation for the present findings was that experience with MA 
self-administration produced neuroadaptations in DA receptor mechanisms that 
rendered pharmacological manipulation of D2-like receptor mechanisms ineffectual. 
Because D2-like antagonists have attenuated drug-seeking following cocaine (Green 
& Schenk, 2002; Khroyan, et al., 2000; Schenk & Gittings, 2003), heroin (Shaham 
& Stewart, 1996), nicotine (Liu, et al., 2010) and MDMA self-administration in the 
present study, the effects of cocaine-produced drug-seeking following MA self-
administration allowed for comparisons between priming injections. Cocaine-
produced drug-seeking was, however, also resistant to the effects of eticlopride. 
Rather, the data suggest a functional impairment in the D2-like receptor mediated 
reinstatement of drug-seeking behaviour as a function of MA self-administration. 
This idea is further supported by the failure of quinpirole to produce drug-seeking. 
Together, these findings suggest that D1-like receptor mechanisms are more critical.  
MA-seeking produced by MA, cocaine and GBR 12909 suggests that this is 
a DA mediated behaviour, yet direct stimulation of D1 and D2 receptors did not 
reinstate drug-seeking. The differential effects of SKF 81297 and the indirect DA 
agonists that increase synaptic DA may be explained by effects mediated through 
extrasynaptic D1 receptors. Previous reports suggest that many D1 receptors are 
located at extra-synaptic sites with a substantial portion of D1 receptor-mediated 
effects occurring via DA diffusion at sites outside the synapse (Gonon, 1997; 
Martin-Negrier, Charron, & Bloch, 2000; Smiley, et al., 1994).The attenuation of 
drug-seeking following SCH 23390 pre-treatment and the failure of SKF 81297 to 
potentiate drug-seeking was not surprising, as previous studies have reported similar 
findings (Alleweireldt, et al., 2003; Alleweireldt, et al., 2002; De Vries, et al., 1999; 
Khroyan, et al., 2000; Self, Barnhart, et al., 1996), suggesting D1-like agonists and 
antagonists have similar, rather than opposing effects on relapse (Khroyan, et al., 
2000; Khroyan, et al., 2003). Given these findings, it has been suggested that D1- 
and D2-like receptors mediate qualitatively different aspects of drug-seeking, and 
that selective stimulation of D1-like receptors may produce a tonic firing of DA 
neurons that „masks‟ the D2-like receptor-mediated signal for drug-seeking (Missale, 
et al., 1998; Self, 1998, 2004b; Self & Nestler, 1998). Indeed, electrically stimulated 
DA overflow in striatal neurons was delayed and prolonged by IV administration of 
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the D1 agonist, SKF 82958, reduced by SCH 23390 and abolished by 6-
hydroxydopamine lesions, suggesting this excitation was attributable to D1 receptor 
stimulation (Gonon, 1997). It is, therefore, possible that the lack of drug-seeking 
produced by D1-receptor stimulation reflects the extra-synaptic D1 receptor 
mediated-effects produced by SKF 81297.  
The current dose of quinpirole is the same and higher than doses that have 
previously produced drug-seeking following cocaine (De Vries, et al., 2002; Self, 
Barnhart, et al., 1996), MDMA (Schenk, et al., 2011) and heroin (De Vries, et al., 
2002) self-administration. The limitations inherent in the testing of a single 
quinpirole dose, however, suggest that use of several, greater doses may have 
produced greater effects. For instance, a recent study has shown that pre-treatment 
with a selective DA D3 receptor antagonist, SB-277011A, attenuated MA-primed 
reinstatement of extinguished MA-seeking (Higley, et al., 2011). Quinpirole also 
possesses agonist properties at DA D3 receptors (Burris, et al., 1995; Gehlert, 
Gackenheimer, Seeman, & Schaus, 1992; Philip Seeman & Schaus, 1991), with an 
affinity for D3 receptors sevenfold higher than D2 receptors under conditions that 
favour receptor coupling with G-proteins (Burris, et al., 1995), such as following 
psychostimulant exposure (Briand, et al., 2008; P. Seeman, McCormick, & Kapur, 
2007; P. Seeman, Tallerico, Ko, Tenn, & Kapur, 2002). Testing with higher doses of 
quinpirole may, therefore, have activated D3 receptors and produced greater drug-
seeking effects. Differences in the level of MA exposure between the present study 
and the Higley et al. (2011) study may also explain the significant effects of 
pharmacological manipulation of D3 receptor mechanisms on MA-seeking. For 
instance, rats underwent only approximately 14 days of self-administration training 
prior to extinction conditions (Higley, et al., 2011). MA self-administration training 
in the present study spanned a minimum of 20 days, with an average of 32 days, and 
was reinforced by twice the unit dose (MA 0.1mg/kg/infusion), similar to the 
protocols that produced a greater reduction in DA D2-, over D1-like receptor 
binding densities (Stefanski, et al., 1999; 25 days exposure). Half the length of 
exposure to a dose of self-administered MA half the present unit dose may not have 
been sufficient to produce the neuroadaptions in dopaminergic receptor mechanisms 
seen in the Stefanski et al. (1999) study. Additionally, extinction training in the 
Higley et al. (2011) study was enforced for two weeks, whereas the average 
extinction period in the present study was 3.3 (± 0.15) days, and five days prior to 
126 
 
 
 
D2 agonist primed testing of reinstatement of MA-seeking. The reductions in D1- 
and D2-like receptor densities (Stefanski, et al., 1999) and striatal DA levels 
(Chapter 1) following self-administered MA exposure  had returned to control levels 
at seven days withdrawal from MA self-administration (Stefanski, et al., 2002; 
Chapter 1). These findings suggest that any DA receptor density reductions and 
functional impairment in these mechanisms produced by MA self-administration in 
the Higley et al. (2011) study may have recovered at the time of drug-seeking tests, 
whereas there were still functional impairments in D2 receptor mechanisms at the 
time of testing in the present study. It would be very interesting to investigate the 
effects of pre-treatment with a selective D3 antagonist, and direct D3 receptor 
agonist priming-injections on reinstatement of MA-seeking in future experiments.  
The discrepancy between the present findings and self-administration studies 
with other drugs of abuse may be explained by the different consequences of MA 
exposure on DA neurochemistry and synaptic transmission. Reduced levels of DA 
and D2-like receptor density have been consistently reported in humans who abuse 
drugs, including those with a history of MA abuse (B. Lee, et al., 2009; Martinez, et 
al., 2009; Martinez, et al., in press; Volkow, et al., 2001). Reduced levels of D2-like 
receptor availability may explain the lack of significant effect of pharmacological 
manipulation of these mechanisms on the current behavioural indices. For instance, 
self-administered MA exposure, under conditions almost identical to the present 
protocols in Chapters 2 and 3, produced greater decreases in D2-, over D1-like 
receptor binding densities (Stefanski, et al., 1999). A preferential effect of 
pharmacological manipulation of D1-, over D2-like receptor mechanisms might, 
therefore, be expected. Further, the reductions of DA D2-like receptor binding 
densities (Stefanski, et al., 1999) and striatal DA tissue levels (Chapter 1) observed 
at 24 hours, had shown recovery to control levels at seven days (Stefanski, et al., 
2002; section 1). Extending extinction training in Chapter 3 to seven days would 
have permitted direct comparison between the functional status of D1- and D2-like 
receptor mechanisms during reinstatement tests and when striatal DA tissue content 
levels (Chapter 1), and D1- and D2-like receptor binding densities had returned to 
control levels (Stefanski, et al., 2002). This may be a benefit to future studies of 
comparisons between the neurobiological consequences of chronic exposure to self-
administered MA and pharmacological manipulation of the receptor mechanisms 
involved in MA self-administration and reinstatement of MA-seeking. All tests of 
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MA-seeking following selective D2 agonist priming-injections, however, took place 
following five days of extinction training, close to the time when striatal DA tissue 
levels (Chapter 1) and D1- and D2-like receptor densities (Stefanski, et al., 2002) 
had returned to control levels.  
Most neuroadaptations, such as those referred to above, revert to control 
levels within a month or two following cessation of chronic drug self-administration 
(Krasnova, et al., 2010; Self, 2004b; Stefanski, et al., 2002). The high prevalence of 
relapse to MA abuse, extending over years (Barlow & Durand, 2002; Darke, et al., 
2008; Hartz, et al., 2001), however, suggests that drug-induced neuroadaptations 
cannot fully account for the longevity of drug-dependent behavioural changes. It 
may be possible that even transient changes in receptor density, signalling and gene 
expression may produce persistent alterations in synaptic transmission and 
organisation, potentially in learning and memory circuits, which perpetuate the 
vulnerability to relapse to MA dependence. In this manner, the current results extend 
previous findings to suggest that close to the observed recovery of DA D1- and D2-
like receptor densities (Stefanski, et al., 2002), DA tissue levels and DA turnover 
(Chapter 1); there remain functional impairments in DA D2-like receptor mediation 
of reinstatement of MA-seeking behaviour. 
The lack of significant effect of pharmacological manipulation of DA D2-
like receptor mechanisms on maintenance of MA self-administration and 
reinstatement of MA-seeking may have important ramifications for future research 
into MA dependence. Imaging studies have shown that reduced striatal D2-like 
receptor availability may be involved in the maintenance of drug-taking and 
dependence, including that of MA. For instance, compared to control participants 
with no history of drug dependence, detoxified cocaine abusers (Volkow, et al., 1993) 
and heroin-dependent participants (Martinez, et al., in press) showed significantly 
lower levels of striatal DA D2 receptor availability, as measured by PET. PET also 
showed that lower levels of D2 receptors were associated with a more pleasant 
response to IV methylphenidate administration in healthy male participants with no 
history of drug dependence, whereas higher D2 levels predicted more unpleasant 
subjective effects (Volkow, et al., 1999). Correspondingly, monkeys with lower 
striatal D2 receptor levels were more likely to self-administer cocaine (Morgan, et 
al., 2002). These findings suggest D2 receptors have an important influence on the 
nature of drug taking behaviour and dependence. 
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Similar findings have been reported in imaging studies of MA dependence. 
Indeed, MA-dependent participants were found to have significantly lower levels of 
D2 receptor availability compared to healthy, non drug-dependent controls (B. Lee, 
et al., 2009; Volkow, et al., 2001). Furthermore, D2 receptor availability was 
associated with disrupted metabolism in the orbitofrontal cortex (Volkow, et al., 
2001), a region of the brain that has been implicated in the occurrence of compulsive 
behaviours and the regulation of motivation or “drive” (Volkow & Fowler, 2000). 
This suggests that enhanced inappropriate activation of this region secondary to 
drug-induced DA stimulation may increase the incentive motivation to self-
administer MA to compulsive levels in MA-dependent subjects. Lower levels of D2 
receptor availability in MA-dependent subjects was also associated with increased 
impulsiveness, as measured by the Barratt Impulsiveness Scale (version 11, BIS-II; 
B. Lee, et al., 2009; Patton, Stanford, & Barratt, 1995). Impulsivity has been linked 
with compulsive behaviours, such as drug dependence (Belin, et al., 2008), and MA 
users exhibit increased impulsivity and impaired decision-making (Cruickshank & 
Dyer, 2009), further suggesting that lower levels of D2 receptor availability may 
mediate compulsive MA-taking (Everitt, et al., 2008; Everitt & Robbins, 2005).  
Whether lower levels of DA D2 receptor availability is a consequence of 
chronic drug exposure or represents a vulnerability to develop drug dependence 
remains to be seen. The finding that lower levels of D2 receptors in participants with 
no history of drug abuse predicted a pleasant response to psychostimulant 
administration (Volkow, et al., 1999), suggests that D2 receptors, by regulating 
pleasant versus unpleasant effects of drug administration, may contribute to the 
propensity to develop drug dependence. The present findings, together with previous 
reports of reduced levels of both D1- and D2-like receptor densities following MA 
self-administration (Stefanski, et al., 1999), on the other hand, suggest that 
reductions of dopaminergic receptor availability take place as a function of MA self-
administration. These two hypotheses need not be mutually exclusive. It is possible 
that pre-existing low levels of D2 receptor availability may predispose individuals to 
develop drug-dependence. Chronic drug self-administration may then exacerbate 
this predisposition by further reducing D2 receptor availability, contributing to an 
increase in impulsive temperament, and compulsive drug-taking behaviours that are 
so indicative of the drug-dependent state (APA, 2000). The functional impairment in 
DA D2-like receptor mechanisms following MA self-administration observed in the 
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present studies, may clarify the increasing rate of MA use, abuse and dependence, 
relapse to MA-dependence following abstinence, and exceptional difficulty in 
treating MA-dependence (Cho & Melega, 2002; Copeland & Sorensen, 2001; Darke, 
et al., 2008; Degenhardt, et al., 2008; Hartz, et al., 2001; N. K. Lee & Rawson, 2008; 
UNODC, 2010; Wilkins & Rose, 2004). 
The present set of experiments makes a significant contribution to research 
on the neurobiological mechanisms of MA self-administration by presenting 
findings of transient disruption in dopaminergic levels and regulation, and a 
functional impairment in DA D2-like receptor mechanisms produced by self-
administered MA. The results from Chapter 1, showing comparatively mild 
dopaminergic deficits, provided a basis to infer that changes in MA self-
administration and reinstatement of MA-seeking behaviour following 
pharmacological manipulation of DA D1- and D2-like receptors were due to 
functional neuroadaptations in these receptor mechanisms, rather than pervasive 
dopaminergic deficits or neurotoxicity. Subsequent findings following pre-treatment 
with DA D1- and D2-like receptor antagonists and agonists showed a differential 
contribution between these receptor mechanisms, with a greater role of D1- over D2-
like receptor mechanisms in maintenance of MA self-administration and 
reinstatement of MA-seeking behaviour. This suggests that MA self-administration 
may produce dopaminergic neuroadaptations not seen following self-administration 
of other drugs of abuse, rendering DA D2-like receptor mechanisms functionally 
impaired, and may help explain the exceptionally addictive nature of MA and 
increasingly high rates of MA-dependence.  
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